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Abstract 
 
The general issue of balancing the value of evidence about the performance of a technology and the 
value of access to a technology can be seen as central to a number of policy questions. Establishing 
the key principles of what assessments are needed, as well as how they should be made, will enable 
them to be addressed in an explicit and transparent manner.  This report presents the key finding 
from MRC and NHIR funded research which aimed to: i) Establish the key principles of what 
assessments are needed to inform an only in research (OIR) or Approval with Research (AWR) 
recommendation. ii) Evaluate previous NICE guidance where OIR or AWR recommendations were 
made or considered. iii) Evaluate a range of alternative options to establish the criteria, additional 
information and/or analysis which could be made available to help the assessment needed to inform 
an OIR or AWR recommendation. iv) Provide a series of final recommendations, with the involvement 
of key stakeholders, establishing both the key principles and associated criteria that might guide OIR 
and AWR recommendations, identifying what, if any, additional information or analysis might be 
included in the Technology Appraisal process and how such recommendations might be more likely to 
be implemented through publicly funded and sponsored research.  The key principles and the 
assessments and judgments required are discussed in Section 2.  The sequence of assessment and 
judgment is represented as an algorithm, which can also be summarised as a simple set of explicit 
criteria or a seven point checklist of assessments. The application of the check list of assessment to a 
series of four case studies in Section 3 can inform considerations of whether such assessments can 
be made based on existing information and analysis in current NICE appraisal and in what 
circumstances could additional information and/or analysis be useful.  In Section 4, some of the 
implications that this more explicit assessment of OIR and AWR might have for policy (e.g., NICE 
guidance and drug pricing), the process of appraisal (e.g., greater involvement of research 
commissioners) and methods of appraisal (e.g., should additional information, evidence and analysis 
be required) are drawn together.  
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Executive summary 
 
The general issue of balancing the value of evidence about the performance of a technology and the 
value of access to a technology can be seen as central to a number of policy questions. This research 
was commissioned to inform when NICE should approve health technologies only in research (OIR) 
or with research (AWR).  It has implications for policy (e.g., NICE guidance and drug pricing), the 
process of appraisal (e.g., greater involvement of research commissioners) and methods of appraisal 
(e.g., should additional information, evidence and analysis be required).   However, establishing the 
key principles of what assessments are required and how they might be informed has much wider 
relevance beyond NICE and the UK NHS (e.g., informing the questions posed by coverage with 
evidence development initiatives).   
 
Key principles and assessment needed 
The key principles and assessments needed fall into four broad areas: i) expected cost-effectiveness 
and population net health effects (including benefits, harms and NHS costs); ii) the need for evidence 
and whether the type of research required can be conducted once a technology is approved for 
widespread use; iii) whether there are sources of uncertainty which cannot be resolved by research 
but only over time; and iv) whether there are significant (opportunity) costs which will be committed 
and cannot be recovered once the technology is approved. 
 
Decisions (NICE Guidance) will depend on the combined effect of all these assessments because 
they influence whether the benefits of research are likely to exceed the costs and whether any 
benefits of early approval are greater than withholding approval until additional research is conducted 
or other sources of uncertainty are resolved.  The sequence of assessment and judgments required is 
represented as an algorithm, which can be summarised as a simple seven point checklist.  
 
Each sequence of assessment and decision, leads to different categories of guidance (e.g., Approve, 
AWR, OIR or Reject) for technologies with differing characteristics, indications and target populations. 
DLIIHUHQW µW\SHV¶ RI DSSDUHQWO\ VLPLODU JXLGDQFH can be identified. This illustrates how the same 
category of guidance might be arrived at in different ways, helping to identify the particular 
combination of considerations which might underpin decisions. 
  
The principles suggest that restricting approval to OIR, or making it conditional on research through 
AWR, has wider application than is reflected in previous NICE guidance. For example, OIR may be 
appropriate when a technology is expected to be cost-effective.   Even when research is possible with 
approval, OIR or even Reject maybe appropriate if there are significant irrecoverable costs.  
Therefore, the full range of categories of guidance ought to be considered for technologies, which on 
the balance of existing evidence and current prices, are expected to be cost-effective.  It is only 
approval that can be ruled out if a technology is not expected to be cost-effective, i.e., cost-
effectiveness is a necessary but not sufficient condition for approval and lack of cost-effectiveness is 
neither necessary nor sufficient for rejection.  
 
Distinguishing principles (what assessment are needed) from methods of analysis (how they might be 
informed) allows potentially wide application of principles embodied in the algorithm and associated  
checklist, whist recognising that how the assessment might be made is likely to differ in different 
contexts.  
 
Implications for value based pricing 
Any change in the effective price of the technology, either through patient access schemes (which 
offer some form of discount that reduces NHS costs), or direct price changes (possibly negotiated 
though a value based pricing scheme) will affect the key assessments, leading to different categories 
of guidance.  The price at which a technology is just expected to be cost-effective is commonly 
regarded as its value based price. This describes the threshold price below which Approve rather than 
Reject would be appropriate if OIR or AWR are not available as policy options.  However, if they are 
available there are often a number of relevant price thresholds. Once uncertainty, the need for 
evidence and the impact of irrecoverable costs are recognised, the threshold price that would lead to 
Approval rather than OIR will always be lower than a single value based price based on expected 
cost-effectiveness alone, i.e., disregarding uncertainty in costs and effects. 
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Even if price negotiation becomes possible alongside NICE appraisal, it will be important to retain OIR 
and AWR as available categories of guidance for two reasons: i) there is no guarantee that 
manufacturers will always agree to the lower price below which Approval rather than OIR or AWR 
would be appropriate; and ii) there may be many circumstances when no effective price reduction 
which would make Approval appropriate, e.g., Reject or OIR guidance may be appropriate even if the 
effective price of a technology was zero if there is substantial uncertainty about its effectiveness 
and/or potential for harms.  
 
Incentives for evaluative research 
An explicit assessment of OIR and AWR provides clear signals and an incentive to ensure the type of 
evidence, requiring research that cannot be conducted once approved for NHS use, is available and 
is sufficient at launch (e.g., relative effectiveness and subtle but important differences in side effect 
profiles).  Therefore, a predictable OIR and AWR policy signals what type of evidence is likely to be 
most important at an early stage.  It offers manufacturers a choice, to either: i) accept OIR Guidance 
at a higher price but restricted volume; ii) reduce the effective price to achieve Approval, or AWR 
where that is possible; or iii) conduct the evaluative research at an earlier stage so that additional 
evidence is available at launch.   
 
How the NHS and manufacturers are likely to share the value of evidence might inform whether 
manufacturers should be expected to conduct the research specified in AWR or OIR guidance or 
contribute to the costs of publicly funded research which may ultimately benefit their product.  The 
success of AWR when manufacturers are asked to conduct the research will depend on whether 
appropriate contractual arrangements can be established, i.e., those that can be monitored and 
enforced with credible penalties to ensure agreed research is conducted and in the way intended.   At 
present, NICE does not have a credible mechanism since removing approval of a technology simply 
because recommended research had not been conducted was not considered an ethical or credible 
threat.   
 
The assessments required can be used to consider the value to the NHS of: i) being able to conduct 
research while a technology is approved (value of AWR); ii) making evidence that is needed by the 
NHS available at launch; and iii) being able to acquire evidence more quickly. This can inform 
investments in better data collection, registries or information systems that might make AWR possible.  
The value to the NHS of having access to the evidence needed at launch can inform a range of 
policies, such as early advice, public investment in transitional and evaluative research earlier in the 
development process or other incentives for research and development.  Understanding the 
relationship between the time taken for research to report and the value of the evidence to future 
populations can help to inform: i) investments which might make research findings more quickly 
available; ii) the trade-off implicit in the choice of alternative research designs; and iii) those areas 
where if research is to be undertaken there must be confidence that it can report quickly.    
 
The value of early evidence at launch and AWR can also be considered from the perspective of the 
manufacturer and inform whether they or the NHS might be expected to conduct the research 
needed. In principle, AWR and OIR research could be publicly funded rather than undertaken by 
manufacturers if the costs of research could be recovered directly from manufacturers or indirectly 
through other price discounts.  Since the costs of public research are likely to be substantially lower 
than for manufacturers this might be mutually beneficial in many circumstances; providing appropriate 
support to innovation, while allowing wider access to the data generated and more transparency and 
accountability in the conduct of the research.     
 
How should the assessment be undertaken? 
The order of the assessments in the checklist relate to the sequence of decision nodes that fully 
describe the algorithm in Appendix A. This order of considerations means that all 7 assessments do 
not necessarily need to be made when an earlier judgement can lead directly to guidance.  Therefore, 
one model for an efficient process of assessment would be to consider points 1-5 routinely.  The 
Appraisal Committee would then be in a position to either rule out OIR or AWR and issue guidance in 
the usual way or indicate in the appraisal consultation document (ACD) that OIR or AWR was 
provisionally recommended subject to advice from a research advisory committee and subsequent 
analysis to support an assessment of points 6 and 7 of the checklist prior to FAD.  This model would 
avoid unnecessary analysis and incorporate the judgments of the research community without 
necessarily delaying appraisal.  
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Some assessment of: i) the type of research needed to address the key uncertainties; ii) whether this 
will be regarded as ethical and can be undertaken while the technology is approved for use; iii) 
whether it is likely to be a priority for public funding and be commissioned; and iv) when it is likely to 
report is required.  Although the NICE appraisal process may be well suited to identifying the need for 
evidence, these other critical assessments (the type of research and its priority) are not necessarily 
ones for which NICE and its advisory committees, as currently constituted, have particular expertise.  
Informed judgements and better decisions might be possible through greater involvement of the 
research community.  For example, a research advisory committee could be constituted which could 
consider provisional OIR or AWR guidance (at ACD), making recommendations about the type of 
research needed, its ethics, feasibility and likely priority during the consultation period before final 
appraisal and guidance.  It might also make recommendations about whether research should be 
publicly funded or undertaken by the manufacturer with appropriate contractual arrangements (which 
may require the involvement of DH at some stage).   
 
What additional information and analysis might be required? 
In the assessments, cost-effectiveness was presented as net health effects per patient treated and for 
the population of patients over time.  This provides information in a way that is directly relevant to the 
assessments that need to be made using information generally already available during appraisal. 
  
An early indication of potential importance of irrecoverable costs can be based on their scale relative 
to expected net health effects, the point at which any initial losses are expected to be compensated 
by later gains, whether treatment decisions are reversible and what opportunities to improve health 
might be forgone by a delay to initiating treatment.   
 
The question of whether further research might be worthwhile requires some assessment of: i) how 
uncertain a decision based on expected cost-effectiveness might be; and ii) what the consequences, 
in terms of population NHE, are likely to be if an incorrect decision is made.  This can be made in a 
series of steps each presenting what is already available within current methods of appraisal but in 
ways that can more directly inform the assessment required.  How the consequences of uncertainty 
between as well as within scenarios can be presented and interpreted is also explored.   
 
An assessment of the type of evidence needed requires judgements about:  i) how important 
particular types of parameters (inputs to the economic model) are to estimates of cost and QALY; ii) 
what values these parameters  would have to take to change a decision based on expected cost-
effectiveness; iii) how likely is it that parameters might take such values and iv) what would be the 
consequences if they did, i.e., what might be gained in terms of population NHE if the uncertainty in 
the values of these parameters could be immediately resolved?  The methods of analysis presented 
in Section 3 take these steps in turn; presenting what is available within current appraisal but in ways 
that more directly inform the assessment required.  It is only when assessing the consequences of 
uncertainty associated with particular parameters that additional analysis is required to provide 
quantitative estimates.   
 
The current appraisal process generally already provides the information and much of the analysis 
required to complete all the quantitative assessment reported in Section 3.  However, the information 
required to assess whether other sources of uncertainty will resolve over time requires information 
that is not commonly sort as part of NICE appraisal.  NICE many need to consider how access to this 
type of information can be provided or whether it should extract this type of information itself at an 
earlier stage of appraisal. 
  
Any additional analysis to support a more explicit consideration of OIR and AWR would need to be 
LQFOXGHG LQ PDQXIDFWXUHUV¶ submissions and be reviewed by the ERG.  Although the additional 
analysis itself is limited (most is already required but sometimes presented in different forms), more 
explicit consideration of OIR and AWR and their link to price would make the critique of how 
uncertainty and its consequences has been characterised more important.   An assessment of 
whether the point estimate of cost±effectiveness is reasonable is inevitably a more limited task than 
also assessing whether the uncertainty surrounding that assessment is credible.  Any additional 
burden on ERGs (and manufacturers) might be eased with clear guidance on the details of how 
analysis should be conducted and presented, what common assumptions are deemed reasonable 
and provision of additional information by the Institute as well as only considering points 6 and 7 on 
the checklist after ACD and following advice from a research advisory committee. 
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1. Introduction and overview 
NICE is increasingly making decisions about health technologies close to licence through the single 
technology assessment (STA) process. Inevitably these decisions are being made when the evidence 
base to support these technologies is least mature and when there may be substantial uncertainty 
surrounding their cost-effectiveness, including their effectiveness and potential for harms. In these 
circumstances further evidence may be particularly valuable as it would lead to better decisions which 
improve patient outcome and/or reduce resource costs. However, a decision to approve a technology 
will often have an impact on the prospects of acquiring further evidence to support its use. This is 
because the incentives on manufacturers to conduct research, once positive guidance has been 
issued, are limited. Also the clinical community is unlikely to regard further randomised controlled 
trials (RCTs) to be ethical once positive guidance provides access with a funding mandate. Therefore, 
the decision to approve a technology should account for both the potential benefits of access to a 
cost-effective technology, and the potential costs to future NHS patients in terms of the value of 
evidence that maybe forgone by early adoption. The general issue of balancing the value of evidence 
about the performance of a technology and the value of access to a technology can be seen as 
central to a number of policy questions. Establishing the key principles of what assessments are 
QHHGHG IRU µRQO\ LQ UHVHDUFK¶ 2,5RU µDSSURYDOZLWK UHVHDUFK¶ $:5UHFRPPHQGDWLRQVDVZHOODV
how these assessments should be made, will enable them to be addressed in an explicit and 
transparent manner by the Institute.  
 
The MRC and NIHR methodology programme recently funded the Universities of York and Brunel to 
undertake research to help inform when NICE should recommend the use of health technologies only 
in the context of an appropriately designed programme of evidence development.  This report 
presents the key findings of this research, including i) the key principles of what assessments are 
needed to inform an OIR or AWR recommendation; ii) what additional information and/or analyses 
might help inform the assessments needed; and iii) the implications that this more explicit assessment 
of OIR and AWR might have for policy (e.g., NICE guidance and drug pricing), the process of 
appraisal (e.g., greater involvement of research commissioners) and methods of appraisal (e.g., 
should additional information, evidence and analysis be required) are drawn together.  
 
This report is intended to be accessible to a wide audience; providing intuitive explanations of why 
certain assessments are important and illustrating how they might be informed with examples.  The 
full HTA report[1]  provides substantial additional material, including: i) a critical review of policy, 
practice and literature in this area; ii) a review of NICE Technology Appraisal guidance; iii) a Technical 
Appendix which provides a more formal treatment of why, in principle, each type of assessment is 
important; iv) an Addendum which provides the full details of the analysis undertaken for each of the 
four case studies and v) a series of Technical Notes which deal with some conceptual and analytic 
details which are common to the case studies reported in the Addendum. At each stage this research 
was informed by a diverse and international Advisory Group and the feedback from participants at a 
series of two workshops involving a wide range of key stakeholders. Briefing documents and 
summaries of feedback from workshop participants, is available at:  
http://www.york.ac.uk/che/research/teams/teehta/workshops/only-in-research-workshop/. 
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2. What assessments are needed? 
Since an important objective of the NHS is to improve health outcomes across the population it 
serves, a technology can be regarded as valuable if its approval is expected to increase overall 
population health.  The resources available to the NHS must be regarded as fixed (certainly by NICE), 
so it is not sufficient to establish that a technology is more effective (the health benefits compensate 
for any potential harms) than the alternative interventions available, because approving a more costly 
technology will displace other health care activities that would have otherwise generated 
improvements in health for other patients [2].  Therefore, even if a technology is expected to be more 
effective, the health gained must be compared to the health expected to be forgone elsewhere as a 
consequence of additional NHS costs, i.e. a cost-effective technology will offer positive net health 
effects [3-5].  A social objective of health improvement and an ethical principle that all health impacts 
are of equal significance, whether they accrue to those who might benefit from the technology or other 
NHS patients, is an established starting point for the NICE appraisal process[6].  
 
An assessment of expected cost-effectiveness or net health effects relies on evidence about 
effectiveness, impact on long-term overall health and potential harms, as well as the costs which fall 
on the NHS budget together with some assessment of what health is likely to be forgone as a 
consequence (the cost-effectiveness threshold)[7].  Such assessments are inevitably uncertain and 
without sufficient and good quality evidence, subsequent decisions about the use of technologies will 
also be uncertain. There will be a chance that the resources committed by the approval of a new 
technology may be wasted if the expected positive net health effects are not realised.  Equally, 
rejecting a new technology will risk failing to provide access to a valuable intervention if the net health 
effects prove to be greater than expected.  Therefore, if the social objective is to improve overall 
health for both current and future patients then the need for and value of additional evidence is an 
important consideration when making decisions about the use of technologies[8-10].  This is even 
more critical once it is recognised that the approval of a technology for widespread use might reduce 
the prospects of conducting the type of research that would provide the evidence needed[11].  In 
these circumstances there will be a trade-off between the net health effects for current patients from 
early access to a cost-effective technology and the health benefits for future patients from withholding 
approval until valuable research has been conducted[12].   
 
Since publicly funded research also consumes valuable resources which could have been devoted to 
patient care, or other more valuable research priorities, there are a number of trade-offs which must 
be made. Consideration also needs to be given to uncertain events in the near or distant future, which 
may change the value of the technology and the need for evidence [13].  In addition, implementing a 
decision to approve a new technology is, in general, not a costless activity and may commit resources 
which cannot subsequently be recovered if guidance changes in the future [14-16].  For example, 
there may be costs associated with implementing guidance, training health care professionals, or 
other investment costs associated with equipment and facilities [17-18].  The irrecoverable nature of 
these costs can have a particular influence on a decision to approve a technology if new research is 
likely to report or other events may occur in the future (e.g. launch of new technologies or change in 
the prices of existing technologies).   
 
The primary purpose of this Section is to provide a non-technical exposition, which identifies the key 
principles and assessments which are needed when considering both approval and research 
decisions. Section 2.1 outlines the key principles and the different types of assessment needed and 
how each sequence might lead to different categories of guidance.  Section 2.2 examines how 
guidance might change if there are changes in the effective price of the technology or evidence.  
Section 2.3 highlights the social values and ethical principles associated with OIR and AWR.
1
 
Importantly, we do not presuppose how the assessments ought to be made since there are a range of 
different types of additional information, evidence and methods of analysis which might be useful.  
These alternatives are examined in Section 3 where they are more fully explored and evaluated 
through four case studies.    
 
                                                 
1
 Only in research (OIR) is defined as when a technology is only approved for NHS use (i.e., with the current funding directive) 
within the context of suitable research study.  Approval with research (AWR) refers to approval while research is being 
conducted.  In principle it is when approval is conditional on research being undertaken, which in the context of NICE guidance 
is where the research recommendation is part of the guidance in section 1.  Whether such research will be undertaken and 
successfuly report is examined in later sections. 
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2.1 Key principles and assessments needed 
The key principles and assessments fall into four broad areas: 
 
 i)  Expected cost-effectiveness and population net health effects (including benefits, harms and 
NHS costs).  
ii)  The need for evidence and whether the type of research required can be conducted once a 
technology is approved for widespread use. 
iii)  Whether there are sources of uncertainty which cannot be resolved by research but only over 
time. 
iv)  Whether there are significant (opportunity) costs which will be committed and cannot be 
recovered once the technology is approved. 
 
Guidance will depend on the combined effect of all these assessments because they influence 
whether the benefits of research are likely to exceed the costs and whether any benefits of early 
approval are greater than withholding approval until additional research is conducted or other sources 
of uncertainty are resolved.   
 
This can be complex since these different considerations interact. For example, the effect of 
irrecoverable costs will depend on the need for additional research and will also influence whether 
research is worthwhile. The sequence of assessments, decisions and resulting guidance can be 
represented by a flow chart or algorithm.  Although such a representation is an inevitable 
simplification of the necessary trade-offs it helps to:  i) identify how different guidance might be arrived 
at; ii) indicate the order in which assessments might be made; iii) identify how similar guidance might 
be arrived at through different combinations of considerations; and iv) identify how guidance might 
change (e.g., following a reduction in price), and when it might be reviewed and decisions 
reconsidered. The complete algorithm is complex (reported in Appendix A, Parts I to III), representing 
the sequences of assessments and associated decisions, each leading to a particular category and 
type of guidance.  However, the key decision points in the algorithm, reflecting the main assessments 
and judgments required during appraisal, can be represented as a simple 7 point check list (see 
Section 3.1).  
 
Four broaGFDWHJRULHVRIJXLGDQFHDUHUHSUHVHQWHGZLWKLQWKHDOJRULWKPDQGLQFOXGHµ$SSURYH¶µ$:5¶
µ2,5¶DQGµ5HMHFW¶(DFKRIWKHFDWHJRULHVLVIXUWKHUVXEGLYLGHGDQGQXPEHUHGWRLQGLFDWHWKHGLIIHUHQW
types of apparently similar guidance that could arise from GLIIHUHQW FRQVLGHUDWLRQV  µ'HOD\¶ LV QRW
considered a particularly useful category since NICE always has the opportunity to revise its 
JXLGDQFH LH DGHFLVLRQ WR µ5HMHFW¶FDQDOZD\VEHUHYLVHGEXW LW LVRQO\ZLWKKLQGVLJKW WKDW µ5HMHFW¶
might appear tR EH GHOD\HG µ$SSURYDO¶  7KH GLVWLQFWLRQ PDGH EHWZHHQ DVVHVVPHQW DQG GHFLVLRQ
reflects the NICE appraisal process; first critically evaluate the information, evidence and analysis (an 
assessment), which can then assist the judgements (decisions) which are required in appraisal when 
formulating guidance.  
 
2.1.1 Technologies without significant irrecoverable costs 
Some element of cost which once committed by approval cannot be subsequently recovered is almost 
always present. However, the significance of these types of costs depends on their scale relative to 
expected population net health effects associated with the technology as well as the nature of 
subsequent events (see Sections 2.1.2 and 3.3.2) [19].  In this section we consider the relatively 
simple sequence of assessments and decisions which lead to guidance for those technologies that 
DUHQRWMXGJHGWRKDYHµVLJQLILFDQW¶LUUHFRYHUDEOHFRVWVDVVRFLDWHGZLWKDSSURYDO 
 
i) Technologies expected to be cost-effective 
The sequence of assessments and decisions, which ultimately leads to guidance, starts with cost-
effectiveness and the expected impact on population net health effects (see Figure 2.1), i.e., where 
existing NICE appraisal currently ends.  This is an assessment of expected cost-effectiveness, i.e., 
µRQDYHUDJH¶EDVHGRQWKHEDOance of the evidence and analysis currently available.  It will include an 
assessment of effectiveness, potential for harms as well as NHS costs[6].  Any assessment may be 
uncertain with the scale and consequences of uncertainty assessed subsequently when considering 
the need for additional evidence.  The sequence of assessments and decisions is illustrated in Figure 
2.1.  This demonstrates that an assessment of cost-effectiveness is only a first step and does not 
itself, inevitably lead to particular category of guidance.  For example, a technology which might on  
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Figure 2.1  Technologies expected to be cost-effective 
 
balance be expected to be cost-effective might nevertheless receive OIR guidance if the additional 
evidence that is needed cannot be acquired if the technology is approved.   
 
Need for evidence 
Some initial assessment of the need for further evidence and a decision about whether further 
UHVHDUFKPLJKWEHSRWHQWLDOO\ ZRUWKZKLOH LV LPSRUWDQW EHFDXVHD µ1R¶DW WKLVSRLQW FDQDYRLG IXUWKHU
and complex assessments, e.g. a technology offering substantial and well-evidenced health benefits 
at modest additional cost is likely to exhibit little uncertainty about whether the expected population 
net health effects are positive.  In these circumstances, further research may not even be potentially 
worthwhile (the opportunity costs of conducting this research exceed its potential value) so guidance 
Assessment
Decision
Guidance
Key
#
Assess need for evidence
Does 
more research seem 
worthwhile?
What type of evidence is needed?
Is the 
research possible with
Approval?
Yes
Yes
Yes
No
No
No
Assess irrecoverable  costs
Are there 
significant irrecoverable 
costs?
Assess cost-effectiveness and
population net health effects
Is it cost-effective?
AWR
Re-assess the benefits and costs 
of further research
Are the
benefits of research greater 
than the costs? 
Yes
No
Approve
Go to 
Appendix A
Part II 
No
Assess the benefits and costs of 
early approval
Are the
benefits of approval greater 
than the costs? 
Approve OIR
Yes
No
Re-assess the benefits and costs 
of further research
Are the
benefits of research greater 
than the costs? 
Yes
No
Approve Approve
Yes
1 1 12 3 4
Go to Figure 2.2
Will research be conducted?
When will it be available?
How much will be resolved? 
Assess other sources of uncertainty
Will this 
Uncertainty be resolved
over time? 
Yes
No
Will research be conducted?
When will it be available?
How much will be resolved? 
Assess other sources of uncertainty
Will this 
Uncertainty be resolved
over time? 
Yes
No
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to approve could be issued on the basis of existing evidence and at the current price of the 
technology (e.g. Approve
 4
 in Figure 2.1).  If additional evidence is needed and further research might 
be worthwhile, then further assessments and decisions are required before guidance can be issued.  
Critically, some assessment is required of the type of evidence that is needed and whether or not the 
type of research required to provide it is likely to be conducted if approval is granted [20]. 
 
Research is possible with approval 
If research is possible with approval, some further assessment of the long term benefits of research is 
required, including: i) the likelihood that the type of research needed will be commissioned by 
research funders or conducted by manufacturers; ii) how long until such research will recruit and 
successfully report; and iii) how much of the uncertainty might be resolved by the type of research 
which is likely to be undertaken[11].   An assessment of other sources of uncertainty which will only 
resolve over time is also needed, e.g., changes in prices or the launch of new technologies[13].  
These sources of uncertainty will influence the future benefits of research that could be undertaken as 
part of AWR.  For example, even if the current benefits of research, which might be very likely to be 
undertaken are considerable, if the price of the technology is likely to fall significantly before or shortly 
after the research reports (or if future innovation makes the current technology obsolete) then the 
future benefits, once the research reports, might be very limited.  In these circumstances it might be 
better to approve (rather than AWR) and reconsider whether and what type of research is needed at a 
later date once these uncertainties have resolved.  The judgement of whether the long term benefits 
of research are likely to exceed its expected costs determines guidance, with AWR 
1 
and Approve 
1
 in 
Figure 2GHSHQGHQWRQµ<HV¶DQGµ1R¶UHVSHFWLYHO\ 
 
Research is not possible with approval 
The type of research needed may not be possible once a technology is approved for widespread NHS 
use, e.g. randomised clinical trials (RCTs) may not be possible once the technology is approved (due 
to ethical concerns, recruitment problems and limited incentives for manufacturers). In these 
circumstances the expected benefits of approval for current patients must be balanced against the 
benefits to future patients of withholding approval to allow the research to be conducted.  Initially, the 
same assessment of the long term value of the type of research that might be conducted if approval is 
withheld is still required.  Similarly, the impact of other sources of uncertainty on the longer term 
benefits of research is also needed.  If the benefits of research are judged to be less than the costs 
(i.e. research is not worthwhile anyway), the technology can be approved based on current evidence 
and prices (Approve 
3
 in Figure 2.1).  However, judging that research is worthwhile at this point is not 
sufficient for OIR guidance.  In addition, an assessment of whether the benefits of early approval 
(expected population net benefits for current patients) are greater than the opportunity costs (the net 
benefit of the evidence likely to be forgone for future patients as a consequence of approval) is 
required.  If the expected benefits of early approval are judged to be less than the opportunity costs 
then OIR
 
guidance would be appropriate (OIR
 1
 in Figure 2.1).  Alternatively, if the expected benefits 
of early access for current patients are judged to be greater than the opportunity costs for future 
patients, then approval would be appropriate (Approve
 2
 in Figure 2.1).  All these assessments, 
including the benefits of early approval and the value of evidence will change if the effective price of 
the technology is reduced (see section 2.2.1). 
 
ii) Technologies not expected to be cost-effective 
A technology which is not expected to be cost-effective will, on balance, impose negative population 
net health effects if it is approved. These negative net health effects can arise because the technology 
may not be effective, the potential for harm exceeds any benefits and/or the additional NHS costs are 
not justified by the magnitude of the expected health benefits offered. In these circumstances 
Approval can be ruled out, but which of the other categories of Guidance might be appropriate will 
depend on subsequent assessments and decisions (see Figure 2.2).  
 
Need for evidence 
Any assessment will be uncertain, so it remains possible that a technology which is not expected to 
be cost-effective on the balance of existing evidence might offer positive net health effects. Therefore, 
the scale and consequences of this uncertainty must be considered to make an initial assessment of 
the need for additional evidence and whether additional research might, in principle, be worthwhile.  If 
it is not, then the technology can be rejected based on existing evidence and its current price (Reject
 4
 
in Figure 2.2).  Alternatively, if further research might be worthwhile then an additional assessment is 
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required of whether the type of evidence and research that is needed can be conducted without 
approval.  
 
Research is possible without approval 
Generally, most types of research (including RCTs) will be possible without approval.  Further 
assessment of the longer term benefits of the type of research which is likely to be conducted, and 
when it might report is required, including the impact of other sources of uncertainty which will resolve 
over time.  If, following this re-assessment, the expected benefits of research are judged to exceed 
the associated costs then OIR would be appropriate (OIR 
2
 in Figure 2.2).  Alternatively, if the costs of 
research are likely to exceed the longer term expected benefits then the technology should be 
rejected at this point (Reject
 1
 in Figure 2.2).   
 
Research is not possible without approval 
In some circumstances it is possible that certain types of evidence might only be acquired, or be more 
easily acquired (more quickly and at lower cost), once a technology is in widespread use, e.g., linking 
surrogates (specific to the technology) to longer term health outcomes, longer term and/or rare 
adverse events, greater understanding of learning and incremental improvements in the use of a 
technology, or identifying the particular types of patients that might benefit most[21].  In this less 
common situation, where the type of research needed is not possible (or is significantly more costly) 
without approval, the same assessment of the longer term benefits of research is required.  If further 
research is judged not to be worthwhile following this re-assessment, the technology can be rejected 
(Reject
 2
 in Figure 2.2).  Alternatively, if research is judged worthwhile an additional assessment of 
whether the benefits of approval exceed the costs is required. In this case, approval, which would 
make the research possible, will impose opportunity costs (negative expected population net health 
effects of widespread use of a cost-ineffective technology).  The key question is whether the net 
EHQHILWVRIWKHUHVHDUFKH[FHHGWKHVHRSSRUWXQLW\FRVWV,IWKH\GRQ¶WWKHQWKHWHFKQRORJ\VKRXOGEH
rejected even though research, had it been possible without approval, would have been worthwhile 
(Reject
 3
 in Figure 2.2).  Alternatively, if the net benefits of research more than offset the opportunity 
costs then AWR would be appropriate even though the technology is expected to be cost-ineffective 
(AWR
 2
 in Figure 2.2).  
 
Therefore, AWR guidance for technologies not expected to be cost-effective is certainly possible but 
only appropriate in certain circumstances, where: i) the type of research needed is not possible 
without approval; ii) the long term benefits of the research are likely to exceed the expected costs and 
iii) the additional net benefits of such research exceeds the opportunity costs of approving a cost-
ineffective technology.  More commonly, research might be possible but more costly without approval.  
In these circumstances, AWR guidance could only be considered if the additional costs of research 
without approval exceed the opportunity costs of approving a cost-ineffective technology.    
 
2.1.2 Technologies with significant irrecoverable costs 
Irrecoverable costs are those which once committed cannot be recovered should guidance be revised 
at a later date.  In most NICE appraisals these are included in the expected (per patient) cost of a 
technology. However, rarely is their potential additional impact explored when future events, such as 
research reporting or other sources of uncertainty resolving, might mean that guidance will be revised 
in the near or distant future [14, 16].  These types of cost are commonly thought of as capital 
expenditure on equipment or facilities which have a long life expectancy. They might also include the 
resources required to implement guidance, to train staff to use a new health technology or a period of 
µOHDUQLQJ¶ZKHUHKHDOWKRXWFRPHVDUHORZHU$OWKRXJKWKHVHFRVWVDUHLQFXUUHGµXS-IURQW¶WKH\WHQGWR
be included in NICE assessments as if they are paid per patient treated over the life time of the 
equipment or facility. This common assumption will have no effect, so long as guidance is certain not 
to change during this period.  However, if it is possible that initial approval might be withdrawn at 
some point, then, although future patients will no longer use the technology, these upfront costs 
cannot be recovered (see Section 2.3.2).  Therefore, the possibility that Approve or AWR might be 
reconsidered after research reports, for example, and the impact this would have on expected costs 
needs to be considered, i.e. it may be better to withhold approval and avoid commitment of resources 
until the uncertainty is resolved.    
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Figure 2.2  Technologies not expected to be cost-effective 
 
However, irrecoverable costs may be much more common.  Even in the absence of capital 
LQYHVWPHQW LQ HTXLSPHQW DQG IDFLOLWLHV PRVW QHZ WHFKQRORJLHV RIIHU D µULVN\ LQYHVWPHQW SURILOH¶ IRU
each patient treated. Generally they impose initial per patient treatment costs which exceed the 
immediate health benefits (see Section 3.3.1).  These irrecoverable treatment costs are only offset by 
cost savings and health benefits in the longer run, i.e. initially negative net health effects (losses) are 
only gradually compensated by later positive ones (gains). Therefore, a technology expected to be 
cost-effective may be H[SHFWHGWRµEUHDNHYHQ¶ZKHQDFFXPXODWHGµJDLQV¶FRPSHQVDWHHDUOLHUµORVVHV¶ 
after some considerable time. If guidance is likely to change it is possible that initial losses will not be 
compensated by later gains and the expected additional net health effects will not be realised[19].  
7KLVW\SHRIµLQYHVWPHQWSURILOH¶EHFRPHVVLJQLILFDnt (has some influence on a decision to approval) if 
Yes
No
Assess cost-effectiveness and
population net benefits
Is it cost-effective?
Is the 
research possible without
Approval?
Will research be conducted?
When will it be available?
How much will be resolved? 
Assess other sources of uncertainty
Will this 
Uncertainty be resolved
over time? 
Yes
Yes
No
No
Does 
more research seem 
worthwhile?
Yes
No
What type of evidence is needed?
Assess investment and reversal costs
Are there 
significant investment or 
reversal costs? 
No
OIR
Re-assess the benefits and costs 
of further research
Are the
benefits of research greater 
than the costs? 
Yes
No
Reject AWR Reject
Re-assess the benefits and costs 
of further research
Yes
No
Assess the benefits and costs of 
early approval
Are the
benefits of approval greater 
than the costs? 
Yes
No
Assess other sources of uncertainty
Will this 
Uncertainty be resolved
over time? 
Yes
No
Are the
benefits of research greater 
than the costs? 
Go to
Appendix A 
Part III
Yes
Reject
Will research be conducted?
When will it be available?
How much will be resolved? 
2 1 2 2 4
3
Go to
Figure 2.1 
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the decision to treat a presenting patient can be delayed until uncertainty is resolved (e.g. research 
reports or other events occur) because the commitment of irrecoverable opportunity costs (negative 
net health effects) can be avoided (see Section 3.3.2). In these circumstances, OIR or reject avoids 
this commitment and preserves the option to approve the technology at a later date when its purchase 
E\WKH1+6UHSUHVHQWVDµOHVVULVN\LQYHVWPHQW¶[19].2 
 
Although aspects of irrecoverable cost are almost always present, their potential significance also 
depends on their scale relative to expected population net health effects of the technology.  Critically, 
their impact depends on the chance that guidance will be revised in the near or distant future due to 
new evidence becoming available or changes in prices and technologies. The full algorithm becomes 
more complex (see Parts II and III of the Algorithm in Appendix A), so here we focus on the key 
differences from section 2.1.1. 
 
(i) Technologies expected to be cost-effective 
The presence of irrecoverable costs associated with a technology that is expected to be cost-effective 
will only LQIOXHQFH JXLGDQFH DQG EH UHJDUGHG DV µVLJQLILFDQW¶ LI WKHUH DUH IXWXUH HYHQWV UHVHDUFK
reporting or other sources of uncertainty resolving) which might change guidance. For example, if 
research is possible with approval and is expected to be worthwhile, AWR does not necessarily follow 
as previously (e.g., see AWR
 1
 in Figure 2.1) because the impact of irrecoverable cost must also be 
considered. Now OIR may be more appropriate than AWR (e.g., the choice between OIR
 4
 or AWR
 4
 
in Part II), even though the research would be possible with approval, because OIR avoids the 
commitment of irrecoverable costs until the results of research are known.  This is especially so when 
there are also other sources of uncertainty which might resolve while the research is being conducted 
in so far as they increase the chance that guidance will be revised (e.g., OIR
 3
 or AWR
 3
 in Part II). 
 
If research is not possible with approval, but is expected to be worthwhile, then OIR will be 
appropriate if the opportunity costs of early approval are judged to exceed the benefits (e.g. OIR
 6
 
rather than Approve
 9
 in Part II).  These opportunity costs will now also include the impact of 
irrecoverable costs when guidance might be changed as well as the value of evidence that will be 
forgone by early approval. Therefore, irrecoverable costs will tend to make OIR rather than approval 
more likely, particularly when there are other sources of uncertainty which might resolve while the 
research is being conducted (e.g., OIR
 5
 rather than Approve
 7
 in Part II).  
 
If research is not judged worthwhile, approval does not necessarily follow as previously (e.g., 
Approve
1,3,4 
in Part I).  Now the technology should only be approved if there are no other sources of 
uncertainty.  If there are other sources of uncertainty, then an assessment of the benefits and costs of 
early approval is needed which takes account of irrecoverable costs and the risk that guidance might 
change in the future. Therefore, reject rather than approval is possible, even though a technology is 
expected to be cost-effective, because the decision to commit the irrecoverable costs can be 
reconsidered once the other sources of uncertainty have resolved (e.g., Reject 
5, 6
 in Part II).  
 
(ii) Technologies not expected to be cost-effective 
The presence of irrecoverable costs for technologies not expected to be cost-effective does not 
change the categories of guidance, or how they might be arrived at.  However, it does mean that 
reject is more likely to be appropriate than AWR when research is not possible without approval (see 
AWR
 5
 in Appendix A, Part III).  This is because a decision to reject, although it may be revised to 
approve, generally does not commit irrecoverable costs.  Although there may be resources 
associated with making sure subsequent approval is properly implemented, these costs are properly 
considered as an irrecoverable cost associated with approval (rather than a reversal cost of reject). 
There may be circumstances when implementing guidance to reject a technology also requires 
resources if it has already diffused into clinical practice. If these are significant they should be taken 
into account in the same way as other irrecoverable costs, tending to make AWR more likely to be 
appropriate.   
 
 
 
  
                                                 
2
 When considering OIR rather than Approve in these circumstances full account must be taken of the irreversible effects of 
withholding access to the technology for the population of patients that could have benefited from it, e.g., some may not survive 
to benefit from the results of the research or disease may have progressed so that the expected health benefits are lower.     
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No significant irrecoverable costs Significant irrecoverable costs
Research Not 
needed
Possible without 
approval
Not possible without 
approval
Not 
needed
Possible without 
approval
Not possible without 
approval
Benefits > 
costs
Benefits 
< costs
Benefits > 
costs
Benefits < 
costs
Benefits > 
costs
Benefits 
< costs
Benefits > 
costs
Benefits < 
costs
Approve (0)
AWR (2) 2 5
OIR (2) 2 7
Reject (8) 4 1 2 3 11 8 9 10
2.1.3 Different types of guidance 
(DFKVHTXHQFHRIDVVHVVPHQWDQGGHFLVLRQOHDGVWRGLIIHUHQWFDWHJRULHVDQGµW\SHV¶RIJXLGDQFHIRU
WHFKQRORJLHVZLWKGLIIHULQJFKDUDFWHULVWLFVLQGLFDWLRQVDQGWDUJHWSRSXODWLRQV7KHGLIIHUHQWµW\SHV¶RI
guidance illustrates how similar guidance might be arrived at in different ways, helping to identify the 
particular combination of considerations which might underpin guidance; contributing to the 
transparency of the appraisal process. The possible categories and types of guidance are 
summarised in Table 2.1 where the numbers in the body of the table refer to the numbered guidance 
in Figures 2.1 and 2.2 and the full algorithm in Appendix A. 
 
The categories of guidance available to NICE have wider application than is reflected in previous 
guidance [1]. For example, there are 5 different types of OIR which may be appropriate when a 
technology is expected to be cost-effective. Indeed, OIR maybe appropriate even when research is 
possible with approval if there are significant irrecoverable costs.  AWR can only be considered when 
research is possible with approval but Reject remains a possibility even for a cost-effective technology 
if there are irrecoverable costs.  Therefore, the full range of categories of guidance (OIR and Reject 
as well as AWR and Approve) ought to be considered for technologies, which on the balance of 
existing evidence and current prices, are expected to be cost-effective.   
 
Table 2.1a Different types of guidance (technologies expected to be cost-effective) 
 
Table 2.1b Different types of guidance (technologies not expected to be cost-effective) 
 
It is only approval that can be ruled out if a technology is not expected to be cost-effective, i.e., cost-
effectiveness is necessary but not sufficient for approval but lack of cost-effectiveness is neither 
necessary nor sufficient for rejection.  Although likely to be uncommon, there are circumstances when 
AWR may be appropriate even when a technology is not expected to be cost-effective.  More 
commonly the choice of appropriate guidance will be either Reject or OIR.  Importantly, which 
category of guidance will be appropriate only partly depends on an assessment of expected cost-
effectiveness and hence this assessment should only be regarded as an initial step in formulating 
guidance.  Guidance will depend on a number of other key assessments which include: i) the need for 
evidence; ii) whether the type of research required is possible with approval; iii) the expected longer 
term benefits and costs of the type of research likely to be conducted; iv) the impact of other sources 
of uncertainty which will resolve over time; and v) the significance of any irrecoverable costs.   
No significant irrecoverable costs Significant irrecoverable costs
Research Not 
needed
Possible with approval Not possible with approval Not 
needed
Possible with approval Not possible with approval
Benefits > 
costs
Benefits 
< costs
Benefits > 
costs
Benefits < 
costs
Benefits > 
costs
Benefits 
< costs
Benefits > 
costs
Benefits < 
costs
Approve (12) 4 1 2 3 11, 12 5,6 7, 9 8, 10
AWR (3) 1 3,4
OIR (5) 1 3,4 5,6
Reject (3) 7 5 6
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2.2 Changes in prices and evidence 
The type of guidance that might be appropriate will be influenced by changes in the effective price of 
the technology, the type of evidence available to support its use and whether further research is likely 
to be undertaken, either by manufacturers or research commissioners, as a result of OIR or AWR 
guidance.   
 
2.2.1 Changes in effective prices 
Any change in the effective price of the technology, either through patient access schemes (which 
offer some form of discount that reduces NHS costs), or direct price changes (possibly negotiated 
though a future value based pricing scheme) will affect key assessments and decisions, leading to 
GLIIHUHQWµSDWKV¶WKURXJKWKHDOJRULWKPFRQVHTXHQWO\FKDQJLQJWKHFDWHJRU\RIJXLGDQFHWKDWZRXOGEH
appropriate [22-23].  For example, provisional OIR guidance for a technology, which is expected to be 
cost-effective, might be revised to Approve with a sufficient price reduction because the benefits of 
early approval will be greater and uncertainty about its cost-effectiveness and therefore the value of 
additional evidence will tend to be lower (e.g., from OIR
 1
 to Approve
 2
 in Figure 2.1).
3
  Similarly, AWR 
might be revised to Approve if the benefits of early approval now exceed the value of additional 
evidence (e.g., from AWR
 1
 to Approve
 2
 in Figure 2.1). 
4
  
 
Equally, provisional guidance to reject a technology which is not expected to be cost-effective, might 
be revised to OIR if the reduction in price was not sufficient to make it cost-effective, but made the 
costs associated with a reject decision more uncertain and hence made the value of research 
worthwhile (e.g., from Reject 
1
 to OIR 
2
, in Figure 2.2).
5
  If the reduction in price was greater and was 
sufficient to make the technology cost-effective, then guidance might be revised to AWR, if research 
remains worthwhile and possible with approval (e.g., from Reject
 1
 or OIR
 2
 in Figure 2.2  to AWR
 1
 in 
Figure 3.1). Clearly, with an even greater reduction in price, it is possible that provisional guidance to 
reject could be altered to early approval (e.g., Approve
1
 in Figure 2.1).  Even if research is not 
possible with approval a sufficient reduction in price could also lead to early approval (e.g., from 
Reject
 1
 or OIR
 2
 in Figure 2.2  to Approve
 2, 3, 4
 in Figure 2.1).
6
  
 
Therefore, consideration of the effect of price changes on OIR and AWR is needed when assessing 
the potential impact of patient access schemes and more direct price negotiation through value based 
pricing [5, 24-26].  It should be noted that, all other things equal, the presence of significant 
irrecoverable costs will require greater reductions in effective price to achieve the same revision to a 
more permissive category of guidance.  
 
Threshold prices and VBP 
The price at which the technology would just be expected to be cost-effective is commonly regarded 
as the value based price for the technology, i.e., the maximum price the NHS can afford to pay 
without imposing negative health effects [5,27].  This single price describes the threshold for 
Approve/Reject decisions and would be the relevant threshold price or VBP where: i) OIR or AWR 
guidance is not available to the decision maker or there is no uncertainty in cost-effectiveness; or ii) 
the research, if needed, can be conducted with approval; and iii) there are no irrecoverable costs.  In 
all other circumstances there are a number of other threshold (value based) prices.  The number and 
value of these thresholds depends on the characteristics of the technology (the path through the 
algorithm), however, the threshold prices for Approval will always be lower than the single 
Approve/Reject price based on expected cost-effectiveness. 
                                                 
3
 If the primary source of uncertainty is whether the technology is effective (i.e., whether there any health benefits compared to 
LW¶VFRPSDUDWRUVDQGLIVRGRWKH\FRPSHQVDWHIRUDQ\SRWHQWLDOKDUPVWKHQUHGXFWLRQVLQSULFHZLOOKDYHDPRUHOLPLWHGLPpact 
on uncertainty and the need for evidence compared to where there might be confidence of improved overall effectiveness but 
there is uncertainty about whether then magnitude of benefit is sufficient to justify the NHS costs. In all cases a reduction in 
price will increase the expected benefits of early approval for current patients so it will change the final assessment (where it is 
relevant) of whether the benefits of approval are greater than the opportunity costs (see point 7 in the check list in Section 3.1). 
4
 See footnote 3. 
5
 Any reduction in price will make a cost-ineffective technology less so (the net health effects, even if remaining negative will be 
greater, so a decision to reject will be more uncertain. However, there are limits to the effects of price reductions since even at 
a zero price the technology might not be cost-effective and/or further research still may be required, because there is no 
confidence that it is effective (harms may not be compensated by benefits) and/or it imposes other non acquisition costs on the 
NHS   
6
 The price reduction required for these different types of approval will generally be greater if research is not possible with 
approval.  However, these also differ. Approve
 2
 would require the greatest reduction in price and  Approve
 4
 would require the 
lowest.  However, any price reduction (price greater than zero) may not make approval appropriate in these circumstances.   
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For example, for a technology (without significant irrecoverable cost) where research could be 
conducted without approval but not with it, there are two threshold prices: i) the threshold which would 
move guidance from Reject to OIR; and ii) from OIR to Approve.  The latter will always be lower than 
the price which would move the same technology from Reject to Approve if OIR was excluded from 
consideration.  If a technology also imposes significant irrecoverable costs then there may be more 
threshold prices.  For example, when research can be conducted with or without approval there are 
three thresholds: i) Reject to OIR; ii) OIR to AWR; and iii) AWR to Approve.  Again the latter will be 
lower than the Approve/Reject threshold for the same technology if AWR was excluded from 
consideration.  All other things equal the presence of irrecoverable costs will tend to reduce the 
threshold price for Approval. 
 
Even in circumstances where price negotiation becomes possible alongside NICE appraisal, it will be 
important to retain the OIR and AWR as available categories of guidance for two reasons.  Firstly, 
there is no guarantee that manufacturers will always agree to the lower price threshold which would 
lead to Approval rather than OIR or AWR.  Secondly, and possibly more importantly there may be 
many circumstances when there is no effective price reduction which would make Approval 
appropriate.
7
  For example, Reject or OIR Guidance may still be appropriate even if the effective price 
of a technology was zero if there is substantial uncertainty about its effectiveness and/or potential for 
harms.  
 
2.2.2 Incentives for evaluative research 
These threshold prices represent the maximum effective price at launch to achieve a particular 
category of guidance when the results of any subsequent research, which might be undertaken, are 
not yet known.  This is different to the type of flexible pricing agreements, described in the current 
PPRS, where price is revised once the research reports and the results are known; increasing prices 
if the evidence suggests that benefits were originally underestimated, or reducing it if they were 
overestimated [28].  This means that manufacturers retain an incentive to conduct further evaluative 
research if they believe that there are additional benefits which could not be evidenced at launch.  
Publicly funded evaluative research, however, will still be required where these incentives are 
insufficient and especially in those cases where the original evidence is likely to have overestimated 
the benefits or underestimated the potential for harm.  However, it should be noted that linking 
effective prices to the results of publicly funded research means that the NHS will only benefit (realise 
the value of evidence) if the results lead to a lower price or more restrictive Guidance because the 
technology is found not be cost-effective (thus avoiding the losses associated with negative net health 
effects).  Manufactures will, however, be able to appropriate the value of evidence when it suggests 
that net health effects were originally underestimated through higher prices within a flexible or value 
based pricing scheme.  Even under current arrangements this value can be appropriated when the 
technology is reappraised by NICE (e.g., any PAS could be withdrawn or less restrictive positive 
Guidance issued).  Consideration of how the NHS and manufacturers are likely to share the value of 
evidence might inform whether manufacturers should be expected to conduct the research specified 
in AWR or OIR guidance, as long as incentive consistent contractual arrangements can be set in 
place, i.e., those that can be monitored and enforced with credible penalties to ensure any agreed 
research is conducted in the way intended.  Alternatively, manufactures might be expected to make 
some contribution to the costs of publicly funded research which may ultimately benefit their product 
(see Section 3.6).   
 
It is important that policy provides (or at least does not undermine) appropriate incentives for 
manufacturers to conduct the type of research needed to support NICE guidance at launch. The use 
of OIR and AWR Guidance, as described in the Algorithm provides clear signals and incentives.  For 
example, the threshold price for Reject/OIR will be higher than for OIR/Approve but guidance 
restricted to OIR offers very limited NHS volumes to manufacturers.  This provides a strong incentive 
to ensure the type of evidence, which would require research that cannot be conducted once 
approved for NHS use, is available and is sufficient at launch (e.g., relative effectiveness and subtle 
but important differences in side effect profiles).  Therefore, a predictable OIR and AWR policy signals 
what type of evidence is likely to be most important at an early stage.   
 
The use of OIR and AWR, as described in the Algorithm, offers manufacturers a choice, to either: i) 
accept OIR Guidance at a higher price; ii) reduce the effective price to achieve Approval, where that is 
                                                 
7
 See footnotes 1, 3 and 5. 
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possible; or iii) conduct the evaluative research at an earlier stage so that cost-effectiveness is not 
uncertain at launch.  Other things being equal, those new technologies which are supported at NICE 
Appraisal by more, better quality and relevant evidence will be more likely to be approved (rather than 
OIR or AWR) and at higher prices than those that are not, because additional evidence is less likely to 
be needed.  Therefore, greater consideration of OIR and AWR will tend to reward those 
manufacturers who have invested in good quality and relevant evidence, with earlier approval of their 
technology.  In addition, the effect of price on OIR and AWR recommendations suggests that those 
technologies supported by better evidence will tend to get approval at higher effective prices, 
providing an incentive for manufacturers to invest in the type of evidence needed earlier in the 
development process.  
 
2.2.3 Assessing the prospects of research 
When considering OIR or AWR guidance there must be some assessment of: i) the type of research 
needed to address the key uncertainties; ii) whether this will be regarded as ethical and can be 
undertaken while the technology is approved for use; iii) whether it is likely to be a priority for public 
funding and be commissioned; and iv) when it is likely to report.   
 
Although the NICE appraisal process may be well suited to identifying the need for evidence when 
assessing cost-effectiveness, these other critical assessments are not necessarily ones for which 
NICE and its advisory committees, as currently constituted, have particular expertise, not least 
because they reflect the decisions of those responsible for research design, prioritisation and 
commissioning [29-30].  Without sufficient coordination between these communities there is a danger 
that OIR or AWR could be issued when either the type of research required would not be regarded as 
ethical or feasible, or not of sufficient priority compared to other competing research needs.  Since 
publicly funded research is also budget constrained, it is perfectly possible that research which might 
be valuable from a wider NHS perspective might nevertheless not be a priority if other more valuable 
research might be displaced.  This might be a particular concern if there is a possibility that the 
research could be undertaken by the manufacturer rather than displacing other research without a 
commercial interest.  Therefore, a decision of whether OIR or AWR research should be undertaken by 
the manufacturer or through publicly funded research is one that NICE cannot properly take alone.   
 
Although some judgement about how the research community might respond to OIR or AWR 
recommendations when NICE is formulating guidance is clearly possible, more informed judgements 
and better decisions might be possible through greater involvement of the research community.  For 
example, a research advisory committee could be constituted which could consider provisional OIR or 
AWR guidance, making recommendations about the type of research needed, its ethics, feasibility 
and likely priority during the consultation period before final appraisal and guidance.  It might also 
make recommendations about whether research should be publicly funded or undertaken by the 
manufacturer with appropriate contractual arrangements.  There are of course many different ways in 
which greater coordination might be achieved. However, since some of the assessments that NICE 
must make in formulating OIR or AWR guidance are, in fact, research decisions which fall outside its 
remit, it would seem sensible to draw on the expertise of those involved in, and responsible for, these 
types of research decisions to help make these assessments. 
 
2.3 Social value judgements and ethical principles8 
The question considered here is whether OIR and AWR recommendations are consistent with the 
values and principles that currently underpin standard NICE practices[6].  It is not in the remit of this 
report to evaluate those underpinning values and principles themselves.  In particular, it is assumed 
here that the health budget is necessarily limited; also that, generally speaking ± and whilst also 
taking into account issues of need and equity as discussed in the NICE values statements[31] ± 
scarce health care resources ought to be broadly allocated so as to maximise health outcomes of the 
population as a whole; and hence that treatments that benefit one group of patients will be funded at 
an opportunity cost to other patients.  Given these assumptions, the emphasis in this discussion is on 
new ethical challenges created by OIR and AWR decisions[32], as distinct from issues shared with 
standard NICE recommendations. 
                                                 
8
 We would like to thank Steve Holland and Tony Hope, as ethics advisors to the project, and Iain Chalmers, as a member of 
the Advisory Group, for their overall contribution, but especially to this section of the report.  We would like to acknowledge that 
they have substantially revised the original version of this discussion of ethical principles presented in the briefing documents to 
the first workshop (http://www.york.ac.uk/che/research/teams/teehta/workshops/only-in-research-workshop/).  
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2.3.1 Issues common to OIR and AWR recommendations 
Generally speaking, the benefit of attaching research conditions to NICE recommendations is an 
improved evidence base for resource allocation decisions in the future.  The beneficiaries of the 
research are members of future populations who will profit from better informed allocation decisions.  
But achieving this benefit can impose significant opportunity costs on current patients.  This is true for 
both some OIR decisions and some AWR decisions.   
 
Two issues need to be carefully considered.  The first is what is meant by present and future 
populations.  The present population comprises people whose interests are directly affected by a 
NICE recommendation (for example, they receive an innovative treatment approved by NICE, or 
benefit from resources made available because NICE rejects an innovative treatment).  Future 
populations comprise people whose interests are indirectly affected by decisions, in particular by the 
subsequent research results that improve the evidence base for future NICE judgements.  It is 
important to note that sometimes individuals in the present population may benefit from the research 
condition because they will also be members of the future population (e.g., those with chronic 
conditions).  This will not be true of all, so the issue of balancing the interests of some individuals in 
the present population against some individuals in future populations remains.   
 
The second issue is, under what conditions the present population is disadvantaged by the research 
condition compared with the alternative recommendation that NICE might make.  This will depend 
both on what the alternative recommendation would be, and on the level of current evidence about 
cost-effectiveness for the intervention.  In judging whether it is right to make a research conditional 
recommendation there are four key issues to consider: i) what is the likely effect on the current 
population of a research conditional recommendation compared with whichever would be the 
alternative recommendation; ii) what is the likely benefit to the future population from the research; iii) 
what proportion of individuals in the present population is also likely to be in the future population; and 
iv) how should we weigh up the disadvantages to individuals in the present population in relation to 
the advantages to individuals in the future population (some of whom will be in the present 
population)?  The first three of these considerations are essentially empirical issues and NICE will 
have to assess, possibly informed by the information and analysis presented in Section 3.  The fourth 
issue is an ethical one.  Do the interests of members of future populations count?  If so, how are they 
to be weighed against the interests of members of the present population?  Which set of interests 
should prevail?   
 
One way of addressing this question is to consider how radical a departure from current NICE values, 
principles and practices it would be to accord weight to the interests of future populations.  Arguably, 
doing so would not be much of a departure at all.  For one thing, taking the interests of future 
populations into account is consistent with fundamental NICE assumptions about how to make 
allocation decisions.  Specifically, NICE takes the identifiability of patients who benefit from an 
intervention to be irrelevant.  So, the fact that beneficiaries of putting a research condition on approval 
are unidentifiable because they will only exist in the future does not seem to add anything to 
considerations NICE currently recognises and weighs.  Similarly, some consideration of future 
populations is already implicit in standard NICE judgements.  It would seem, then, that decisions that 
WDNHLQWRDFFRXQWWKHLQWHUHVWVRIIXWXUHSRSXODWLRQVDUHFRQVLVWHQWZLWK1,&(¶VYDOXHVSULQFLSOHVDQG
practices.   
 
2.3.2 Issues specific to OIR recommendations 
To tease out the ethical issues raised by OIR it will be useful to construct an illustrative case.  
Suppose NICE appraises a new treatment for which there is strong evidence of effectiveness ± that 
is, the innovation is known to be clinically superior to existing treatments ± but there is considerable 
uncertainty over its cost-effectiveness.  Whether the new treatment would prove to be cost-effective 
depends not only on how expensive it is, but also on how much health benefit it would produce.  NICE 
might consider an OIR judgement in these circumstances in order to establish more exactly the size 
of benefit which, in turn, is deemed necessary to establish cost-effectiveness.  For example, NICE 
could approve the new treatment only in the context of an RCT comprising two trial arms, the 
innovative treatment arm and the standard treatment arm.  Crucially, on this decision, patients outside 
the trial, and participants randomly allocated to the standard arm of the RCT, would be denied what is 
almost certainly the better treatment for their condition.  This scenario creates a number of important 
ethical issues. 
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i) Equipoise 
A criterion established in research ethics for the legitimacy of carrying out an RCT is that there is 
substantial uncertainty as to which of the treatments being compared ± that is, an innovative 
treatment and a standard treatment ± is the more effective.  This is sometimes known as the principle 
of equipoise.  The principle is meant to capture the intuition that no one ± patient or participant ± 
should knowingly be offered less than the best treatment for their condition.  OIR decisions may be 
made when there is such substantial uncertainty.  In such cases, the principle is respected and ethical 
review of the relevant research poses only issues already considered as standard by researchers and 
research ethics committees.  However, in the situation envisaged here, NICE is considering 
recommending OIR when the intervention in question is clearly superior to alternatives, but the 
degree of its superiority remains uncertain, and so its cost-effectiveness is uncertain.  Evidently, in 
this scenario researchers are not in equipoise about the relative effectiveness of the two interventions.  
The substantial uncertainty relates to whether the more effective, but more expensive, treatment 
produces sufficient extra benefit compared with alternatives for it to be recommended by NICE; but it 
does not relate to whether it is more effective.  Is it permissible to flout the principle of equipoise 
concerning effectiveness and give an OIR decision in such circumstances? 
 
An intuitive response is that patients are harmed by an OIR decision that denies them the best known 
treatment for their condition in the interests of research.  Theoretical support for this intuition is 
provided by the well known principle of maleficence: above all, do no harm.  But harm based 
objections to OIR are inconclusive for two reasons.  First, the concept of harm is contested.  The 
WKUHH PDLQ DFFRXQWV GHILQH VRPHRQH¶V EHLQJ KDUPHG E\ FRQWUDVW ZLWK UHVSHFWLYHO\ L WKHLU VWDWH
before the harm was perpetrated, (ii) the state they could have been in, and (iii) a minimum or 
baseline standard of wellbeing.  When clinicians and patients are not sufficiently uncertain about the 
effectiveness of the treatments being compared, patients denied a better treatment by OIR are 
harmed according to the definition of harm based on (ii), because they are put in a worse state than 
was possible.  But the patients are not harmed on the basis of the construal of harm based on (i) and 
(iii) because they will receive the standard NHS treatment (that is, the same treatment as patients 
who do not take part in the research, or as all NHS patients would have received had NICE rejected 
WKH WUHDWPHQW UDWKHU WKDQDSSURYHG LW µRQO\ LQ UHVHDUFK¶ 6RKDUPEDVHGREMHFWLRQV WR2,5DUHDV
inconclusive as the current debate on the definition of harm.  Second, harm based objections to OIR 
are question-begging, in the following way.  Suppose there were a consensus on the nature of harm 
and, further, on the fact that OIR without equipoise harms some patients.  To conclude that this 
makes OIR impermissible is to assume that the harm in question outweighs the benefits of research.  
But this is precisely what is in dispute, namely, the relative values of the benefits of early approval and 
of further research.  Given NICE values, principles and practices, it is perfectly feasible to conclude 
that the harm perpetrated by OIR is justified by the benefits to future patients of a better evidence 
base for allocation decisions. 
 
There are more fruitful lines of thought about OIR without equipoise.  First, the principle of equipoise 
itself is under considerable strain from pressures that have nothing to do with OIR and AWR.  For 
example, it has been argued that it is permissible to trial less than the best known treatment for HIV in 
developing countries unable to afford the most effective interventions[33].  It is generally accepted 
that, as a result of such pressures, the principle of equipoise needs to be refashioned by addressing 
WKH TXHVWLRQ µDERXW ZKDW PXVW UHVHDUFKHUV EH XQFHUWDLQ"¶  7KH WUDGLWLRQDO UHTXLUHPHQW LV WKDW
researchers must be in equipoise about the best known treatment; but, for bodies such as NICE the 
answer maybe that, the really salient uncertainty is not about effectiveness per se, but about the 
extent of effectiveness, and hence about the cost-effectiveness.  Since, in the scenario envisaged 
here, the OIR recommendation is made precisely because of uncertainty about the extent of 
effectiveness, the refashioned principle of equipoise is respected.  This argument is part of a larger 
research ethics question about what is required in terms of equipoise, so will not be addressed here.  
In the present context, there is a more important practical consideration to emphasise.  An RCT 
required by OIR would have to be reviewed by a Research Ethics Committee (REC); RECs are used 
to requiring traditional equipoise (that is, substantial uncertainty about which is the better treatment).  
So, if RECs are to approve research of the kind considered here, where researchers are not in 
equipoise as traditionally understood, they will have to be informed of, and agree with, the rationale 
for conducting these distinctive studies. 
Another way of looking at this issue is as follows.  If NICE does not advise OIR then it must advise 
either to approve or not to approve.  If it advises not approve, because, although the treatment is 
clinically the more effective it is judged not to be sufficiently effective to be cost-effective, then no one 
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receives this treatment on the NHS.  Compared with that situation, an OIR decision would benefit 
some patients, and harm none.  If NICE were to approve the treatment then all patients for whom the 
treatment is relevant would benefit, and, by comparison, an OIR decision would harm some patients 
(on definition (ii) above).  But other patients might be unfairly harmed by the decision to approve 
because if, in fact, the treatment is not sufficiently effective to be cost-effective, the opportunity costs 
of providing the treatment outweigh the benefits.  And because the relevant research is not being 
carried out, it will remain unknown that this is the case.  In any event it would be problematic for a 
REC to refuse to sanction the type of research we are considering once NICE had made an OIR 
decision because that condemns both present and future populations to receive only the inferior 
treatment, whether or not the more effective treatment is sufficiently effective. 
 
ii) Coercion 
Another research ethics principle is that competent patients have the right to consent to participate in, 
DQG ZLWKGUDZ IURP D UHVHDUFK SURMHFW  7KLV LV DNLQ WR WKH FRPSHWHQW SDWLHQW¶V ULJKW WR FRQVHQW WR
treatment, both rights being underpinned by the principle of respect for individual autonomy.  
Conversely, it is impermissible to coerce competent patients to participate in research.  In OIR, the 
patient can have the more effective intervention on the NHS only if she agrees to be a research 
participant.  Does this coerce patients to participate in the trial? 
 
Any research study involving care clinically superior to that available on the NHS provides an 
incentive to enrol in that study.  Whether such an incentive constitutes coercion depends on whether 
the patient is being presented with a threat, as opposed to an offer to participate.  Importantly, in the 
sort of OIR decisions under discussion, patients who do not receive the new treatment ± that is, 
patients not enrolled on the trial, and participants not allocated to the new treatment arm ± will receive 
standard NHS care.  Arguably, then, the trial provides an offer, namely, the chance of receiving better 
than standard treatment, as opposed to any threat, and so does not constitute coercion.  To clarify, 
suppose, by contrast, that patients will be refused access to normal NHS care unless they agree to 
participate in the research; this would present a threat as opposed to an offer to participate, and 
thereby constitute coercion.  In sum, providing that standard research ethics requirements are met ± 
principally, that prospective participants are properly informed about, and give valid consent to 
participate in, the trial; and that if they do not participate their access to standard NHS care will not be 
affected ± the research required by OIR is not coercive and respects the principle of individual 
autonomy because patients retain the right to choose whether or not to accept the chance of better 
than standard treatment offered by the trial. 
 
iii) Equity 
A further ethical worry is that OIR decisions result in inequity because participants in one arm of the 
trial would receive better treatment than both those in the other arm of, and those not enrolled on, the 
trial.  Here it is important to distinguish two versions of this inequity charge.  The first is that it is 
always wrong to allocate health resources in ways that will lead to an unequal distribution of health 
benefits.  This version of the worry is bound to founder in this context beFDXVH1,&(¶VYDOXHVDQG
principles, which are taken as granted here, entail that limited health resources will and should be 
allocated so as to maximise benefit to the whole population, even at the expense of subgroups within 
it.  So, the fact that OIR resXOWVLQDQXQHTXDOGLVWULEXWLRQRIKHDOWKEHQHILWVFDQEHMXVWLILHGRQ1,&(¶V
assumptions if the research will provide sufficiently valuable evidence. 
 
A second version of this inequity worry is more involved.  Under OIR, some patients will receive the 
intervention (paid for on the NHS) and others will not, simply because the former happen to be in a 
position to participate in the research.  Many of the factors that determine access to a formal 
treatment comparison ± such as geographical location, socio-economic status, and patient 
characteristics ± should not be considered relevant to whether patients have access to the treatments 
being studied.  This is a significant consideration but one that can be overridden.  Specifically, in 
deciding whether or not an OIR recommendation is ethically acceptable, a judgement would need to 
be made as to whether the benefits of such a recommendation outweigh the lack of equity (although, 
in fulfilling an OIR recommendation, it would always be important to minimise such inequities). 
 
 
2.3.3 Issues specific to AWR recommendations 
AWR raises a problem about consent, which is related to the discussion of coercion, above; AWR 
also raises a further distinctive issue centring on the likelihood of the research taking place. 
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i) Consent 
Two established principles of medical ethics are that competent patients have a right to confidentiality 
(including a right to decide whether to disclose their personal medical information) and a right to 
informed consent to participate in research (including a right to decline to participate in, or to decide to 
withdraw from, a study with impunity).  It might be argued that some AWR decisions transgress these 
rights because the required research may involve collecting data on long-term outcomes and adverse 
events on patient registries (or some similar system of epidemiological data collection) without the 
explicit consent of patients.  This argument is unsound.  IQPDQ\FDVHVDSDWLHQW¶VGHFLVLRQWRKDYHD
treatment that was approved with research can be taken to imply consent to the relevant data 
collection.  Furthermore, although it comprises personal medical information, the data collected will be 
anonymous, ameliorating concerns about breaching confidentiality.  Finally, the data collection 
required by an AWR decision is equivalent to current large-scale epidemiological research studies 
that are considered ethically permissible.  So, concerning consent, and on grounds of consistency, 
AWR should be permitted as long as the research is conducted to the ethical standards normally 
required of data collection of this sort. 
 
ii) Incentivising research 
A further ethical issue raised specifically by AWR recommendations involves the mechanisms used to 
JLYH µWHHWK¶ WR WKH UHVHDUFK UHTXLUHPHQWKRZZLOO1,&(HQVXUH that the relevant research is carried 
out?  One option has a subtle ethical dimension.  NICE might threaten that, if the research is not 
satisfactorily completed (for example, by the relevant manufacturing company), the intervention would 
cease to be made available on the NHS.  Although this would provide an incentive for the 
manufacturer to carry out the research, it raises the following problem.  At time T(1) the AWR decision 
is made; that is, the intervention is funded by the NHS.  Suppose that, at time T(2) ± the time when 
NICE reconsiders the decision to fund ± the research has not been carried out (or has failed to 
provide any further relevant information).  At time T(2) NICE will be making a decision on exactly the 
same information and evidence as at T(1).  In this case, it would seem that NICE should make exactly 
the same decision, namely, to provide the intervention on the NHS.  But if NICE decides to reject the 
intervention (on the grounds, for example, that the manufacturer had failed to carry out the relevant 
research) then patients could claim unfairness.  The unfairness is that they were provided with the 
treatment on the NHS between T(1) and T(2) but not after T(2) even though the evidence is exactly 
the same in both situations. 
 
This is a serious problem for AWR decisions but it is not essentially an ethical matter.  Rather, it is 
another point at which the ethical discussion segues into practical considerations familiar from other 
sections of this report.  Specifically, various problems will result from the research condition put on an 
AWR decision not being met, and not just the ethical quandary outlined here.  This situation should be 
avoided by doing everything reasonable to ensure that the relevant research will be conducted and 
reported (e.g. contractual arrangements with penalties that would be deemed ethical and therefore 
credible).  Without credible mechanisms to ensure research conditions are met, AWR with research 
undertaken by manufacturers may not be feasible.  If the research is not a sufficient priority for public 
funding then OIR may be the only credible alternative to Approve or Reject, i.e., the ethical issue 
described here has a direct influence on when OIR rather than AWR might be considered.  
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3. Informing the assessments 
How the sequence of assessments required might be made is examined by take existing methods of 
NICE appraisal as an accepted starting point and focus instead on what additional information and 
analysis might feasibly be included in appraisal and how it might be interpreted to inform the 
judgements required.  We also consider whether this type of additional information and analysis might 
be routinely required within appraisal or only conducted when OIR or AWR appear to be particularly 
relevant, e.g., more sophisticated additional analysis might only be required if it is established that 
further research might in principle be worthwhile.   
 
3.1 A checklist of assessment 
The sequence of assessment and judgement required can be summarised as a simple checklist that 
could be considered by the TAR team/ERG and Appraisal Committee as well as manufacturers during 
appraisal.  There are two checklists: one for technologies expected to be cost-effective (Table 3.1a) 
and one for those not expected to be cost-effective based on the balance of existing evidence and 
current effective prices (Table 3.1b).  The only difference between the checklists is at point 4,  where, 
for technologies expected to be cost-effective, the judgment is whether the research is possible with 
approval whereas a judgment of whether research is possible without approval is required if the 
technology is not expected to be cost-effective. 
 
Each of the seven points on the checklist relate to the sequence of decision nodes that fully describe 
the algorithm in Appendix A.  Therefore, each sequence of Yes or No judgements defines a single 
pathway leading to a particular type and category of guidance (the type and category of guidance 
implied by each combination is described in Table B1, Appendix B).  However, all 7 assessments do 
not necessarily need to be undertaken because sometimes earlier decisions will lead directly to 
JXLGDQFH)RUH[DPSOHDµ1R¶DWSRLQWDOZD\VOHDGVGLUHFWO\WRHLWKHU$SSURYHRU5HMHFWDQGKHQFH
further assessment is unnecessaU\  6LPLODUO\ D µ1R¶ DW SRLQW  DOVR OHDGV GLUHFWO\ WR $SSURYH RU
Reject if there are no significant irrecoverable costs associated with the technology (See Table B1, 
Appendix B). 
 
Table 3.1a Checklist for OIR and AWR (technologies expected to be cost-effective) 
 
  
Point Assessment Judgement
Yes                 No
1 Is it cost-effective? Yes
2 Are there significant irrecoverable costs?
3 Does more research seem worthwhile?
4 Is the research possible with approval?
5 Will other sources of uncertainty resolve over time?
6 Are the benefits of research greater than the costs? 
7 Are the benefits of approval greater than the costs? 
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Table 3.1b Checklist for OIR and AWR (technologies not expected to be cost-effective) 
 
 
3.2 Introduction to case studies 
The objective of developing a series of case studies was to:  i) demonstrate how the key principles 
and assessments might inform the development of guidance through application of the checklist and 
ii) establish whether existing methods of appraisal are sufficient, or whether (and when) additional 
information and analysis might be useful.   
 
3.2.1 Selection of case studies 
Case studies were selected to ensure that the full range of possible analysis was feasible within the 
time and resource constraints of this research project, while exploring situations where OIR or AWR 
might be particularly relevant and challenging.  Therefore, de novo or substantial re-analysis of 
original assessments is not possible.  Nor would it be necessary or informative, since one of the 
objectives is to explore what additional information and analysis might be required.  For this reason 
candidate case studies which met the following feasibility criteria were considered: i) the economic 
analysis was regarded as a suitable basis for developing guidance; ii) an analysis of uncertainty in 
expected cost-effectiveness (PSA as specified in the NICE reference case) was conducted and iii) 
ready access was available to the electronic versions of the models which informed guidance. 
 
There are three groups of potential case studies where the key principles and assessment described 
above might have influenced guidance: i) where OIR or AWR was included in the FAD; ii) where OIR 
or AWR was considered during appraisal (e.g., included in ACD or section 6 of TA Guidance); and iii) 
where OIR or AWR was not obviously considered at any stage. As well as examples of AWR for 
technologies expected to be cost-effective and OIR for those not, there are also a number of 
particularly interesting ways in which guidance might be influenced by these additional considerations.  
For technologies expected to be cost-effective these include: i) OIR rather than Approve when 
research is not possible with approval; and ii) OIR or even Reject rather than AWR or Approve even if 
research is possible with approval because there are significant irrecoverable costs. 
 
To fully explore the implications of these principles and assessments it is useful to select case studies 
which reflect the range of possible and interesting characteristics.  For example, i) technologies which 
are and are not expected to be cost-effective; ii) with and without irrecoverable costs; iii) where other 
sources of uncertainty are and are not present; iv) where the research needed is and is not possible 
with approval; v) consideration of non pharmaceutical interventions and vi) those appraised under the 
MTA and STA process. Four studies will not be enough to demonstrate the full range of possible 
combinations of interesting characteristics or illustrate all of the potential impacts of interest.  
Point Assessment Judgement
Yes                 No
1 Is it cost-effective? No
2 Are there significant irrecoverable costs?
3 Does more research seem worthwhile?
4 Is the research possible without approval?
5 Will other sources of uncertainty resolve over time?
6 Are the benefits of research greater than the costs? 
7 Are the benefits of approval greater than the costs? 
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Therefore, in selecting case studies there was a need to balance feasibility and coverage of those 
characteristics of greatest interest.   
 
3.2.2 Background to the case studies 
The following four case studies were selected.  A range of additional information was sought, and 
further analysis conducted, to inform the sequence of assessment and judgements required when 
completing the OIR/AWR checklist in Tables 3.1a and 3.1b.  
 
i) Enhanced External Counterpulsation for chronic stable angina (EECP) 
The NIHR-HTA programme identified EECP as an important topic and commissioned a short report to 
examine the clinical effectiveness and cost-effectiveness of EECP as an adjunct to standard therapy 
in patients with chronic stable angina.  Although the topic was not ultimately considered by NICE it 
was commissioned in the same way and with the same resources as other assessment reports which 
inform NICE guidance.  The assessment followed the NICE reference case and is consistent with the 
type of analysis which would have been required in an MTA appraisal.  Like other MTA TARs it was 
published in full as a HTA monograph [19, 34]. 
 
EECP is a non-invasive procedure (adjunct to standard therapy) used to provide symptomatic relief 
from stable angina.  The analysis compares EECP to standard therapy alone.  RCT evidence 
suggests an improvement in HRQL with EECP at 12 months. To characterise the uncertainty 
associated with possible longer durations of treatment effect, formal elicitation of expert clinical 
judgement was undertaken.  This provided an estimate of the probability, with uncertainty, of 
continuing to respond to treatment with EECP in subsequent years. 
 
The possible pathways through the algorithm that EECP illustrate are reported in Figure B1 in 
Appendix B.  In this case study the new technology is expected to be cost-effective but with potentially 
significant irrecoverable costs.  These irrecoverable costs include both: i) long lived costs associated 
with the purchase of equipment;  and ii) large initial per patient treatment costs, combined with a 
chronic condition where a decision not to treat a particular patient with EECP can be changed at a 
later date (decisions are not irreversible) when research reports or other events occur.  Consequently 
these irrecoverable costs might influence the category of guidance, e.g., OIR rather than Approve.  
EECP also provides an opportunity to explore the impact of research design (length of follow-up) on 
guidance and to examine the potential role of elicitation rather than extreme scenarios to characterise 
uncertainty.  
 
ii) Clopidogrel for the management of patients with non-ST-segment elevation acute 
coronary syndromes (CLOP) 
The use of CLOP (for up to 12 months) in combination with low dose aspirin was recommended by 
NICE following an MTA appraisal for patients with non-ST-segment-elevation acute coronary 
syndrome (NSTE-ACS) presenting with a moderate to high risk of ischemic events (TA80 in 2004 and 
updated in 2010 in CG94).  In TA80 the Appraisal Committee considered 12 month or lifetime 
treatment with CLOP, but recommended research to inform optimal treatment duration.  The original 
Assessment Report had included an analysis of shorter treatment durations (<12 months) and the 
NIHR-HTA programme subsequently commissioned additional re-analysis based on this original work 
to inform this research recommendation in 2009.  This case study is based on the re-analysis of TA80 
undertaken in 2009 which included standard therapy compared to 4 alternative treatment durations of 
clopidogrel of 1, 3, 6, and 12 months.  Importantly, while the case study is based on the later re-
analysis of TA80, the analysis considered here has been undertaken from the standpoint of the 
original TA80 appraisal asking, what assessments might have been made at that time when standard 
therapy was low dose aspirin? 
 
The research recommendation was made in Section 6 of TA80, therefore, CLOP is not an example of 
AWR at FAD, but where AWR was considered during appraisal.  The possible pathways through the 
algorithm that the CLOP case study illustrates are reported in Figure B2 in Appendix B, where the 
new technology is expected to be cost-effective and with no significant irrecoverable costs.  The 
CLOP case study also illustrates a number of other important characteristics, including: (i) the impact 
that other sources of uncertainty (price change following patent expiry) can have on the value of 
further research; (ii) the interpretation of analyses where there are multiple alternatives; and (ii) the 
use of scenarios to represent alternative but credible assumptions.  
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iii) Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 
11 years (OMAL) 
The use of OMAL for the treatment of severe persistent allergic asthma in children aged 6 to 11 years 
was not recommended by NICE following an STA appraisal (TA201 in 2010).   The analysis 
compared OMAL as an add-on to standard care versus standard care alone. The primary analysis 
was based on a pre-specified severe asthma population within an international, multicentre, placebo-
controlled RCT.  However, a high-risk subgroup within this population (recent hospitalisation for an 
asthma exacerbation) was also identified post-hoc.  
 
Omalizumab was not found to be cost-effective in either the severe or severe/high risk populations.  
However, an RCT was recommended comparing OMAL to oral corticosteroids (OCS) in children to 
establish reduction in OCS use.  This was made in Section 6 of TA201; therefore, OMAL is not an 
example of OIR at FAD, but where OIR was considered during appraisal.  The possible pathways 
through the algorithm that OMAL illustrate are reported in Figure B3 in Appendix B, where the new 
technology is not expected to be cost-effective and with no significant irrecoverable costs.  OMAL also 
illustrates assessment in small patient populations (rare disease) for the assessment and how sub 
group analysis can be considered.  
 
iv) Etanercept, infliximab and adalimumab for patients with active and progressive 
Psoriatic arthritis (PsA) 
Following an MTA appraisal (TA199 in 2010), the use of biologic treatment with etanercept, infliximab 
and adalimumab was recommended by NICE for patients with active and progressive PsA and who 
have an inadequate response to standard treatment, including two conventional disease-modifying 
antirheumatic drugs (DMARDs).  However, the guidance also recommended that treatment should 
start with the least expensive biologic, taking account of dose, route of administration and price. This 
guidance updated an earlier MTA appraisal in 2006 (TA104), which had recommended etanercept 
and restricted guidance on the use of infliximab to only those patients shown to be either intolerant or 
contraindicated to etanercept.
9
   The analysis in this case study is from the standpoint of TA199, using 
the updated model which included new evidence and adalimumab as an additional comparator.  At 
this point NICE guidance recommended etanercept, so the first question posed in the checklist can be 
interpreted as, are the other technologies available (infliximab, adalimumab or palliative care) 
expected to be cost-effective compared to etanercept?   
 
In Section 6 of TA199 the importance of data on long term outcomes and adverse events from patient 
registries was highlighted.  Therefore, PsA is not an example of AWR at FAD, but where AWR was 
considered during appraisal.  The possible pathways through the algorithm that PsA illustrate are 
reported in Figure B4 in Appendix B.  In this case study the alternatives to etanercept are not 
expected to be cost-effective. However, etanercept as well as infliximab and adalimumab have 
potentially significant irrecoverable costs because of the high initial per patient treatment costs, 
combined with a chronic condition where treatment decisions are not irreversible.  PsA, like EECP, 
also provides an opportunity to examine the potential role of elicitation in the appraisal process.  
 
3.3 Is it cost-effective and what are the risks? 
The judgements made at points 1 and 2 of the checklist are critical because, although neither leads 
directly to a particular category of guidance, they do determine the subsequent path that might be 
taken, sometimes avoiding further and potentially complex assessments.  For example, the absence 
of significant irrecoverable costs means that only 4 out of the 12 possible pathways require all 7 
assessments to be made (see Table B1, Appendix B).  
  
                                                 
9
 TA104 included an AWR recommendation in the ACD but this was removed in the FAD.  The recommended research was to 
enter patients into the BSR register, on the grounds of the possibility of severe side effects and little information on the use of 
these agents beyond the duration of RCTs 
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3.3.1 Point 1 - Is it expected to be cost-effective? 
The sequence of assessments starts with cost-effectiveness and the expected impact on population 
net health effects. i.e., at the following point in the algorithm: 
 
 
 
 
This requires an assessment of expected cost-effectiveness based on the balance of the evidence 
and analysis currently available.  Methods to estimate expected cost-effectiveness are well 
established within the NICE appraisal process and are extensively described in the Guide to Methods 
of Technology Appraisal[6]. 
10
   Commonly, expected cost-effectiveness is summarised and presented 
using incremental cost-effectiveness ratios (ICERs).  Equivalently, but more usefully in this context, 
cost-effectiveness can be expressed in terms of expected net health effects (NHE), which can be 
expressed per patient treated or for a population of patients.  This is especially important when later 
assessments require a comparison of benefits to current or future patient populations and when 
assessing the significance of irrecoverable costs (see Section 3.3.2).  All the information required to 
express expected cost-effectiveness in these ways is already available during appraisal.   
 
i)  Cost-effectiveness at the patient level  
Estimates of the expected NHS costs and QALYs for each patient treated over an appropriate time 
horizon - WKHµSDWLHQWWLPHKRUL]RQ¶11 - can be summarised as an ICER, which must be compared to a 
cost-effectiveness threshold to judge cost-effectiveness. Equivalently, this can be expressed as the 
per patient NHE of each intervention, i.e., the difference between any health gained and health 
forgone elsewhere. 
12
 
 
Technologies expected to be cost-effective 
The results for EECP are summarised in Table 3.2a. There are only two alternatives (EECP and 
standard care, so only one ICER.  EECP is just expected to be cost-effective at a threshold of 
£20,000 per QALY.
13
  Consequently the NHE of EECP are greater than standard care but the 
difference per patient treated (the incremental NHE) is small. 
 
 
 
 
 
 
                                                 
10
 In each case-study the estimates of expected costs and QALYs reported and used throughout are the mean costs and 
QALYs derived from probabilistic analysis using Monte Carlo simulation.  The costs and QALYs from a deterministic analysis 
will be incorrect unless the model is multi-linear with independent parameters.  
11
 This is the time horizon over which costs and benefits are likely to differ for an individual patient (commonly termed the model 
time horizon). In some circumstances (e.g., where there is a mortality effect) this will be the lifetime of the patient.  Expected 
costs and QALYs each period are the expectations (means) from the results of probabilistic analysis. All future costs and QALY 
(per patient or population) are discounted at 3.5% throughout. 
12
 The expected per patient net health effects for each intervention (i) is the difference between the expected health (QALYs) 
with the intervention (hi) and the health likely to be forgone elsewhere are a consequence of the costs of the intervention (ci), 
which requires an estimate of the cost-effectiveness threshold (k).  Therefore, the per patient expected net health effects of 
each intervention (NHEi = hi - ci/k) can be expressed using the same information required to present the more familiar ICERs.  
It can also be expressed in terms of the NHS resources required to generate the NHEi (k.hi-ci) The intervention which is 
expected to be cost-effective is the one with the highest expected net health effects. This is entirely equivalent to drawing 
conclusions about cost-effectiveness based on ICERs but has many advantages once an assessment of uncertainty and its 
consequences is required.  It is also needed when considering the impact of irrecoverable costs and is especially important 
when decisions require a trade-off to be made between benefits to current or future patients. 
13
 All analysis has been conducted at the upper and lower bound for the range NICE has adopted for the threshold.  However, 
unless otherwise stated results in the text relate to a threshold of £20,000 per QALY. 
Yes
No
Assess cost-effectiveness and
population net health effects
Is it cost-effective?
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Table 3.2a Expected cost-effectiveness of EECP per patient treated 
 Cost-effectiveness threshold at: 
£20,000 per QALY £30,000 per QALY 
Treatment Costs QALYs ICER NHE, QALY (£) Incr NHE, 
QALY (£) 
NHE, QALY (£) Incr NHE, 
QALY (£) 
EECP £4,744 7.6045 £19,391 7.3673 
(147,346) 
0.0074 
(£149) 
7.4464 
(£223,391) 
0.0865 
(£2,595) 
Std - 7.3598 - 7.3598 
(147,197) 
- 7.3598 
(£220,795) 
- 
 
 
,WLVDOVRLPSRUWDQWWRFRQVLGHUKRZ1+(DFFXPXODWHRYHUWLPHRUWKHµLQYHVWPHQWSURILOH¶SHUSDWLHQW
treated with EECP.  Figure 3.1a illustrates the cumulative incremental NHE over the patient time 
horizon.  The initial per patient costs of EECP are high and are far in excess of the immediate health 
benefits in the initial period of treatment.  These negative NHE are gradually offset by positive NHE in 
later periods.  In this case, it is only after 14 years that the initial losses are compensated by later 
JDLQVLH((&3LVQRWH[SHFWHGWRµEUHDNHYHQ¶XQWLO\HDUVIURPLQLWLDOWUHDWPHQW,WLVRQO\EH\RQG
30 years that the modest incremental NHE reported in Table 3.2a are eventually achieved.
14
 
 
 
 
Figure 3.1a  Cumulative incremental NHE of EECP over the patient time horizon   
 
 
Multiple alternatives  
Similar analysis can be conducted when there are more than two alternatives.   For example, in CLOP 
four treatment durations as well as current NHS treatment (aspirin alone) were considered at the time 
of TA80.  The results in Table 3.2b indicate that 12 month treatment with CLOP is expected to be 
cost-effective, although the difference in NHE between 12 and 6 months treatment duration is small. 
 
 
 
                                                 
14
 7KHWLPHDWZKLFKLQLWLDOO\QHJDWLYH1+(DUHH[SHFWHGWREHRIIVHWE\FXPXODWLQJSRVLWLYH1+(RUWKHµEUHDNHYHQ¶SRLQWLV
only an indicator or proxy for the scale of irrecoverable opportunity costs, e.g., the scale of initial loses as well as the breakeven 
point also matters.  The presence of even very large irrecoverable opportunity costs does not necessarily mean they are 
significant and will influence guidance.  That will depend on whether treatment decisions are reversible and the impact of 
withholding treatment for patients who might receive it (see Section 2.2.2 and 3.3.2), as well as whether uncertainty is likely to 
resolve (research reporting or other sources of uncertainty resolving.   
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Table 3.2b Expected cost-effectiveness of CLOP per patient treated 
 Cost-effectiveness threshold at: 
£20,000 per QALY £30,000 per QALY 
Treatment Costs QALYs ICER 
(£/QALY) 
NHE, QALY (£) NHE, QALY (£) 
clop12 £20,127 8.122 18,663 7.115 (142,307) 7.451 (223,525) 
clop6 £19,860 8.107 10,477 7.114 (142,288) 7.445 (223,362) 
clop3 £19,712 8.093 9,396 7.108 (142,154) 7.436 (223,087) 
clop1 £19,598 8.081 4,961 7.101 (142,025) 7.428 (222,837) 
NHS £19,502 8.062 - 7.087 (141,734) 7.412 (222,353) 
 
7KH µLQYHVWPHQW SURILOH¶ of CLOP, per patient treated, is illustrated in Figure 3.1b.  The per patient 
costs of CLOP are in excess of the health benefits during the period of treatment.  These negative 
NHE are eventually offset by positive NHE in later periods.  In this case, it is only after 5 years that 12 
PRQWKVRI WUHDWPHQWZLWK&/23 µEUHDNVHYHQ¶DJDLQVWFXUUHQW1+6FDUHDQG LW LVQRWXQWLO\HDUV
that it is better than a shorter treatment duration of 6 months.  Notice that shorter treatment durations 
with CLOP offer a much OHVVµULVN\SURILOH¶HJWKHµEUHDNHYHQ¶SRLQWIRURQHPRQWKRIWUHDWPHQWLV
years against current NHS care. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1b  Cumulative incremental NHE of CLOP over the patient time horizon   
 
Technologies not expected to be cost-effective 
The ICER for omalizumab in Table 3.2c is greater than the threshold so it is not expected to be cost-
effective compared to standard care alone.  Consequently the incremental NHE of OMAL is negative. 
 
Table 3.2c Expected cost-effectiveness of OMAL per patient treated 
 Cost-effectiveness threshold at: 
£20,000 per QALY £30,000 per QALY 
Treatment Costs QALY ICER 
(£/QALY) 
NHE, QALY (£) Incr 
NHE, 
QALY (£) 
NHE, QALY (£) Incr NHE, 
QALY (£) 
Omal + Std £94,992 
 
16.64 
 
93,844 
 
11.8861 
(237,721) 
-2.1908 
(-43,815) 
13.4693 (404,078) -1.2627 
(-37,882) 
Std £39,310 16.04 - 14.0768 
(281,536) 
- 14.7320 (441,960) - 
 
7KHSHUSDWLHQWµLQYHVWPHQWSURILOH¶IRU OMAL is illustrated in Figure 3.1c and shows that it is always 
expected to offer negative NHE compared to standard care over the entire patient time horizon, i.e., 
the high costs of treatment are never compensated by future health gains.  In this example, the initial 
treatment costs with OMAL continue for 10 years (10 years is assumed to represent the duration a 
patient would continue to receive treatment with OMAL) with health effects predominately while on 
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WUHDWPHQW7KHUHIRUH20$/LVQRWVRPXFKDµULVN\SXUFKDVH¶EXWRQHWKDWLVVLPply not cost-effective 
at its current price. 
 
 
Figure 3.1c  Cumulative incremental NHE of OMAL over the patient time horizon   
 
Multiple alternatives  
PsA offers an example where the alternatives to the treatment already recommended by NICE 
(etanercept at the time of TA199 ) are not expected to be cost-effective, i.e., the results in Table 3.2d 
indicate that etanercept is expected to be cost-effective.  Notice that although adalimumab is less 
effective than etanercept it is also cheaper.  However, the resources savings it offers do not 
compensate for the reduction in health benefits. 
 
Table 3.2d Expected cost-effectiveness in PsA per patient treated 
 Cost-effectiveness threshold at: 
£20,000 per QALY £30,000 per QALY 
Treatment Costs QALYs ICER 
(£/QALY) 
NHE, QALY (£) NHE, QALY (£) 
1: Infliximab £90,343 7.269 60,965 2.752 (5504) 4.258 (8516) 
2: Etanercept £78,150 7.069 17,733 3.161 (6322) 4.464 (8928) 
3: Adalimumab £72,972 6.777 14,622 3.129 (6258) 4.345 (8690) 
4: Palliative care £51,800 5.329 - 2.739 (5478) 3.602 (7204) 
 
&RQVHTXHQWO\ WKH µLQYHVWPHQW SURILOH¶ RI WKH DOWHUQDWLYHV WR etanercept, illustrated in Figure 3.1d, 
differs in appearance.  However, all the biologic treatments for PsA have high initial costs which are 
only gradually compensated by later health benefits.  All three ultimately offer positive NHE compared 
WR SDOOLDWLYH FDUH EXW RQO\ µEUHDNHYHQ¶ DW   DQG  \HDUV IRU adalimumab, etanercept and 
infliximab respectively.  Adalimumab offers a slightly less risky profile than etanercept, so it is only at 
21.25 years that etanercept is expected to offer the highest NHE. 
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Figure 3.1d Cumulative incremental NHE in PsA over the patient time horizon   
 
ii) Cost-effectiveness at the population level 
Per patient NHEs can also be expressed for the population of current and future patients.  This 
requires information about prevalence and future incidence of the target population (already required 
in appraisal).  It also requires a judgement about the time horizon over which the technology will be 
used.  7KLVµWHFKQRORJ\WLPHKRUL]RQ¶RXJKWWRUHIOHFWWKHSHULRGRYHUZKLFKWKHWHFKQRORJ\LV likely to 
be part of clinical practice and generate the expected NHEs.
15
 An estimate of the scale of the total 
population NHEs and how they cumulate over time is important for subsequent assessments, 
including: i) where the NHE for current patient populations must be compared with the benefits to 
future patients; and ii) where the treatment decision can be changed so the irrecoverable opportunity 
costs of initially negative NHE become significant, i.e., might influence the category of guidance.   
 
For example, there is a large prevalent population eligible for EECP relative to future incident 
populations in this chronic condition.  The total population NHE, assuming the technology will be used 
to treat prevalent and incident patients over 10 years, are reported in Table 3.3a.  Expected cost-
effectiveness is unchanged (ICER is the same as Table 3.2a) but the incremental NHE although small 
per patient, is more significant at a population level. 
 
Table 3.3a Expected cost-effectiveness of EECP for the population 
 Cost-effectiveness threshold at: 
£20,000 per QALY £30,000 per QALY 
Treatment Costs 
(£m) 
QALY ICER 
(£/QALY) 
NHE 
QALY (£m) 
Incr NHE, 
QALY (£m) 
NHE 
QALY (£m) 
Incr NHE, 
QALY (£m) 
EECP 896 1,435,787 £19,391 1,391,001 
(27,820) 
1,405 
(28) 
1,405,930 
(42,177) 
16,334 
(490) 
Std - 1,389,596 - 1,389,596 
(27,792) 
 1,389,596 
(41,688) 
 
 
7KHµLQYHVWPHQWSURILOH¶IRU((&3ZKHQXVHGWRWUHDWSDWLHQWVRYHUyears is illustrated in Figure 2.2.  
At a population level it is not until 17 years (rather than 14 years at a patient level) that initial losses 
DUHFRPSHQVDWHGE\ODWHUJDLQVDQG((&3µEUHDNVHYHQ¶,QRWKHUZRUGV((&3DSSHDUVDPRUHULVN\
investment when evaluated at a population rather than individual level.  This is because, although 
each patient treated with EECP is expected to offer the same profile of NHEs shown in Figure 3.1a, 
                                                 
15 The time horizon for the technology might be longer or shorter than the patient time horizon. Technology time horizons might be based on historical 
evidence of the obsolescence of health technologies but any estimate will be a proxy for a complex and uncertain process of future changes in new 
technologies, prices and evidence.  Therefore the impacts of different technology time horizons have been explored in each case study.    
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WKH QHJDWLYH1+(DVVRFLDWHG ZLWKSDWLHQWV¶ LQFLGHQW DQG WUHDWHG LQ \HDU ZRQ¶W EHRIIVHWE\ ODWHU
JDLQV XQWLO \HDU   7KH SRSXODWLRQ OHYHO µLQYHVWPHQW SURILOH¶ ZRXOG H[KLELW JUHDter risk (breakeven 
later) if the prevalent population was smaller relative to the incident population and/or the technology 
WLPHKRUL]RQZDVORQJHU)RUH[DPSOHWKHµEUHDNHYHQ¶SRLQWH[WHQGVWR\HDUVZKHQWKHWHFKQRORJ\
time horizon is increased to 20 years.  
 
 
Figure 3.2  Cumulative incremental NHE of EECP for the population   
 
The effect on the other case studies of assessment at the population level is similar to EECP.  It 
simply increases the magnitude of differences in per patient NHE (to a greater extent for longer 
technology time horizons), but leaves expected cost-effectiveness unchanged.  However, the 
µLQYHVWPHQW SURILOHV¶ DW D SRSXODWLRQ OHYHO DOVR GLIIHU H[KLELWLQJ JUHDWHU µULVN¶ LQGLFDWHG E\ ODWHU
µEUHDNHYHQ¶ SRLQWV IRU WKHVDPH UHDVRQVDV((&3  )RUH[DPSOH WKH µEUHDNHYHQ¶ SRLQWV IRU&/23
when evaluated at a population level are reported in Table 3.3b.  At a technology time horizon of 10 
years it is only at 11 years, rather than 5 years for a single patient,  that 12 months of CLOP treatment 
µEUHDNVHYHQ¶DJDLQVWFXUUHQW1+6FDUHDQGQRWXQWLO\HDUVUDWKHUWKDQ years) that it is better 
WKDQDVKRUWHUWUHDWPHQWGXUDWLRQRIPRQWKV(YHQWKHVKRUWHUGXUDWLRQVRIWUHDWPHQWRIIHUDµULVN\
SURILOH¶HJWKHµEUHDNHYHQ¶SRLQWIRURQHPRQWKRIWUHDWPHQWLV\HDUVUDWKHUWKDQ\HDUV 
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Table 3.3b Expected cost-effectiveness of CLOP for the population 
 
 
3.3.2 Point 2 - Are there significant irrecoverable costs? 
 
The second point on the checklist requires: i) an assessment of whether there are irrecoverable costs 
and ii) a judgement of their potential significance, i.e., at the following point in the algorithm 
 
 
 
Irrecoverable costs are those which once committed cannot be recovered if guidance is changed at a 
ODWHU GDWH  ,UUHFRYHUDEOH FRVWV DUH PRVW FRPPRQO\ WKRXJKW RI DV µXS-IURQW¶ RU FDSLWDO FRVWV RI QHZ
facilities or equipment with long life expectancy (they might also include any practitioner training and 
the costs of implementation efforts).  In NICE appraisal these types of cost are first annuitized 
16
 and 
then allocated pro-rata to the number of patients likely to be treated during the lifetime of the 
equipment. That is, capital costs are treated as if they are paid per patient treated over the life time of 
the equipment.   If guidance remains unchanged throughout this period (i.e., research does not report 
or other sources of uncertainty resolve) then this common assumption has no influence.  However, 
should guidance change (initial approval is withdrawn) before the end of the lifetime of the equipment 
then, although future patents will no longer use the technology, the cost of the equipment allocated to 
them cannot be recovered.  The possibility that initial guidance might change and its impact on 
expected costs needs to be considered before costs are made irrecoverable through approval or 
AWR.  The impact of irrecoverable costs will tend to be greater if they represent a greater proportion 
of the total costs, if guidance is more likely to change and to change in the near rather than distant 
future. 
 
                                                 
16
 The annual payments required each year over the life time of the equipment (discounted at 3.5%) which would be equivalent 
to the capital cost at the start of the 1
st
 year.  
Assess irrecoverable costs
Are there 
significant irrecoverable
costs? 
No
Yes
   µ%UHDNHYHQSRLQWV¶\HDUV 
Technology 
time horizon 
Treatment Incr NHE, 
QALYs (£m) 
12 months vs 6 
months 
12 months vs 
NHS 
1 month vs 
NHS 
5 years 1: clop12 269 (5.4) 
24 8 4 
 2: clop6 1,881 (37.6) 
 3: clop3 1,804 (36.1) 
 4: clop1 4,073 (81.5) 
 5: NHS - 
10 years 1: clop12 495 (9.9) 
27 11 4 
 2: clop6 3,465 (69.3) 
 3: clop3 3,324 (66.5) 
 4: clop1 7,502 (150) 
 5: NHS - 
15 years 1: clop12 686 (13.7) 
30 12 4 
 2: clop6 4,799 (96) 
 3: clop3 4,603 (92.1) 
 4: clop1 10,389 (207.8) 
 5: NHS - 
20 years 1: clop12 846 (16.9) 
33 12 4 
 2: clop6 5,921 (118.4) 
 3: clop3 5,680 (113.6) 
 4: clop1 12,820 (256.4) 
 5: NHS - 
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EECP is the only case study in which these types of cost are present to any great extent because 
treatment requires capital investment in the EECP machines themselves.  The expected per patient 
and population costs reported in Tables 3.1a and 3.2b allocated this capital cost in the usual way (i.e., 
annuitized over the 10 year life time of the machines and allocated to the number of patients treated 
each year).  The irrecoverable costs are reported separately in Table 3.4 and represent 19% of the 
total. However, this will have no influence on expected cost-effectiveness so long as guidance does 
not change during the lifetime of the equipment. 
 
Table 3.4 Capital costs associated with EECP 
 Cost-effectiveness threshold 
£20,000 per QALY 
Treatment Capital 
costs 
Non capital 
costs 
QALY ICER 
(£/QALY) 
NHE 
QALY (£m) 
Incr NHE 
QALY (£m) 
EECP £170,304,591 £725,408,798 1,435,787 19,391 1,391,001 
(27,820) 
1,405 
(28) 
Std - - 1,389,596 - 1,389,596 
(27,792) 
- 
 
µ,QYHVWPHQWSURILOH¶RI1+( 
Even in the absence of capital costs of equipment and facilities, NHE accumulate over time both at a 
patient and population level.  With the possible exception of OMAL 
17
 the analysis in Section 3.3.1 
indicates a common pattern of initially negative NHE that are only gradually offset by positive NHE in 
later periods.  Therefore, approval or AWR commonly commits opportunity costs of negative NHE 
which are irrecoverable.  
 
i) Are they likely to be significant?  
Whether or not irrecoverable costs are significant, i.e., might influence guidance, depends critically on 
whether guidance is likely to change and whether that is more likely in the near or distant future.  That 
will depend on whether research is likely to be undertaken and when it is likely to report, as well as 
other events that might occur, e.g., a change in price following patent expiry.  These are assessed 
later, at points 5 and 6 in the checklist.  However, the potential significance of any irrecoverable costs 
can be assessed at this point.  For example, capital costs can be judged based on the proportion of 
total population cost which are irrecoverable and their scale relative to the additional population NHE 
offered (e.g., see Table 3.4).   
 
Judging the potential significance of the investment profiles of NHE is more nuanced.  It depends 
whether treatment decisions for individual patients are irreversible, which in part depends on the 
nature of the disease.  For example, in an acute condition the decision to treat a particular presenting 
patient with a technology cannot be reconsidered at a later date ± it is irreversible.  Although it is 
possible that the later benefits are not realised, it is also possible that they will realise more (the 
profiles of NHE in Figure 3.1a to 3.1d are the average over these possibilities).  Similarly the 
possibility that guidance might change in the future (e.g., research suggests that the longer term 
benefits will not offset initial losses), will not influence the irreversible decision to treat a presenting 
patient with a technology that is expected to be cost-effective prior to the research reporting. 
  
Implication for the case studies  
CLOP is a treatment for acute coronary syndromes and, although decisions about treatment and its 
duration are not irreversible in the very short run, over the time scales more likely for research being 
conducted (and reporting) or other events occurring, which would change guidance, they can be 
regarded as such.  Therefore, although the investment profile of CLOP (at a patient and more so at a 
population level) exhibits irrecoverable opportunity costs these should not be judged significant in the 
sense that they have little potential to influence guidance.  There are also no significant irrecoverable 
costs associated with OMAL but for different reasons; although treatment decisions are reversible in 
this chronic condition, any irrecoverable opportunity costs appear very limited (see Figure 3.1c).  
Both EECP and the biologics in PsA are for chronic conditions where the decision to treat a particular 
patient can be changed at some later date (decisions are not irreversible).  Therefore, the type of 
                                                 
17
 The profile of NHE at a patient level did not exhibit significant irrecoverable opportunity costs.  Assessment at a population 
level and for longer technology time horizons simply increases the magnitude of the expected negative NHE.  Therefore, there 
are no irrecoverable costs in this case study.  
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µLQYHVWPHQW SURILOH¶ RI 1+( DW D SDWLHQW DQG SRSXODWLRQ OHYHO LV VLJQLILFDQW EHFDXVH LQVWHDG RI
committing irrecoverable costs by deciding to use technologies expected to be cost-effective now, the 
decision and commitment of costs can be made later, after research reports, other events occur 
and/or guidance changes.  Of course, proper account must be taken of the impact of withholding 
initiation of treatment on expected health benefits and costs (see Section 3.6), e.g., some patients 
who might have been treated may not survive to benefit from the results of the research or disease 
may have irreversibly progressed so that the expected health benefits are lower[19]. 
 
EECP is the only case where both types of irrecoverable costs are potentially significant.  Figure 3.2 
illustrates the impact of accounting for the actual timing of expenditure on EECP machines rather than 
treating it as if it was paid when each patient was treated, i.e., where expenditure is treated like a 
consumable cost by spreading the capital cost over 10 years.
18
  If approval of EECP might be 
withdrawn before 10 years, the potential losses in NHE will be greater than initially indicated in Figure 
3.2 because the equipment costs allocated to treating future patients cannot be recovered.  The 
earlier such a change might occur the greater the additional loss.  The impact of these possibilities 
should be considered at point 7 of the checklist before guidance to approve or AWR commits both 
types of irrecoverable costs.  
 
Pricing and irrecoverable costs 
The significance of irrecoverable treatment costs should also consider the scale of initially negative 
NHE as well as the duration of such losses (KRZORQJXQWLOWKHXVHRIWKHWHFKQRORJ\µEUHDNVHYHQ¶IRU
an individual patient and for the population of patients who are likely to be treated if it is approved).  
Health technologies with patent protection are more likely to be priced close to the point at which the 
expected incremental NHE are close to zero, i.e., where the ICER is close to or equal to the 
threshold.  A value based pricing scheme would formalise these existing incentives.  The use of a 
technology which is only just expected to be cost-HIIHFWLYHZLOOQRWµEUHDNHYHQ¶XQWLOFORVHWRWKHHQG
of the patient time horizon and much longer for the population of patients likely to benefit from its use 
(up to the technology time horizon plus the patient time horizon - less if patent expiry and cheaper 
generics enter before the technology time horizon).  The scale of initial losses will also tend to be 
greater.  Therefore, those technologies already priced close to the threshold, and all new technologies 
considered in a value based pricing scheme, will tend to increase the scale of irrecoverable costs 
committed by approval, making OIR or Reject more likely even when a technology is just expected to 
be cost-effective at point 1 of the checklist.
19
 
 
3.4 Is further research required? 
The judgements made at points 3 and 4 of the checklist are critical because if more research is not 
judged to be worthwhile no further assessments are required, unless there are significant 
irrecoverable costs (see table D1 in Appendix D).  If research is worthwhile, then what type of 
evidence is needed and whether the research required to generate it can be conducted while the 
technology is approved will determine whether AWR or OIR are possibilities. 
 
3.4.1 Point 3 ± Does more research seem worthwhile? 
The third point on the checklist requires an assessment of the potential benefits of conducting further 
research, i.e., at the following point in the algorithm: 
 
                                                 
18
 In Figure 3.2  the technology time horizon happens to coincide with the life time of the equipment but it need not   
19
 It is also important to consider the risk profile of the health technologies and activities likely to be displaced.  Insofar as 
additional NHS costs do not just displace new technoORJLHVWKHQHWHIIHFWZLOOVWLOOWHQGWRLQFUHDVHµULVN¶VHHWKHWHFKQLFDOQRWH
in the Addendum to the HTA report).  
Assess need for evidence
Does 
more research seem 
worthwhile?
Yes
No
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This requires judgements about: i) how uncertain a decision to approve or reject a technology might 
be based on the estimates of expected cost-effectiveness; and ii) whether the scale of the likely 
consequences of this uncertainty might justify further research.  Some assessment of the potential 
consequences of uncertainty is important because it indicates the scale of the population NHE that 
could be gained if the uncertainty surrounding this decision could be immediately resolved, i.e., it 
represents an expected upper bound on the benefits of more research.
20
  If the potential benefits of 
further research are unlikely to justify the costs, then a judgement that more research does not seem 
worthwhile will lead directly to guidance in the following circumstances (extracted from Table B1 in 
Appendix B): 
 
 
 
i) Assessing the consequences of uncertainty 
Some assessment is required of: i) how uncertain a decision based on expected cost-effectiveness 
might be; and ii) what the consequences, in terms of population NHE, are likely to be if an incorrect 
decision is made. 
 
EECP is expected to be cost-effective compared to standard care (see Tables 3.2a and 3.5a) but the 
estimates of cost and QALYs are uncertain so there is a chance that a decision to approve EECP 
based on existing evidence will be incorrect, i.e., standard care might offer greater NHE.  Some 
assessment of the likely consequences of approving EECP when standard care might be better could 
be based on the difference in expected NHE, i.e., the expected incremental population NHE reported 
in Tables 3.3a and 3.5a).  This is illustrated in Figure 3.3a where a judgement about the probability 
that a decision based on expected cost-effectiveness is correct translates into expected 
consequences based on the expected incremental population NHE.  For example, if the decision was 
judged to be 100% certain then there are no consequences and so there would be nothing to be 
gained by more research. However, as the probability that the decision is correct becomes less 
certain, the expected consequences (and hence potential value of more research) increase.  
 
This judgment, of how uncertain a decision might be, can be informed by the probabilistic analysis 
(PSA) already used to estimate costs and QALY and is required as part of the NICE reference 
case[35-36]. The probability that EECP is cost-effective is 0.428 (see Table 3.5a),
21
  which would 
translate into approximately 800 QALYs (see Figure 3.3a) over the technology time horizon,
22
 based 
on the expected or average difference between NHE.  However, the difference in NHE when EECP is 
not the correct decision is not necessarily the average.  In fact, it is very unlikely to be the average 
and such estimates may substantially under or overestimate the expected consequences of 
uncertainty.
23
   
 
 
 
                                                 
20
 In mathematics and economics this is referred to as expected opportunity loss. In decision theory and its applications 
including economic evaluation it is referred to as the expected value of perfect information (EVPI).  It is also directly related to 
option value in financial economics. 
21
 The alternative which is expected to be cost-effective may not have the highest probability of being cost-effective if, as in this 
case, the distribution of NHE are skewed, i.e., when the NHE of EECP are greater than std they are much greater but when std 
offers higher NHE they are only a little higher than EECP.  
22
 The time horizon over which evidence generated by research about a technology might be valuable may be longer (or 
shorter) than the period over which the technology is used.  Therefore there is a distinction between the technology time 
horizon and the time horizon for the benefits of research.  To simplify the exposition in this summary of the case studies they 
are assumed to be equal but other credible assumptions are explored more fully in the addendum to the main report.  
23
 If an assessment of expected consequences based on mean NHE was always an underestimate this would be a useful, 
simple assessment of a lower bound to the potential benefits of research.  However, such estimates can also overestimate 
expected consequences, e.g., in the analysis of EECP at a threshold of £30,000. Unfortunately such circumstances cannot be 
specified in advance without conducting a proper analysis of the expected consequences anyway (see Technical Notes to the 
Addendum to the HTA Report).    
Assessment 1 2 3 4 5 6 7 Guidance
6 Yes No No - - - - Approve 4
12 No No No - - - - Reject 4
35 No Yes No - - - - Reject 11
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Table 3.5a Expected consequences of uncertainty for EECP 
 Cost-effectiveness threshold at: 
£20,000 per QALY £30,000 per QALY 
Treatment ICER 
(£/QALY) 
Incr 
NHE 
QALY 
(£m) 
Probability 
cost-
effective 
Expected 
consequences, 
QALY (£m) 
Incr 
NHE, 
QALY 
(£m) 
Probability 
cost-
effective 
Expected 
consequences, 
QALY (£) 
EECP 19,391 1,405 
(28.1) 
0.428 
9,287 
(185.7) 
1,405,930 
(490) 
0.7 
2,774 
(83.2) 
Std  - 0.572 - 0.3 
 
The same probabilistic analysis can be used to record the difference between the NHEs of EECP and 
standard care and the frequency of such errors.  This distribution of consequences is illustrated in 
Figure 3.4a.  Commonly there are no consequences, because EECP is the correct decision (42.8%).  
However, when EECP offers lower NHE than standard care the consequence of error may be 
relatively small, e.g., 9% are less than 5,000 QALYs.  However, they may be very large, although less 
likely, e.g., there is a small chance (5.7%) that they are greater than 30,000 QALYs.  The average 
over this distribution provides the expected consequences of uncertainty, which in this case is 9,287 
QALYs.
24
  
  
Figure 3.3a Probability that EECP is cost-effective and the consequences of uncertainty 
 
These expected consequences can be interpreted as an estimate of the population NHE over the 
technology time horizon that could be gained if the uncertainty surrounding this decision could be 
resolved immediately, i.e., it indicates an expected upper bound on the benefits of more research[35, 
37].
25
  The consequences can also be expressed as the equivalent NHS resources required to 
generate the same population NHE (£185.7m in Table 3.5a).  They will increase with the size of the 
patient population and the technology time horizon.  In the case of EECP the consequences fall with 
the cost-effectiveness threshold because a decision to approve EECP will be less uncertain (see 
Table 3.5a).  A judgment at this point that more research might be worthwhile seems reasonable, 
since the upper bound on its potential benefits exceed the likely costs.  
 
                                                 
24
 This is substantially greater than the estimate of 800 QALYs based on mean incremental population NHEs, demonstrating 
that such simple estimate may be misleading - see Figure 3.3a.   
25
 It should be noted that these estimates of QALYs that might be gained are for the population over the time horizon for the 
benefit of research (in this case equal to the technology time horizon ± see foot note 22) if all sources of uncertainty could be 
immediately resolved.  It includes both improvements in health outcomes for this population but also NHS resource saving that 
could be made and used to generate QALYs elsewhere.  
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Figure 3.4a Distribution of the consequences of uncertainty for EECP 
 
Multiple alternatives 
Similar analysis can be conducted when there are more than two alternatives but greater difficulties 
are encountered unless the results of PSA are used to assess both uncertainty and its consequences.   
For example, in the CLOP case study, 12 month treatment duration with CLOP is expected to be cost-
effective but this is also uncertain.  A judgement is required about the chance that 12 months of 
treatment is incorrect and if so which of the other four alternatives are likely to offer higher NHE, and 
how much higher.  In other words, for decisions involving multiple alternatives, a judgement is 
required on the level of uncertainty surrounding the decision, how this uncertainty is distributed across 
the various alternatives and what the consequences are likely to be. The results of PSA can inform 
this judgement. The probabilities that each of the 5 alternatives is cost-effective are reported in Table 
3.5b. This indicates that 12 months treatment is uncertain (probability that it is incorrect is 0.476).  
However, much of this probability of error is allocated to 6 months treatment with CLOP (0.18) where 
the difference in NHEs is likely to be relatively modest. 
 
Table 3.5b Expected consequences of uncertainty for CLOP 
 Cost-effectiveness threshold at: 
£20,000 per QALY £30,000 per QALY 
Treatment ICER 
(£/QALY) 
Incr 
NHE * 
QALY 
(£m) 
Probability 
cost-
effective 
Expected 
consequences 
QALY (£m) 
Incr 
NHE * 
QALY 
(£m) 
Probability 
cost-
effective 
Expected 
consequences 
QALY (£m) 
1: clop12 
18,663 
495 
(9.9m) 
0.524 
5,194 
(103.9) 
2,798 
(56.0m) 
0.677 
3,657 
(109.7) 
2: clop6 
10,477 
3,465 
(69.3m) 
0.180 4,736 
(94.7m) 
0.092 
3: clop3 
9,396 
3,324 
(66.5m) 
0.018 4,305 
(86.1m) 
0.009 
4: clop1 
4,961 
7,502 
(150.0m) 
0.075 8,327 
(166.5m) 
0.052 
5: NHS - - 0.202 - 0.170 
* The mean additional population NHE of moving from the least to most effective alternative, i.e., the incremental NHE of 12 
month compared to NHS is the sum of these increments (14,786 QALY or £295.7m at £20,000 per QALY) 
 
The distribution of consequences is illustrated in Figure 3.4b.   Most commonly (52.4%) there are no 
consequences, because 12 months duration of treatment with CLOP is the correct decision.  When it 
is not, there is a greater chance of relatively small consequences (30% are less than 10,000 QALYs) 
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which occur predominantly when 6 months treatment duration offers the highest NHE.  But there is a 
small chance of larger consequences (less than 5% chance that they are greater than 30,000 QALYs) 
when standard NHS treatment offers the highest NHE, i.e., there remains important uncertainty about 
the cost-effectiveness of CLOP itself, not just its duration.  The expected consequence of uncertainty 
(5,194 QALYs) is simply the average over this distribution.  Again this can be interpreted as an 
estimate of the population NHE that could be gained, over the time horizon of this technology, if the 
uncertainty about treatment and its duration could be immediately resolved.  Therefore, like EECP, a 
judgement at this point that more research might be worthwhile seems reasonable, since the potential 
benefits exceed the likely costs.  
 
Figure 3.4b Distribution of the consequences of uncertainty for CLOP 
 
PsA provides a similar picture to CLOP, where approval of the alternative which is expected to be 
cost-effective (etanercept) is uncertain (probability that approval is incorrect is 0.557), but in this case 
most of this probability of error is associated with palliative care (probability of 0.4 that it is cost-
effective).  Again, there is a greater chance of relatively small consequences (19% are less than 
28,000 QALYs), most of which occur when adalimumab has the highest NHE, but a smaller chance of 
very large consequences (4.7% chance that they are greater than 138,000 QALYs), which occur 
when palliative care offers the greatest NHE. The expected consequences of uncertainty and the 
upper bound on the population NHE that might be gained by immediately resolving uncertainty 
(35,342 QALYs or £707m over the technology time horizon) supports a judgement that more research 
maybe worthwhile. 
  
ii)  Analysis of subgroups 
OMAL was not expected to be cost-effective based on existing evidence.  The ICER in Table 3.2c 
was substantially greater than the threshold and a decision to reject this technology does not appear 
uncertain.  This judgement is supported by the results of PSA (the probability that OMAL is cost-
effective is zero in Table 3.5c).  Therefore, a decision to reject (Reject
 4
 in the algorithm) is not 
uncertain; there are no consequences of uncertainty and nothing to be gained by more research.  
However, it is possible to consider a high risk subgroup within this population.  Subgroups, once 
credibly defined, need to be considered in the same way; starting at point 1 on the checklist, i.e., 
entering at the top of the algorithm.  Although the ICER for this high risk subgroup is somewhat lower, 
it is still significantly higher than the threshold.  The results of PSA suggest that even at a threshold of 
£30,000 the probability that OMAL is cost-effective is very small and the upper bound on the gains 
from more research are very limited (10.61 QALYs).  Therefore, even after an analysis of subgroups 
OMAL is not expected to be cost-effective and more research does not seem worthwhile.  OMAL can 
be rejected at this point and no further assessment is required. 
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Table 3.5c  Expected consequences of uncertainty for OMAL 
Severe population Cost-effectiveness threshold at: 
£20,000 per QALY £30,000 per QALY 
Treatment ICER 
(£/QALY) 
Incr NHE 
QALY 
(£m) 
Probability 
cost-
effective 
Expected 
consequences 
QALY (£) 
Incr 
NHE 
QALY 
(£m) 
Probability 
cost-
effective 
Expected 
consequences 
QALY (£) 
Omal + 
Std 
93,844 
 
-5,789 
(-116) 
0.0 
0 
-3,337 
(-100) 
0.0 
0.0 
Std  - 1.0 - 1.0 
High risk subgroup Cost-effectiveness threshold at: 
£20,000 per QALY £30,000 per QALY 
Treatment ICER 
(£/QALY) 
Incr NHE 
QALY 
(£m) 
Probability 
cost-
effective 
Expected 
consequences, 
QALY (£) 
Incr 
NHE 
QALY 
(£m) 
Probability 
cost-
effective 
Expected 
consequences, 
QALY (£m) 
Omal + 
Std 
69,463 -3,851 
(-77) 
0.0 
0 
-2,048 
(-61) 
0.013 
 
10.61 
(0.32) 
Std  - 1.0 - 0.987 
 
iii) Alternative scenarios 
There are often alternative views about the quality and relevance of evidence as well as other 
assumptions that might be made when estimating expected costs and QALYs.   These are commonly 
presented as separate scenarios, with estimates of costs and QALY presented for each.  Much of the 
deliberation by the Appraisal Committee often surrounds the scientific value judgments required to 
judge the credibility of the alternative assumptions represented by such scenarios.  The type of 
probabilistic analysis reported represents the uncertainty within each scenario and will be sufficient to 
indicate the potential benefits of research when only one scenario is regarded as credible.   However, 
ZKHQ PRUH WKDQ RQH VFHQDULR PLJKW EH FUHGLEOH DQG FDUU\ VRPH µZHLJKW¶ WKHUH ZLOO EH XQFHUWDLQW\
between as well as within VFHQDULRV7KHµZHLJKWLQJ¶RIVFHQDULRVFDQEHPDGHH[SOLFLWE\DVVLJQLQJ
probabilities to represent how credible each is believed to be.  The weighted average of costs and 
QALY across scenarios can easily be calculated.  It is also tempting to take a simple weighted 
average of the expected consequences of uncertainty across these scenarios as well.  However, a 
simple weighted average may under or overestimate the combined consequences of uncertainty 
within and between scenarios [1, 38]. The correct estimate requires the probabilities (weights) to be 
applied directly to the simulated output from PSA rather than to the mean values.  Although this 
GRHVQ¶W UHTXLUHadditional simulation and is quick and easy to implement, it does require that either 
the probabilities are made explicit in advance or for estimates to be presented for a range of 
probabilities that might represent the judgement of the Appraisal Committee following deliberation. 
 
For example, the CLOP analysis presented above assumes a constant relative treatment effect for 
different durations of treatment (scenario A).  An alternative assumption (scenario B) was that the 
relative treatment effect also differed by duration based on the data reported in the SIGN guidelines.  
This alternative assumption made longer durations less cost-effective and reduced the expected 
consequences of uncertainty from 5,195 to 3,969 QALYs.    Although scenario A was regarded as 
more credible by the AC, scenario B might nevertheless carry some weight or have some probability 
associated with it.  In this case the simple weighted average of expected consequences (linear 
combination of mean estimates) is very similar to the correct estimate based on weighting the output 
of PSA in Figure 3.5a. This also shows how these estimates can be presented for a range of 
probabilities.  
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Figure 3.5a Expected consequences of uncertainty with alternative scenarios (CLOP) 
 
An alternative assumption of a common class effect across the three biologics was considered in the 
PsA case study (scenario B), but was judged less credible than the analysis which allowed differential 
effects (scenario A).   The alternative scenario made etanercept less likely to be cost-effective and 
increased the expected consequences of uncertainty from 34,930 to 38,521 QALYs (see Figure 3.5b).  
In this case a simple weighted average of expected consequences based on the probability assigned 
to each scenario is, in general, lower than the correct estimate of expected consequences based on 
the output from PSA. 
 
Figure 3.5b Expected consequences of uncertainty with alternative scenarios (PsA) 
 
Elicitation 
The single RCT of EECP showed evidence of improvements in quality of life at 12 months; however, 
the degree to which these are sustained in the long run is uncertain.  Rather than make alternative 
assumptions and present extreme scenarios, formal elicitation of the judgement of clinical experts 
about the likelihood of QALY gains in subsequent years was undertaken.
26
  The uncertainty in these 
                                                 
26
 Five experts with experience and knowledge of EECP in the UK, independently completed an Excel based exercise.  The 
uncertainty associated with any judgement is critical, so a frequency chart format, where experts place 20 crosses on a 
frequency chart to represent a distribution was adopted.  The results from each expert were linearly pooled, with equal weight, 
providing the probability of continuing to respond to treatment in each subsequent year.  The uncertainty associated with these 
pooled estimates was characterised by fitting Beta distributions to pooled responses.   
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elicited values is included in the estimates of the expected consequences of uncertainty reported in 
Table 2.5a, which might otherwise have been represented by alternative scenarios.  For example: no 
4$/<EHQHILWVEH\RQGPRQWKVFRXOGEHDVVXPHGIRUVFHQDULR$EHQHILWVVXVWDLQHGIRUDSDWLHQW¶V
life time for scenario B; and sustained for 4 years for scenario C.  The results of elicitation implied 
probabilities of: 0.243; 0.353; and 0.404 associated with each of these scenarios respectively.    A 
simple weighted average of the expected consequences within each scenario using these 
probabilities (1,442 QALYs) significantly underestimates both the estimate of expected consequences 
based on the all the information from elicitation (9,287 QAYs) and the estimate based on weighting 
scenarios using the simulated output rather than the mean estimates (13,081 QALYs).  This illustrates 
that: i) a simple weighted average of expected consequences may be misleading; and ii) that 
elicitation may provide a richer characterisation of uncertainty as well the probabilities associated with 
alternative assumptions (see Technical Notes in the Addendum to the HTA Report[1]. 
 
3.4.2 Point 4 - Is research possible with approval? 
The fourth point on the check list requires an assessment of what type of evidence is needed and a 
judgement of whether the research required to generate it can be conducted while the technology is 
approved, i.e., at the following point in the algorithm: 
 
 
 
Although the decision at this point does not lead directly to guidance, it does determine whether AWR 
or OIR are possibilities.  This judgement will depend, in part, on whether the type of evidence that is 
needed will require experimental research design.  For example, more precise estimates of relative 
treatment effect are likely to require an RCT if the dangers of selection bias are to be avoided.  
However, further RCTs for this particular indication and patient group are unlikely to be possible once 
a technology is approved for widespread NHS use. 
 
This requires judgements about:  i) how important particular types of parameters (inputs to the 
economic model) are to estimates of cost and QALY; ii) what values these parameters  would have to 
take to change a decision based on expected cost-effectiveness; iii) how likely is it that parameters 
might take such values and iv) what would be the consequences if they did, i.e., what might be gained 
in terms of population NHE if the uncertainty in the values of these parameters could be immediately 
resolved? 
 
i) Assessing the importance of parameters 
The type of economic model used to estimate expected cost-effectiveness in NICE appraisal specifies 
the relationship between the inputs (the parameters) and outputs (costs and QALYs).  A simple 
summary of the direction and strength of these relationships can be provided by calculating 
elasticities for each, i.e., the proportionate change in the NHE of each alternative, or differences in 
NHE, due to a one percent change in the value of the parameter, e.g., those parameters with high 
HODVWLFLWLHV HVSHFLDOO\ ZLWK UHVSHFW WR GLIIHUHQFHV LQ 1+( PLJKW EH UHJDUGHG DV PRUH µLPSRUWDQW¶
These elasticities are presented for CLOP case study in Table 3.6a.   They give some indication of i) 
relative importance for certain comparisons (e.g., RR_death seems particularly important for all 
comparisons); ii) identifies those that are of no or very limited importance (e.g., parameters 1-6 in the 
comparison of 12 and 6 months treatment duration); and iii) the direction of the relationship (e.g., the 
elasticity for C_Well is negative indicating that if the costs of NHS care in the Well state are greater, 
then 12 month treatment  will be less cost-effective compared to 6 months or current NHS care).   
  
                                                                                                                                                        
 
What type of evidence is needed?
Is the 
research possible with
Approval?
Yes
No
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Table 3.6a Elasticities associated with parameters (CLOP) 
 
Parameter 
Elasticity over the NHE (QALY) of 
Elasticity over the INHE 
(QALY) of 
clop12 clop6 clop3 clop1 NHS clop12 
vs. NHS 
clop12 
vs. 
clop6 
clop12 
vs. all 
N
a
tu
ra
l 
h
is
to
ry
 
1 P_die_0.1 -0.208 -0.207 -0.207 -0.207 -0.222 0.014 - 0.003 
2 P_NFMI_0.1 -0.012 -0.012 -0.011 -0.011 -0.015 0.004 - - 
3 P_die_1.3 -0.137 -0.137 -0.137 -0.147 -0.145 0.008 - 0.004 
4 P_NFMI_1.3 -0.002 -0.002 -0.002 -0.002 -0.002 0.001 - - 
5 P_die_3.6 -0.146 -0.146 -0.157 -0.157 -0.154 0.008 - 0.007 
6 P_NFMI_3.6 -0.005 -0.005 -0.007 -0.007 -0.007 0.002 - 0.001 
7 P_die_6.12 -0.148 -0.159 -0.158 -0.157 -0.155 0.007 0.011 0.01 
8 P_NFMI_6.12 -0.005 -0.007 -0.007 -0.007 -0.007 0.002 0.002 0.002 
9 TP_AC -0.121 -0.12 -0.12 -0.12 -0.118 -0.003 -0.001 -0.002 
10 TP_AD -3.637 -3.622 -3.604 -3.594 -3.541 -0.096 -0.016 -0.047 
11 TP_CD -0.233 -0.235 -0.239 -0.24 -0.253 0.02 0.002 0.009 
12 TP_BD -0.586 -0.593 -0.602 -0.605 -0.641 0.055 0.007 0.024 
U
ti
li
ti
e
s
 13 U_Well 0.746 0.745 0.743 0.742 0.737 0.009 0.001 0.004 
14 U_Well1 6.09 6.064 6.034 6.017 5.929 0.16 0.026 0.079 
15 U_NFMI 0.133 0.134 0.136 0.136 0.144 -0.011 -0.001 -0.005 
16 U_POSTMI 1.138 1.15 1.165 1.171 1.236 -0.099 -0.012 -0.043 
R
E
 17 RR_death -0.639 -0.491 -0.344 -0.207 
 
-0.641 -0.15 -0.38 
18 RR_NFMI -0.024 -0.018 -0.013 -0.011 
 
-0.025 -0.006 -0.014 
C
o
s
ts
 
19 C_Well -0.74 -0.737 -0.733 -0.731 -0.72 -0.019 -0.003 -0.009 
20 C_MI_LT -0.051 -0.052 -0.053 -0.053 -0.056 0.004 0.001 0.002 
21 C_PostMI -0.142 -0.143 -0.145 -0.146 -0.154 0.012 0.002 0.005 
22 TC_Well_Dead -0.027 -0.027 -0.027 -0.027 -0.027 - - - 
23 C_t1 -0.045 - - - - -0.045 -0.045 -0.045 
24 C_t2 - -0.033 - - - - 0.033 0.008 
25 C_t3 - - -0.026 - - - - 0.007 
26 C_t4 - - - -0.022 - - - 0.005 
27 C_t5 - - - - -0.016 0.016 - 0.004 
 
Although these measures of importance are more instructive than a series of arbitrary one way 
sensitivity analysis, they do not directly help the assessment of what values parameters must take to 
change decisions and how likely such values might be.   A simple summary of the values particular 
parameters must take to make each of the alternatives cost-effective can also be provided. These 
µWKUHVKROGYDOXHV¶ IRr parameters are presented for CLOP case study in Table 3.6b.   This provides 
additional information to the elasticities in Table 3.6a, e.g., there are only 6 parameters which could 
possibly take values that would lead to current NHS care (without CLOP) generating higher NHE than 
 PRQWKV RI WUHDWPHQW ZLWK &/23 +RZHYHU DOWKRXJK LQVWUXFWLYH VXFK µWKUHVKROG YDOXHV¶ GR QRW
indicate how likely it is that threshold will be crossed or the combined effect of groups of related 
parameters. 
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Table 3.6b Thresholds associated with parameters (CLOP) 
 
Parameter 
Mean 
value 
Clop12 Clop6 Clop3 Clop1 NHS 
N
a
tu
ra
l 
h
is
to
ry
 
1 P_die_0.1 0.032 0 to 0.10 0.11 to 0.54 
0.54 to 
0.63 
0.63 to 1 - 
2 P_NFMI_0.1 0.04 0 to 0.14 0.14 to 0.71 
0.71 to 
0.82 
0.82 to 1 - 
3 P_die_1.3 0.022 0 to 0.10 0.10 to 0.55 0.55 to 1 - - 
4 P_NFMI_1.3 0.004 0 to 0.10 0.10 to 0.7 0.7 to 1 - - 
5 P_die_3.6 0.023 
0.01 to 
0.10 
0.10 to 1 0 to 0.01 - - 
6 P_NFMI_3.6 0.011 0 to 0.11 0.11 to 1 - - - 
7 P_die_6.12 0.024 0.02 to 1 0 to 0.02 - - - 
8 P_NFMI_6.12 0.009 0.005 to 1 0 to 0.005 - - - 
9 TP_AC 0.018 0 to 0.06 0.06 to 1 - - - 
10 TP_AD 0.072 0 to 0.08 0.08 to 0.10 - - 0.10 to 1 
11 TP_CD 0.188 0.12 to 1 0 to 0.12 - - - 
12 TP_BD 0.07 0.06 to 1 0.04 to 0.06 - - 0 to 0.04 
U
ti
li
ti
e
s
 13 U_Well 0.798 0.29 to 1 0 to 0.29 - - - 
14 U_Well1 0.93 0.90 to 1 0.74 to 0.90 - - 0 to 0.74 
15 U_NFMI 0.801 0 to 1 - - - - 
16 U_POSTMI 0.931 0 to 1 - - - - 
R
E
 17 RR_death 0.931 0 to 0.93 0.94 to 0.97 
0.97 to 
0.98 
0.98 to 
0.99 
1.00 to 
max
*
 
18 RR_NFMI 0.71 0 to 0.82 0.83 to 1.55 
1.56 to 
1.83 
- 
1.84 to 
max
*
 
C
o
s
ts
 
19 C_Well 2061.5 0 to 2690 2690 to 5611 - - 
5611 to 
max
*
 
20 C_MI_LT 6050 0 to max
*
 - - - - 
21 C_PostMI 2309.7 
870 to 
max
*
 
0 to 870 - - - 
22 TC_Well_Dead 871.5 0 to 20474 
20474 to 
max
*
 
- - - 
23 C_t1 895.1 0 to 910 910 to max
*
 - - - 
24 C_t2 651.6 
630 to 
max
*
 
0 to 630 - - - 
25 C_t3 524.2 
370 to 
max
*
 
- 0 to 370 - - 
26 C_t4 434.8 
150 to 
max
*
 
- - 0 to 150 - 
27    C_t5  329.8 0 to max  -  -  -  -  
 
ii) Assessment of uncertainty 
The judgement about how likely it is that parameters might take values which will change the 
technology expected to be cost-effective can be informed by the results of probabilistic analysis.  This 
is because the distributions assigned to parameters in PSA ought to reflect the amount and quality of 
exiting evidence and describe how uncertain the parameter estimates are.  The probability that each 
parameter might take values which would lead to each of the alternatives being cost-effective are 
reported for the CLOP case study in Table 3.6c. This, essentially, decomposes the overall 
probabilities reported in Table 3.5b into the contribution that each parameter makes.
27
  Interestingly, it 
indicates that it is uncertainty in the estimates of relative effect (RR_Death) that contributes most to 
the probability of error associated with 12 months of treatment.  It is the only parameter which (alone) 
might take values that could make any of the other alternatives cost-effective.  It is also worth noting 
WKDW WKHUH LVDYHU\VPDOOFKDQFH WKDWFRVW LQWKH µZHOOVWDWH¶&B:HOOPLJKWEHVXIILFLHQWO\KLJKWKDW
                                                 
27
 The probability of error associated with 12 month of treatment reported in table 3.5b will, in general, not equal the sum of 
probabilities of error across the parameters, because the overall probability from PSA takes account of the joint effect of 
uncertainty in all parameters simultaneously.  Even if parameters are independent they will be related to differences in NHE in 
different ways (indicated by the sign and magnitude of the elasticities ± see Table 3.6a), so sometimes the effect of uncertainty 
in oQHPD\WRVRPHH[WHQWµVXEVWLWXWH¶RUµFRPSOHPHQW¶WKHHIIHFWRIXQFHUWDLQW\LQRWKHUV 
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standard NHS care would be cost-effective, i.e., if the NHS costs associatHGZLWKWKHµZHOOVWDWH¶DUH
higher than any cost savings associated with moving more patients more quickly to the well state will 
tend to be lower.   
 
Table 3.6c Probabilities associated with parameter values (CLOP) 
 Parameter Clop12 Clop6 Clop3 Clop1 NHS 
N
a
tu
ra
l 
h
is
to
ry
 
1 P_die_0.1 1 - - - - 
2 P_NFMI_0.1 1 - - - - 
3 P_die_1.3 1 - - - - 
4 P_NFMI_1.3 1 - - - - 
5 P_die_3.6 1 - - - - 
6 P_NFMI_3.6 1 - - - - 
7 P_die_6.12 0.65 0.35 - - - 
8 P_NFMI_6.12 0.91 0.09 - - - 
9 TP_AC 1 - - - - 
10 TP_AD 0.83 0.17 - - - 
11 TP_CD 1 - - - - 
12 TP_BD 0.85 0.15 - - - 
U
ti
li
ti
e
s
 13 U_Well 1 - - - - 
14 U_Well1 0.94 0.06 - - - 
15 U_NFMI 1 - - - - 
16 U_POSTMI 1 - - - - 
R
E
 17 RR_death 0.55 0.18 0.01 0.10 0.16 
18 RR_NFMI 0.97 0.03 - - - 
C
o
s
ts
 
19 C_Well 0.78 0.19 - - 0.03 
20 C_MI_LT 1 - - - - 
21 C_PostMI 0.89 0.11 - - - 
22 TC_Well_Dead 1  - - - - 
23 C_t1 0.95 0.05 - - - 
24 C_t2 0.99 0.01 - - - 
25 C_t3 1 - - - - 
26 C_t4 1 - - - - 
27 C_t5 1 - - - - 
 
iii) What type of evidence is needed? 
Although an understanding of uncertainty and importance of parameters separately is helpful, an 
assessment of the likely consequences of this uncertainty, and therefore what might be potentially 
gained, in terms of population NHE, if uncertainty could be immediately resolved, is required.  This 
assessment can directly inform the judgement of what evidence is needed and whether the type of 
research required to generate it will be possible with approval.  In a similar way to Section 3.4.1, the 
results of PSA can inform this judgement since estimates of the expected consequences of 
uncertainty associated with each parameter combines both uncertainty in its potential values and their 
importance in terms of changing decisions and differences in NHE. The expected consequences of 
uncertainty associated with each parameter in CLOP are reported in Table 3.6d.   This decomposes 
the overall expected consequences reported in Table 3.5b into the contribution that each parameter 
makes and which other alternatives might offer higher NHE than 12 month treatment.
28
 It confirms 
that it is uncertainty in the estimates of relative effect (RR_Death) that contributes most and where 
there is potentially the most to be gained by resolving this uncertainty through additional research 
(4,433 QALYs or £88.7m).  Since more precise estimates of relative effects are likely to require a 
RCT, a judgement that the type of research need will not be possible if 12 month treatment duration is 
approved may be reasonable. However, the potential benefits of resolving the uncertainty associated 
with other groups of parameters, e.g., costs (547 QALYs or £10.9m) and the natural history (369 
QALYs or £7.4m), might mean that other types of cheaper, non experimental research could be 
worthwhile as well or might be conducted prior to commissioning potentialy expensive experimental 
research which may take some time to complete and report[39].
29
 
                                                 
28
 For similar reason to foot note 27 the overall expected consequences of uncertainty reported in table 3.5b (5,194 QALYs) will 
not, in general, equal the sum of the expected consequences for each of the parameters separately (5,432 QALYs).  
29
 The sequence in which research might be conducted can also be considered. This is discussed at greater length and more 
formally in the technical appendix to the main report, i.e., OIR for treatment effects followed by AWR for natural history if that 
research continues to be necessary once research recommended in OIR reports.  It is feasible to withdraw approval of a 
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Table 3.6d Consequences of uncertainty associated with parameter values (CLOP) 
 
 
Expected consequences (QALYs) 
 
 
Decomposed by treatment choice  
 Parameter clop12 clop6 clop3 clop1 NHS Overall 
N
a
tu
ra
l 
h
is
to
ry
* 
1 P_die_0.1 0 - - - - 0 
2 P_NFMI_0.1 0 - - - - 0 
3 P_die_1.3 0 - - - - 0 
4 P_NFMI_1.3 0 - - - - 0 
5 P_die_3.6 0 - - - - 0 
6 P_NFMI_3.6 0 - - - - 0 
7 P_die_6.12 0 250 - - - 250 
8 P_NFMI_6.12 0 9 - - - 9 
9 TP_AC 0 - - - - 0 
10 TP_AD 0 47 - - - 47 
11 TP_CD 0 - - - - 0 
12 TP_BD 0 35 - - - 35 
U
ti
li
ti
e
s
* 13 U_Well 0 - - - - 0 
14 U_Well1 0 10 - - - 10 
15 U_NFMI 0 - - - - 0 
16 U_POSTMI 0 - - - - 0 
R
E
 17 RR_death 0 284 16 518 3614 4433 
18 RR_NFMI 0 3 - - - 3 
C
o
s
ts
* 
19 C_Well 0 153 - - 321 474 
20 C_MI_LT 0 - - - - 0 
21 C_PostMI 0 8 - - - 8 
22 TC_Well_Dead 0 - - - - 0 
23 C_t1 0 8 - - - 8 
24 C_t2 0 0 - - - 0 
25 C_t3 0 - - - - 0 
26 C_t4 0 - - - - 0 
27 C_t5 0 - - - - 0 
 
* Expected consequences for groups of parameters are:  natural history 369 QALY (7.4m); RE 4,504 QALYs (£90.1m); 15 
QALYs (£0.3m) and costs 547 QALYs (£10.9m).  These are not equal to the sum of expected consequences for component 
parameters for the reasons explained in footnotes 23 and 24.   
 
EECP provides a similar pattern of results, with the most significant consequences of uncertainty 
associated with parameters related to relative treatment effect; suggesting that the research needed 
might not be possible following approval of EECP.  Interestingly, although the probability of sustaining 
the QALY benefits of EECP in the long run is very uncertain, the greater part of potential value is in 
more precise estimates of QALY gains in the first 12 months (2,709 QALYs or £54m and 8,511 
QALYs or £170m respectively).   
 
In PsA, on the other hand, the greater potential value is associated with uncertainty in natural history 
of HAQ progression (8,697 QALY or £17.4m) rather than relative treatment effect (1,201 QALYs or 
£2.4m).  Although this might suggest that AWR, which recommended research on HAQ progression is 
possible and worthwhile, the combined potential benefits of resolving uncertainty associated with 
natural history (both in HAQ and PsARC) and treatment effecWWRJHWKHULVPXFKJUHDWHUWKDQWKHµVXP
RI LWV SDUWV¶30 This suggests that both types of research could be conducted while etanercept 
continues to be approved but infliximab and adalimumab are not, i.e., a possible OIR rather than 
reject for infliximab and adalimumab but AWR for etancercept. 
 
 
Implications of between scenario uncertainty 
In part iii) of Section 3.4.1 the contribution alternative scenarios might make to the overall expected 
consequences of uncertainty and therefore the potential gains from further evidence was considered 
and discussed.  In situations where more than one scenario might be regarded as credible, there will 
                                                                                                                                                        
technology that is expected to be cost-effective to allow research to be conducted then in this case AWR followed by OIR if 
necessary is likely to offer greater expected population NHE. 
30
  These values represents an upper bound on what might be gained be resolving each alone. The potential value of resolving 
these uncertainties together is much greater for the reasons given in footnote 28 and 27. 
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be uncertainty between as well as within each of the scenarios.  It was demonstrated in Section 3.4.1 
that an assessment of WKHFRPELQHGFRQVHTXHQFHVRIERWKVRXUFHVRIXQFHUWDLQW\UHTXLUHVµZHLJKWV¶
(probabilities) to be assigned to represent their credibility, which can then be applied directly to the 
simulated output from PSA. However, the same analysis can also be used to identify the expected 
consequences of uncertainty associated with the alternative scenarios themselves, i.e., what might be 
JDLQHGLIHYLGHQFHFRXOGLPPHGLDWHO\GLVWLQJXLVKZKLFKVFHQDULRZDVµWUXH¶[1].  This can help to inform 
the assessment of what type of evidence might be needed and whether the research required to 
generate it is likely to be possible once a technology is approved for widespread NHS use. 
 
For example in the CLOP analysis, scenarios A and B (treatment effect was constant or differed by 
treatment duration respectively) were associated with expected consequences of uncertainty of 5,195 
and 3,969 QALYs respectively.  If both scenarios where regarded as equally likely, the overall 
expected consequences of uncertainty (combining consequences within and between scenarios) 
would be 4,667QALYs.  However, the expected consequences of uncertainty associated with the two 
alternative scenarios themselves and what might be potentially gained if the uncertainty between 
them could be immediately resolved is relatively modest at 85 QALYs, i.e.,  most of what might be 
gained from further evidence is associated with the parameters in Table 3.6d rather than the 
alternative scenarios.    This suggests that more evidence about overall relative effect on mortality is 
more important than resolving uncertainty about whether such an effect differs by treatment duration. 
 
In the EECP case study, formal elicitation of the judgement of clinical experts about whether observed 
QALY gains at 12 months are likely to be sustained in subsequent years was undertaken.  Since the 
uncertainty in these elicited values was incorporated into the analysis in the same way as other 
parameters, the use of alternative scenarios was not necessary.   However, scenarios were used to 
illustrate the type of analysis, which, without elicitation, might otherwise have been required.  The 
scenarios included: A - no QALY benefits beyond 12 months; B - EHQHILWVVXVWDLQHGIRUDSDWLHQW¶VOLIH
time; and C - sustained for 4 years.  The results of elicitation implied probabilities of: 0.243; 0.353; 
DQGDVVRFLDWHGZLWKHDFKRIWKHVHVFHQDULRVUHVSHFWLYHO\%DVHGRQWKHVHµZHLJKWV¶IRUHDFK
scenario the overall expected consequences of uncertainty (combining the consequences within and 
between scenarios) would be 14,146 QALYs.  In this case the expected consequences of uncertainty 
between the scenarios (13,202 QALYs) are much greater than what might be potentially gained from 
resolving the uncertainty within each scenario (1,765 QALYs).  Therefore, unlike CLOP, most of what 
might be gained from further evidence about EECP (in the absence of formal elicitation) would be 
evidence that could help distinguish between the scenarios rather than the parameters associated 
with each. 
 
3.5 Do the benefits of research exceed the costs? 
The judgements made at points 5 and 6 of the check list are critical because if the benefits of 
research are not judged to exceed the costs then no further assessment are required (unless there 
are significant irrecoverable costs, see Table B in Appendix B).  If they are and research can be 
conducted with approval, then AWR would be appropriate.  However, other sources of uncertainty 
need to be assessed first, as they will influence the potential benefits of research and, even when 
research is not conducted, they will also influence the appropriate category of guidance when there 
are significant irrecoverable costs. 
 
3.5.1 Point 5 ± Will other sources of uncertainty resolve over time? 
The fifth point on the check list requires an assessment of whether changes are likely to occur in the 
future which will influence the cost-effectiveness of the alternative technologies and the potential 
benefits of research, i.e., at the following point in the algorithm: 
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The judgement made at this point will influence the potential benefits of research and therefore 
subsequent decisions which lead directly to a particular category of guidance (see point 6 in Section 
3.5.2 below).  Even when research was not considered worthwhile (at point 3) the presence of other 
sources of uncertainty will determine whether significant irrecoverable costs are likely to influence the 
category of guidance.  In some circumstances it can lead directly to guidance, i.e.,  if there are no 
other sources of uncertainty even significant irrecoverable costs will have no influence and a 
technology which is expected to be cost-effective can be approved: 
 
 
 
This assessment requires information about: i) changes in prices of the technology and its 
comparators; ii) the emergence of new technologies which might make existing ones obsolete or 
change their cost-effectiveness; and iii) other relevant research reporting.  A number of potential 
sources of information and evidence were examined to inform this assessment for each case study[1].  
However, many potentially useful sources were either proprietary or public access was restricted, 
making it surprisingly difficult to inform these assessments with publicly available information.  When 
information and estimates were available they were often not complete or directly relevant to a UK 
context.        
 
i)  Changes in the price (the technology and its comparators) 
Changes in prices not only influence expected cost-effectiveness but also uncertainty and the 
potential benefits of research to future patients, e.g., if the price of a technology expected to be cost-
effective is likely to fall significantly just before research reports the potential benefits will not be 
realised because approval of the technology will be less uncertain and there may be much less or 
little to gain from the results of the research. This assessment requires information about when major 
changes in prices are likely and some evidence about the likely extent of the change.  A major event 
in the life cycle of a pharmaceutical technology is the date at which the patent expires and cheaper 
generic versions of the brand become available.  Although the date of patent expiry is, of course 
known, it is surprisingly difficult to obtain the relevant date for particular products in the UK from 
publicly available sources.  Evidence of the extent to which the price of generic versions are below the 
original brand price are also difficult to obtain and are likely to differ by health care system, type of 
technology, indication and time since patent expiry. Therefore, the estimate, reported by the Office of 
Fair Trading, that on average generic prices tend to be 25% of the original price was used in the 
subsequent analysis.  
 
At the time of TA80 the patent for CLOP was expected to expire 7 years later and subsequent 
analysis assumes that at that time equivalent generic prices will be 25% of the original price of CLOP 
at the time of TA80.
31
   Although it was possible for the PsA case study to find patent expiry dates for 
Etanercept (Enbrel), Infliximab (Remicade) and Adalimumab (Humira) in the US (2012, 2014 and 
2017 respectively), they were not available for the UK on the National Patent Database (IPO).  It is 
even more difficult to locate patent information relevant to devices, such as EECP, since a device 
may only have a CE mark, which, unlike a patent, does not offer protection but can be renewed every 
                                                 
31 This assumes that either prescribing will switch from the brand to equivalent generic (brands tend to maintain, or even 
increase premium prices in some health care systems, after patent expiry) or that any new branded technologies will be 
appraised and/or priced using generic versions of the old brand as a comparator. 
Assess other sources of uncertainty
Will this 
Uncertainty be resolved
over time? 
Yes
No
Assessment 1 2 3 4 5 6 7 Guidance
29 Yes Yes No - No - - Approve 12
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10 years. Any patent is likely to relate to some aspect of the device rather than the device itself.  
Although, prices may change over time they can also be relatively stable but with incremental 
innovation of the original device.  Again this is likely to differ by health care system, technology and 
indication.  For these reasons future changes in prices are only quantitatively explored in subsequent 
analysis in CLOP in Section 3.5.2.  There is a need to consider how access to the type of information 
required during NICE appraisal can be provided and how estimates of likely changes in prices 
relevant to the UK can be made readily available, if these assessments are to be routinely made. 
 
ii)  Entry of new technologies 
The entry of a new technology may make the existing technology that is expected to be cost-effective 
obsolete (no longer the most cost-effective alternative).  Even when it does not, it will tend to change 
the relative cost-effectiveness of the alternatives, influencing how uncertain a decision to approve the 
original technology will be for future patients and the potential gains from research.  A number of 
potential sources of information were examined to identify new technologies relevant to the 
indications which were likely to become available.  These included a variety of sources related to 
NICE topic selection, information about licence applications, clinical research in phase I, II and III as 
well as evidence of the probability that earlier phase research leads to entry (probability of successful 
licence)  and the likely time of entry (time to launch from initiating phase I, II and III research).  Again 
this information and evidence is fragmented, and in some cases restricted, e.g., NHS Horizon 
Scanning.  Nevertheless, the information that was available indicated that one new technology 
relevant to CLOP and one relevant to PsA might have been expected to enter.  Information about 
these technologies was limited so scenarios are used to explore the implication for CLOP and PsA in 
Section 3.5.2.      
 
iii) Other research reporting (the technology and its comparators) 
Research which is already underway, commissioned or likely to be undertaken whether in the UK or 
elsewhere, is relevant for two reasons.  Firstly, if it is research based in the UK then guidance might 
impact on recruitment and the successful completion of this research (see Section 3.6).  Secondly, 
when this research reports there is a chance that it will change the estimates of cost-effectiveness 
and resolve some of the current uncertainties. In other words, there is little to be gained by 
recommending OIR or AWR if the uncertainty is likely to be resolved in the near future when other 
research reports.  A number of potential sources of information were examined to identify clinical 
research underway at the time of the relevant appraisal, including: national and international trial 
registries; as well as other databases which report NHS funded research and not just clinical trials 
(e.g., NRR and UKCRN).  Despite an assiduous search no records relevant to the case studies were 
identified.  This may suggest that no other research was ongoing or expected for these comparators 
in these indications, or it may indicate that currently available sources are fragmented, incomplete 
and/or difficult to access.  
 
3.5.2 Point 6 ± Are the benefits of research greater than the costs? 
The sixth point on the checklist requires a re-assessment of the potential benefits of conducting 
further research which were initially considered at point 3 (see Section 3.4.1), and a judgment of 
whether the benefits of research are likely to exceed the costs  i.e., at the following point in the 
algorithm: 
 
 
 
A judgment about whether the potential benefits of research identified in Section 3.4 will be realised 
requires an assessment of: i) whether the type of research that is required is likely to be conducted; ii) 
Will research be conducted?
When will it be available?
How much will be resolved? 
Re-assess the benefits and costs 
of further research
Are the
benefits of research greater 
than the costs? 
Yes
No
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if conducted, when the results are likely to be available; iii) how much uncertainty is likely to be 
resolved and iv) the likely impact of the other sources of uncertainty identified in Section 3.5.1 on the 
longer term benefits of research. 
 
The decision at this point may not necessarily lead directly guidance, e.g., where the benefits of 
research exceed the costs but research is not possible with approval or there are significant 
irrecoverable costs.  Which category of guidance will ultimately be appropriate will depend on whether 
the benefits of approval are judged to exceed the costs, i.e., point 7 of the checklist in Section 3.6. 
However, in many other circumstances the decision at this point will lead directly to a particular 
category of guidance.  These circumstances or pathways through the algorithm are detailed below 
(extracted from Table B1 in Appendix B): 
 
 
The expected consequences of uncertainty reported in Section 3.4.1 represented the NHE that could 
be gained over the lifetime of the technology if the uncertainty surrounding the decision based on 
expected cost-effectiveness could be immediately and completely resolved.  This represents  an 
upper bound on the potential benefits of research for a number of reasons: i) research, although 
recommended, might not be commissioned and/or recruit and report; ii) any research will take some 
time to complete before results are available; and iii) not all of the uncertainty is likely to be resolved.  
In addition, future events (identified in Section 3.5.1) might change the NHE expected to be gained by 
future patient populations.   Finally, the expected benefits of research once properly re-assessed must 
be compared to the likely costs. 
 
i) Will the research be conducted? 
Even if research is recommended in OIR or AWR, it might not be undertaken by manufacturers or 
commissioned by research funders.  Even if undertaken or commissioned, there is no guarantee that 
research will be able to recruit or it may not complete for other reasons.  The expected consequences 
of uncertainty for CLOP and EECP reported in Section 3.4.1 are illustrated for a range of probabilities 
that research will be successfully undertaken in Figures 3.6a and 3.6b respectively.  This indicates 
that the potential gains depend on a judgment of whether the research recommended as part of OIR 
or AWR will be successfully completed.  They also illustrate that the cost of research (in this case 
considered to be either £1.5m or £10m
32
) can be compared directly to the potential benefits by either: 
i) expressing the potential gains in population NHE as the equivalent NHS resources, i.e., the 
resources that would be required to generate the same NHE; or ii) expressing the cost of research in 
terms of the QALYs that could be gained elsewhere in the NHS by using the same resources to 
provide access to health care. 
 
                                                 
32 Based on the range of costs of trials commissioned by NCCHTA ± personal communication.  
Assessment 1 2 3 4 5 6 7 Guidance
1 Yes No Yes Yes Yes/No Yes - AWR 1
2 Yes No Yes Yes Yes/No No - Approve 1
5 Yes No Yes No Yes/No No - Approve3
7 No No Yes Yes Yes/No Yes - OIR 2
8 No No Yes Yes Yes/No No - Reject 1
11 No No Yes No Yes/No No - Reject 3
19 Yes Yes Yes Yes No No - Approve 6
26 Yes Yes Yes No No No - Approve 10
30 No Yes Yes Yes Yes/No Yes - OIR 7
31 No Yes Yes Yes Yes/No No - Reject 8
34 No Yes Yes No Yes/No No - Reject 10
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Figure 3.6a Expected potential benefits of research (CLOP) 
 
ii)  When will it be available? 
Research, even if commissioned and successfully completed, will take time to complete and report.  
Therefore, any assessment of the potential benefits should account for the fact that patient 
populations will not benefit from the results of research until they are available.  Whether those 
patients who are prevalent while research is underway will be able to benefit from the results will 
depend on whether treatment decisions for presenting patients are irreversible or not (see Section 
,IWUHDWPHQWGHFLVLRQVDUHLUUHYHUVLEOHHJLQ&/23LWLVRQO\WKRVHSDWLHQWV¶LQFLGHQWDIWHUWKH
research reports that will realise any of the potential benefits.  In contrast, treatment decisions in 
EECP are not irreversible (it is a chronic condition), so although patients prevalent while research is 
undertaken will not benefit immediately, those that survive can benefit from the results once the 
research is completed.  How long research might take to report will depend in part on the design 
(follow-up, sample size and endpoints), recruitment rates and size of the eligible patient population, as 
well as how efficient the organisation and data collection might be.  The potential value of research in 
CLOP and EECP over a range of possible time horizons is reported in Figures 3.7a and 3.7b 
respectively.  In both cases the potential value of further research declines with the time to research 
reporting.  This relationship gives some indication of the value of improving the timeliness of research 
though, for example, investment in research infrastructure or adopting a research design, which, 
although offering less potential benefits, can be conducted more quickly. 
 
 
Figure 3.6b Expected potential benefits of research (EECP) 
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Figure 3.7a Potential value of research and time to report (CLOP) 
 
 
Figure 3.7b Potential benefits of research and time to report (EECP) 
 
iii) How much will be resolved? 
Most research will not inform all the parameters that determine expected cost and QALYs but usually 
a subset of them. Therefore, the potential benefits of research that might be conducted will not be the 
total expected costs of uncertainty surrounding expected cost-effectiveness, but some part of it.  In 
Section 3.4.3 the potential benefits of different types of evidence was assessed.  In CLOP it was 
additional evidence about relative treatment effects that were most valuable and therefore 
experimental research may be required to provide a more precise estimate of RR_Death.  The 
potential value of research, which only resolved uncertainty about this relative treatment effect over a 
range of times to report, is also represented in Figure 3D GHQRWHG E\ WKH OHJHQG µUHVROYH
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research is likely to take more than 8 years, the potential value is still likely to exceed the costs.  In 
EECP there was most benefit to be gained by resolving the uncertainty in the improvement in quality 
of life at 12 months, which in common with CLOP, is likely to require experimental design.  Figure 
3.6b represents the potential benefits of alternative trial designs with either one or four years of follow-
up (1, 2, 3 and 4 year follow-up designs were evaluated)[1].  Although longer follow-up offers greater 
potential benefits they are relatively small compared to the loss of potential value if longer follow-up 
delays the time until research findings are available, i.e., a 4 year design will require a minimum of 4 
years to complete.  Again, as long as research reports before 8 years, the potential benefits are likely 
to exceed the costs   
 
iv) What is the impact of other source of uncertainty? 
In Section 3.5.1 the information that was publicly available identified that the patent for CLOP was due 
to expire 7 years after the appraisal.  Based on the OFT estimate that generic prices tend to be 25% 
of the original brand price, this other source of uncertainty can be integrated quantitatively when 
estimating the potential value of research over the life time of the technology.  In this case a 
significant fall in price in year 7 will substantially reduce the uncertainty surrounding 12 months of 
treatment with CLOP.  Therefore, after year 7 there is less to be gained from resolving uncertainty, so 
WKH SRWHQWLDO DQG YDOXH RI UHVHDUFK ILQGLQJV IRU SDWLHQWV¶ LQFLGHQW DIWHU \HDU  DUH WKHUHE\ UHGXFHG
The effect of a price change on research which could potentially resolve uncertainty in cost natural 
history, and utilities as well as relative effect is also illustrated in Figure 3.7a.  The potential value of 
the research is lower whenever the research reports, because it includes the value to future as well as 
FXUUHQW SDWLHQW SRSXODWLRQV  1HYHUWKHOHVV HYHQ LI UHVHDUFK GLGQ¶W UHSRUW XQWLO  \HDUV WKH SRWHQWLDO
value is likely to exceed the costs (see Figure 3.7a). The expected price reduction reduces the 
potential value of research at each time point for both scenarios, e.g., for scenario B from 174,519 
QALYs when research is immediately available (see Figure 3.8a) to 165,701 with a price change at 
year 7.
33
 
 
There was some evidence of possible entry of a new technology (comparator) in the indication 
described in the CLOP case study.  However, there was limited information on its characteristics.  
Therefore two alternative but somewhat extreme scenarios are illustrated in Figure 3.8a.  In scenario 
A the new technology enters at years 5 and makes CLOP entirely obsolete, i.e., not cost-effective and 
not uncertain (equivalent to a shorter technology time horizon of 5 years).  At this point there is no 
value in the evidence generated by research about CLOP.
34
  In these circumstances the potential 
value of research is only likely to exceed its costs if it reports quickly.  In scenario B the new 
technology has similar NHE to 12 months of treatment with CLOP
35
  and the uncertainty surrounding 
its expected cost-effectiveness is also similar.  Now research about CLOP has more potential value in 
the future since it will also help resolve some of the uncertainty in the choice between CLOP and the 
new technology for patients that become incident after that time.   Although there was no evidence of 
new technologies emerging in EECP, the same scenarios are explored as the development and 
launch of new devices are more difficult to identify in advance.  The impact on the potential value of 
research is illustrated in Figure 3.8b and demonstrates similar qualitative effects as CLOP.  In 
scenario A (EECP becomes obsolete) the potential benefits of further research about EECP are only 
likely to exceed the costs if the research reports quickly.  Nevertheless, even in this extreme scenario 
the benefits of research with only 1 year follow-up are likely to exceed the costs so long as it reports 
before 4 years. 
 
The potential value of research presented in these figures, even after accounting for the type of 
evidence, follow-up and time until research reports, should still be regarded as an upper bound to the 
value that is likely to be realised by actual research for two reasons: i) even well designed research 
with large sample sizes will not fully resolve the uncertainty in the value that a parameter might take, 
especially in specific  target populations and in a particular (future) context; and ii) insofar as 
LPSOHPHQWDWLRQ RI 1,&( JXLGDQFH LV QRW µSHUIHFW¶ DQG DOO FOLQLFDO SUDFWLFH PLJKW QRW LPPHGLDWHO\
respond to the results of research, the full benefits will only be realised over time or with additional 
implementation efforts.  For these reasons a judgment of whether benefits of research are likely to 
                                                 
33
 These much higher values of immediate research than the 4,495 QALYs or £89.9m in Figure 3.7a without the entry of a new 
technology but with a similar price change.  
34
 There may continue to be value if evidence about CLOP remains an important link in mixed or indirect treatment comparisons 
required to evaluate the new technology. 
35
 This is likely to be an increasingly common scenario if value based pricing effectively makes all branded technologies equally 
cost-effective. 
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exceed the costs might be made conservatively, requiring evidence that, even in pessimistic 
scenarios, the research would still be worthwhile. 
  
 
Figure 3.8a Potential value of research and other sources of uncertainty (CLOP) 
 
 
Figure 3.8b Potential value of research and other sources of uncertainty (EECP)* 
 
3.6 Point 7 ± Are the benefits of approval greater than the costs  
The seventh and final point on the checklist requires an assessment and comparison of the benefits 
and costs of early approval.  The costs of approval, are not financial ones, but opportunity costs, and 
will include the potential value of any research that may be forgone as a consequence, e.g., if the 
research needed cannot be conducted once the technology is approved for use.  It will also include 
any costs that are irrecoverably committed by approval.  As well as the capital costs of equipment and 
facilities (or training and learning), they will also include the irrecoverable opportunity costs of initially 
negative NHE (if treatment decisions are not irreversible - see Section 3.3.2). A judgment of whether 
the benefits of approval and early access for current patients are likely to exceed the opportunity 
costs for future patients is required i.e., at the following point in the algorithm: 
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The decision at this point always leads directly to guidance; allocating all remaining possible 
pathways to a particular type and category of guidance.  These remaining (20) pathways through the 
algorithm are detailed below (extracted from Table B1 in Appendix B): 
 
 
 
 
 
3.6.1  Technologies without significant irrecoverable costs 
Only four of the 20 possible pathways illustrated above are associated with technologies without 
significant irrecoverable costs. In these four pathways, research was either: i) not considered possible 
with approval for those expected to be cost-effective (i.e., Approve
2
 or OIR
1
); or ii) research was not 
possible without approval for those not expected to be cost-effective (i.e., AWR
2
 or Reject 
2
).  CLOP 
provides an example of the former.  It is research that would provide more precise estimates of the 
relative effect of CLOP and of shorter treatment durations, which is potentially valuable (see Section 
3.4.2).  As a consequence, the type of experimental design that is likely to be needed is unlikely to be 
possible if 12 months of treatment with CLOP is already approved for widespread NHS use.  Although 
Assess the benefits and costs of 
early approval
Are the
benefits of approval greater 
than the costs? 
Yes
No
Assessment 1 2 3 4 5 6 7 Guidance
3 Yes No Yes No Yes/No Yes Yes Approve 2
4 Yes No Yes No Yes/No Yes No OIR 1
9 No No Yes No Yes/No Yes Yes AWR 2
10 No No Yes No Yes/No Yes No Reject 2
13 Yes Yes Yes Yes Yes Yes Yes AWR 3
14 Yes Yes Yes Yes Yes Yes No OIR 3
15 Yes Yes Yes Yes Yes No Yes Approve 5
16 Yes Yes Yes Yes Yes No No Reject 5
17 Yes Yes Yes Yes No Yes Yes AWR 4
18 Yes Yes Yes Yes No Yes No OIR 4
20 Yes Yes Yes No Yes Yes Yes Approve 7
21 Yes Yes Yes No Yes Yes No OIR 5
22 Yes Yes Yes No Yes No Yes Approve 8
23 Yes Yes Yes No Yes No No Reject 6
24 Yes Yes Yes No No Yes Yes Approve 9
25 Yes Yes Yes No No Yes No OIR 6
27 Yes Yes No n/a Yes n/a Yes Approve 11
28 Yes Yes No n/a Yes n/a No Reject 7
32 No Yes Yes No Yes/No Yes Yes AWR 5
33 No Yes Yes No Yes/No Yes No Reject 9
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treatment with CLOP does commit initially negative NHE that are irrecoverable, these should not be 
regarded as significant since the treatment decision for a presenting patient is irreversible in relevant 
time frames (see Section 3.3.2).  Therefore, AWR may not be possible, so the benefits of early 
access to 12 months of treatment with CLOP (Approval) must be compared to the potential value of 
OIR. 
 
OIR is more likely to offer greater expected NHE than Approve if the research can be conducted 
quickly and report sooner, since fewer patients forgo their access to CLOP and more can have 
treatment choice informed by the research findings.  This is illustrated in Figure 3.9 which reports the 
difference between Approve and OIR in population NHE over a range of times for when the research 
recommended in OIR might report.  This takes account of both the expected changes in price at year 
7 and research costs of £10m.  It shows that OIR will only be appropriate if the research reports within 
3 years of appraisal (T* = 3) because beyond this time the NHE forgone by withholding access to 
CLOP will exceed the potential gains to future patients.   
 
Figure 3.9 Population NHE of Approve and OIR for time to research reporting (CLOP) 
 
The trade-off between NHE for current and future patients which lies behind Figure 3.9 is illustrated in 
Figure 3.10 using undiscounted values for ease of exposition.  It illustrates the (per period) population 
NHE of approval and OIR, if the research recommended as part of OIR reports at year 3.  At this 
point, the initial losses of NHE, caused by restricting access to CLOP (area A), start to be offset by 
the potential gains from the research findings (area B).  The price change at year 7 increases the 
NHE of approval (i.e., CLOP is more cost-effective ) but on balance reduces the NHE of OIR.  In other 
words, since CLOP is more cost-effective and offers greater NHE the evidence generated by the 
research is less valuable because the choice of treatment and duration is less uncertain (see sections 
3.5.1 and 3.5.2).  With research reporting at 3 years the initial losses of OIR (area A) are just offset by 
the later gains (area B), so T* = 3.   If research reported earlier than 3 years (area A > area B) and 
OIR would be appropriate but if later than 3 years (area A > area B) and Approve would be more 
appropriate. 
 
However, there is no guarantee that the research recommended as part of OIR guidance will be 
conducted by manufacturers or commissioned by research funders. Even if it is, it is not certain that it 
will be successfully completed (see discussion in Section 3.5.2).  Therefore, the probability that 
research will report at a particular time also needs to be considered.  The implications of considering 
whether the recommended research will be conducted and when it might report are illustrated in 
Figure 3.11, which presents a boundary for when OIR might be appropriate or when approval should 
be granted. For example, if research is certain to report but will take 4 years, or when it will only take 
1 year but with only a 50% chance of reporting, then OIR would not be appropriate and 12 month 
treatment of CLOP should be approved, i.e., points that fall to the north east of this boundary.   Points 
to the south west of the boundary indicate that OIR might be appropriate.   
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Figure 3.10 Population NHE of Approve and OIR at T* (CLOP) 
 
 
 
 
Figure 3.11 An OIR or Approve boundary (CLOP)  
 
However, the estimates of the potential value of additional evidence on which these boundaries are 
based are still likely to overestimate the value that will be realised by research so they represent a 
necessary condition for OIR.  Therefore, OIR guidance should require a conservative judgment that 
the point is almost certain to be below the boundary, rather than on balance close to it.  For the same 
reason, points anywhere above the boundary represent a sufficient condition for approval. The 
boundary when the change in price is included is to the south west; reflecting the lower potential value 
of research, and OIR guidance, once CLOP becomes more cost-effective.    In this case it seems 
unlikely that the type of research required could report quickly enough and with sufficient confidence 
that OIR would be appropriate. Therefore, these assessments would support a judgment that the 
benefits of approval are likely to exceed the opportunity costs, and Approve
2
 (pathway 3 for CLOP in 
Table B1, Appendix B) would seem more appropriate.  
 
The assessments that have been undertaken for CLOP can be brought together to consider: i) what 
would be the value of being able to conduct research while CLOP is approved (value of AWR); and ii) 
what would be the value of making evidence that is needed by the NHS available at launch.  These 
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questions can be informed by the results (already presented elsewhere) but also reported together in 
Table 3.7a. 
 
Table 3.7a Population NHE over the technology time horizon for different policies (CLOP) 
 Approve OIR AWR* Reject Value of 
AWR 
Uncertainty 
resolved at 
launch 
Value of 
evidence at 
launch 
Expressed in QALY 
T<T* (T=2) 3,680,187 3,681,480 3,682,995 3,671,660 1,515 3,684,181 2,701 
T>T* (T=7) 3,680,187 3,675,487 3,680,362 3,671,660 175 3,684,181 3,994 
NHE expressed in £m 
T<T* (T=2) 73,604 73,630 73,660 73,433 30 73,684 54 
T>T* (T=7) 73,604 73,510 73,607 73,433 4 73,684 80 
 
 
The difference in population NHE between AWR (if it had been possible) and the next best feasible 
policy (OIR when T<T* and Approve when T>T*) is £30m and £4m respectively and represents the 
value to the NHS of being able to conduct research while CLOP is approved for use, e.g., informing 
whether investment in better data collection, registries or information systems that might make this 
possible.
36
   The difference in population NHE if all uncertainty had been resolved prior to appraisal 
(at launch) and the next best available policy (OIR when T<T* and Approve when T>T*) is £54m and 
£80m respectively and represents the value to the NHS of having access to the evidence needed at 
launch.  This can inform policies which might make better and more relevant evidence available.   
 
It is also possible to consider the commercial as well as NHS value in each of the cells of this table.  
The value of early evidence at launch can then be considered from the perspective of the 
manufacturer (the expected revenue streams), taking account of prices (see Sections 2.2.1 and 2.2.2) 
and expected volumes over the remaining patent life and technology time horizon.  Together with 
estimates of the costs of conducting research by manufacturers or through public funding, this 
assessment might inform when manufacturers might be expected to conduct the research needed 
(high commercial value that exceeds the cost to manufacturers) and when the NHS might be 
expected to undertake it (low commercial value but high potential value to the NHS that exceeds the 
costs to the NHS).  In many circumstances both the commercial and NHS values will exceed their 
respective costs.  In these circumstances the question of who should conduct, or pay for, the research 
might be informed by which sector has the comparative advantage, i.e., which has the highest 
µUHODWLYHHIILFLHQF\¶LQJHQHUDWLQJVRFLDOYDOXH"2IFRXUVHWKHYDOXHWRWKH1+6DQGWRPDQufacturers 
will depend; to a large extent, on what type of flexible pricing arrangements and value based pricing 
scheme might be in place (see discussion in Section 2.2.1 and 2.2.2).  The question will also turn on 
how any agreements can be made and incentive consistent contracts written and enforced.  
 
3.6.2  Technologies with significant irrecoverable costs 
Most of the possible pathways illustrated above are associated with technologies with significant 
irrecoverable costs (16 out of the remaining 20).   This is because even when research is possible 
with approval (or even when not needed), the impact of committing irrecoverable cost through AWR 
(or approval) must be considered, so OIR (or reject) remains a possibility.  EECP provides an 
example of this; where research that would provide more precise estimates of the effect of treatment 
on quality of life accounts for all the potential value (see Section 3.4.2).  EECP does commit both 
capital costs associated with long lived equipment, as well as initially negative per patient NHE.  
Unlike CLOP these irrecoverable opportunity costs at a patient level are significant because treatment 
choice for a presenting patient is not irreversible over relevant time frames (see Section 3.3.2).  As a 
consequence, even if research is possible with approval it is not clear that AWR would be appropriate, 
because OIR avoids the commitment of irrecoverable costs until research findings are available and a 
more informed decision can be made. 
 
i) Research is possible with approval 
Even when research is possible with approval OIR offers greater expected NHE than AWR as long as 
research reports before 9 years in Figure 3.12a.  This is because the consequences (losses of 
population NHE) of committing both aspects of irrecoverable costs through AWR are greater than the 
                                                 
36
 Even with such investment AWR might not be possible if there is insufficient variation in treatment assignment and no robust 
way of controlling for unobserved characteristics through selection models, e.g., use of instrumental variables. 
* This is the expected population NHE if AWR was to become a possibility 
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NHE forgone by restricting access to EECP through OIR.  The costs of research have not been 
included because they are incurred with both AWR and OIR guidance.
37
  
 
As previously for CLOP, there is no guarantee that the research recommended as part of OIR or 
AWR guidance will be conducted and research report. A boundary for when OIR rather than AWR 
might be appropriate is illustrated in Figure 3.13a for four research designs with differing follow-up.  A 
one year follow-up will generate evidence with the lowest potential value (so the boundary is to the 
south west) but it is likely to report sooner.  Therefore, OIR might be appropriate even if the probability 
that the research will be conducted and report is relatively low.  In this case it seems likely that the 
type of research required could report quickly enough and with sufficient confidence that OIR would 
be appropriate even though the research could be conducted while EECP is approved. Therefore, 
these assessments would support a judgment that the benefits of approval (through AWR) are 
unlikely to exceed the opportunity costs (the NHE of OIR), so OIR
4
 (pathway 18 in Table B1, 
Appendix B) rather than AWR
4
 (pathway 17) would seem more appropriate.  
 
 
Figure 3.12a Population NHE of AWR and OIR for time to research reporting (EECP) 
 
ii) Research is not possible with approval 
For the general reasons discussed in Section 3 and those specific to EECP discussed in Section 
3.4.2, the type of experimental research required to robustly estimate the effect of EECP on quality of 
life is unlikely to be possible once it is approved and in widespread use.  Now approval (now through 
Approve rather than AWR) not only commits the type of irrecoverable costs discussed above it also 
means that the potential value of evidence to future patients must also be forgone.    This is reflected 
in Figure 3.12b where the difference between OIR and approve are always greater than between OIR 
and AWR in Figure 3.12a.  It suggests that as long as the cost of the research exceeds the difference 
between OIR and approve, when it is expected to report, OIR rather than approve would be 
appropriate.  This is also reflected in the boundaries for OIR and Approve reported in Figure 3.13b.  
These boundaries are always to the north east of the OIR/AWR boundaries reported in Figure 3.13a, 
again reflecting the fact the approval not only commits irrecoverable costs but also forgoes the 
potential value evidence that might have been generated through an OIR recommendation.  These 
assessments would support a judgment that the benefits of approval are unlikely to exceed the 
opportunity costs (the NHE of OIR), so OIR
6
 (pathway 25 in Table B1, Appendix B) rather than 
Approve
9
 (pathway 24) would be more appropriate.  
 
                                                 
37 Any difference in costs of research under AWR or OIR guidance can easily be integrated into these assessments. 
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Figure 3.12b Population NHE of Approve and OIR for time to research reporting (EECP) 
 
 
 
 
Figure 3.13a An OIR or AWR boundary (EECP)  
 
 
 
1,390,000
1,392,000
1,394,000
1,396,000
1,398,000
1,400,000
1,402,000
0 1 2 3 4 5 6 7 8 9
P
o
p
u
la
ti
o
n
 N
H
E
, 
Q
A
LY
 
Time for research to report, years
OIR
Approve
0.0
0.2
0.4
0.6
0.8
1.0
0 1 2 3 4 5 6 7 8 9
P
ro
b
a
b
il
it
y
 t
h
a
t 
re
se
a
rc
h
 i
s 
co
n
d
u
ct
e
d
Time for research to report, years
4-year design
3-year design
2-year design
1-year design
Necessary condition for OIR
Sufficient condition for AWR
Uncertainty, evidence and irrecoverable costs: Informing approval, pricing and research decisions for health technologies  55 
 
 
 
 
Figure 3.13b An OIR or Approve boundary (EECP)  
 
As with CLOP, the assessments that have been undertaken for EECP are bought together in Table 
3.7b and can help inform the same policy questions: i) what would be the value of being able to 
conduct research while EECP is approved and ii) what would be the value of making the evidence 
that is needed by the NHS available at launch.  In this case, due to the irrecoverable costs associated 
with EECP, there is no value to the NHS of being able to conduct research while EECP is approved 
for use. In fact these figures are negative; indicating that even if AWR was possible it would not be 
appropriate.  However, like CLOP, there is value to the NHS of having the evidence needed prior to 
appraisal.  The value, expressed in the equivalent NHS resources, depends on how long it would 
otherwise have taken for an OIR recommendation to deliver the same evidence e.g., £62m if 3 years 
and £134m if 7 years.  As with CLOP these assessments can also inform policies which might make 
better and more relevant evidence available and the question of how and who might contribute most 
to providing the evidence needed at the right time.   
 
Table 3.7b Population NHE over the technology time horizon for different policies (EECP) 
 
 Approve OIR AWR Reject Value of 
AWR 
Uncertainty 
resolved at 
launch 
Value of 
evidence at 
launch 
Expressed in QALY 
T=3 1,391,001 1,397,192 1,393,578 1,389,596 -3,614 1,400,288 3,096 
T=7 1,391,001 1,393,608 1,392,030 1,389,596 -1,578 1,400,288 6,680 
Expressed in £m 
T=3 27,820 27,944 27,872 27,792 -72 28,006 62 
T=7 27,820 27,872 27,841 27,792 -32 28,006 134 
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4. Implications for policy, process and methods     
A more explicit assessment of OIR and AWR has a number of implications for policy (e.g., NICE 
guidance and drug pricing), the process of appraisal (e.g., greater involvement of research 
commissioners) and methods of appraisal (e.g., should additional information, evidence and analysis 
be required).    
 
Key principles and assessment needed 
The key principles and assessments needed fall into four broad areas: i) expected cost-effectiveness 
and population net health effects (including benefits, harms and NHS costs); ii) the need for evidence 
and whether the type of research required can be conducted once a technology is approved for 
widespread use; iii) whether there are sources of uncertainty which cannot be resolved by research 
but only over time; and iv) whether there are significant (opportunity) costs which will be committed 
and cannot be recovered once the technology is approved. 
 
Guidance will depend on the combined effect of all these assessments because they influence 
whether the benefits of research are likely to exceed the costs and whether any benefits of early 
approval are greater than withholding approval until additional research is conducted or other sources 
of uncertainty are resolved.  There was general consensus among workshop participants that the key 
principles represented by a sequence of assessment and judgments were the relevant ones, 
complete and in an appropriate order.  In response to feedback from the first workshop this sequence 
of assessment and judgement was summarised as a simple seven point checklist (see Section 3.1) 
that could be considered by the TAR team/ERG and Appraisal Committee as well as manufacturers 
during appraisal.  
 
Categories and type of guidance 
(DFKVHTXHQFHRIDVVHVVPHQWDQGGHFLVLRQOHDGVWRGLIIHUHQWFDWHJRULHVDQGµW\SHV¶RIJXLGDQFHIRU
WHFKQRORJLHVZLWKGLIIHULQJFKDUDFWHULVWLFV LQGLFDWLRQVDQG WDUJHWSRSXODWLRQV7KHGLIIHUHQW µW\SHV¶RI
apparently similar guidance illustrates how the same category of guidance (e.g., Approve, AWR, OIR 
or Reject) might be arrived at in different ways, helping to identify the particular combination of 
considerations which might underpin guidance; contributing to the transparency of the appraisal 
process.  Although improving transparency in communicating the considerations that underpin 
guidance, the application of the checklist alone is unlikely to be sufficient, especially in situations 
where OIR guidance was made for a technology that was, on balance, expected to be cost-effective.  
Evidence of how, not just what assessments and judgements were made, would be required.   
 
The principles suggest that the categories of guidance available to NICE have wider application than 
is reflected in previous guidance. For example, there are 5 different types of OIR which may be 
appropriate when a technology is expected to be cost-effective (see Table 2.1a in Section 2.1.3). 
Indeed, OIR or even Reject maybe appropriate even when research is possible with approval if there 
are significant irrecoverable costs.  Therefore, the full range of categories of guidance (OIR and 
Reject as well as AWR and Approve) ought to be considered for technologies, which on the balance 
of existing evidence and current prices, are expected to be cost-effective.  It is only approval that can 
be ruled out if a technology is not expected to be cost-effective, i.e., cost-effectiveness is necessary 
but not sufficient for approval but lack of cost-effectiveness is neither necessary nor sufficient for 
rejection.  Therefore, which category of guidance will be appropriate only partly depends on an 
assessment of expected cost-effectiveness and hence this assessment should only be regarded as 
an initial step in formulating guidance.   
 
Other NICE programmes 
The principles outlined in Section 2 and represented by the checklist do not presuppose how the 
assessments required might be informed and judgments made.  Distinguishing principles from 
methods of analysis in this way means that the principles and the checklist, may be useful in other 
NICE programmes, whilst recognising that how the assessment might be made is likely to differ.  It 
was recognised that some amendments might be required where cost-effectiveness is not the prime 
consideration.  The complexity of multiple outcomes in Public Health, the greater scope and 
complexity of decision problems in Clinical Guidelines and relative paucity of evidence and speed of 
innovation in devices offer greater challenges for quantitative assessment but do not change the key 
principles and considerations.   
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Implications for patient access schemes and value based pricing 
Any change in the effective price of the technology, either through patient access schemes or direct 
price changes will affect the key assessments, leading to different categories of guidance.  Therefore, 
consideration of the effect of price changes on OIR and AWR is needed when assessing the potential 
impact of patient access schemes and more direct price negotiation through value based pricing.  
 
The price at which the technology would just be expected to be cost-effective is commonly regarded 
as the value based price for the technology.  It is the maximum price the NHS can afford to pay 
without imposing negative health effects. This describes the threshold price below which Approve 
rather than Reject would be appropriate when either: i) OIR or AWR guidance is not available to the 
decision maker; ii) there is no uncertainty in cost-effectiveness;  or iii) the research, if needed, can be 
conducted with approval and there are no irrecoverable costs.  In all other circumstances there are a 
number of other value based prices, each representing the threshold price below which guidance 
would change.  Importantly, once uncertainty and the need for evidence as well as the impact of 
irrecoverable costs are recognised the threshold price that would lead to Approval will always be 
lower or equal to a single value based price based on expected cost-effectiveness alone, i.e., 
disregarding uncertainty in costs and effects. 
   
For example, when research could be conducted without approval but not with it, there will be a price 
threshold above which Reject rather than OIR would be appropriate; and a lower price threshold 
below which Approve rather than OIR would be appropriate.   This Approve/OIR threshold price will 
always be lower than a VBP based on expected cost-effectiveness. If a technology also imposes 
significant irrecoverable costs this threshold price will be lower still.   
 
Health technologies with patent protection are more likely to be priced close to the point at which the 
ICER is close to or equal to the threshold, i.e., expected incremental NHE are close to zero.  A value 
based pricing scheme would formalise these existing incentives so technologies will tend to impose 
greater irrecoverable opportunity costs.  The use of a technology which is only just expected to be 
cost-HIIHFWLYHZLOOQRWµEUHDNHYHQ¶XQWLOFORVHWRWKHHQGRIWKHSDWHQWWLPHKRUL]RQDQGPXFKORQJHUIRU
the population of patients likely to benefit from its use.  Therefore, those technologies already priced 
close to the threshold, and all new technologies considered in a value based pricing scheme, will tend 
to increase the scale of irrecoverable costs committed by approval.  If these irrecoverable costs are 
significant (because treatment decisions are not irreversible) then OIR or Reject maybe more likely 
even when a technology is just expected to be cost-effective. 
 
Even in circumstances where price negotiation becomes possible alongside NICE appraisal, it will be 
important to retain the OIR and AWR as available categories of guidance for two reasons.  Firstly, 
there is no guarantee that manufacturers will always agree to the lower price below which Approval 
rather than OIR or AWR would be appropriate.  Secondly, and possibly more importantly, there may 
be many circumstances when there is no effective price reduction which would make Approval 
appropriate. For example, Reject or OIR guidance may still be appropriate even if the effective price 
of a technology was zero if there is substantial uncertainty about its effectiveness and/or potential for 
harms.  
 
Incentives for evaluative research 
Consideration of OIR and AWR recommendations provides a link between uncertainty, evidence and 
price which might appropriately align incentives for manufacturers conducting the type of evaluative 
research that would be most valuable for the NHS.  It provides clear signals and an incentive to 
ensure the type of evidence, which would require research that cannot be conducted once approved 
for NHS use, is available and is sufficient at launch (e.g., relative effectiveness and subtle but 
important differences in side effect profiles).  Therefore, a predictable OIR and AWR policy signals 
what type of evidence is likely to be most important at an early stage.  It offers manufacturers a 
choice, to either: i) accept OIR Guidance at a higher price but restricted volume; ii) reduce the 
effective price to achieve Approval, or AWR where that is possible; or iii) conduct the evaluative 
research at an earlier stage so that additional evidence is available at launch.   
 
Consideration of how the NHS and manufacturers are likely to share the value of evidence might 
inform whether manufacturers should be expected to conduct the research specified in AWR or OIR 
guidance, or whether manufactures might be expected to make some contribution to the costs of 
publicly funded research which may ultimately benefit their product.  Two other issues need to be 
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considered.  Firstly, the resource constraints on publicly funded research may mean that other 
research priorities (often without commercial interest) may be more valuable to the NHS.  Secondly, 
the success of AWR recommendations when manufacturers are asked to conduct the research will 
depend on whether NICE and/or DH are able to establish incentive consistent contractual 
arrangements as part of an AWR recommendation, i.e., arrangements that can be monitored and 
enforced with credible penalties to ensure agreed research is conducted and in the way intended.   It 
was widely recognised that, at present, NICE does not have a credible mechanism to ensure that the 
type of research recommended in AWR Guidance would actually be undertaken by manufacturers.  
Removing approval of a technology simply because recommended research had not been conducted 
was not considered an ethical or credible threat.   
 
Although OIR provides a greater incentive to undertake research, it was recognised there may be 
circumstance where manufacturers would nonetheless choose not to undertake it, i.e., accepting an 
effective Reject.  If the research is also not a sufficient priority to secure public funding, then Approval 
rather than OIR (an effective reject in these circumstances) would only be appropriate at the lower 
Approve/OIR price threshold.  All AWR and OIR research could in principle be publicly funded rather 
than undertaken by manufacturers if the costs of research could be recovered directly from 
manufacturers or indirectly through other price discounts.  Since the costs of public research are likely 
to be substantially lower than for manufacturers this might be mutually beneficial in many 
circumstances; providing appropriate support to innovation, while allowing wider access to the data 
generated and more transparency and accountability in the conduct of the research[40].     
 
Value of AWR and evidence at launch  
The assessments that need to be made (especially in sections 3.5.2 and 3.6) can be used to 
consider: i) what would be the value of being able to conduct research while a technology is approved 
(value of AWR); ii) what would be the value of making evidence that is needed by the NHS available 
at launch; and iii) what is the value of being able to acquire evidence more quickly. This can inform 
whether investment in better data collection, registries or information systems that might make AWR 
possible.  Importantly this will differ by technology and will depend on the scale and significance of 
irrecoverable costs.  The value to the NHS of having access to the evidence needed at launch can 
inform a range of policies, such as early advice, public investment in transitional and evaluative 
research earlier in the development process or other incentives for research and development.  
Understanding the relationship between the time taken for research to report and the value of the 
evidence to future populations can help to inform: i) investments which might make research findings 
more quickly available; ii) the trade-off implicit in the choice of alternative research designs (i.e., 
greater precision or timeliness); and iii) research prioritisation (identifying those areas where if 
research is to be undertaken there must be confidence that it can report quickly).     
 
The value of early evidence at launch and AWR can also be considered from the perspective of the 
manufacturer; taking account of prices and expected volumes over the remaining patent life and 
technology time horizon.  This might inform when manufacturers might be expected to conduct the 
research needed (high commercial value that exceeds the cost to manufacturers) and when the NHS 
might be expected to undertake it (low commercial value but high potential value to the NHS that 
exceeds the costs to the NHS).  In many circumstances both the commercial and NHS values will 
exceed their respective costs.  The question of who should conduct, or pay for, the research might be 
LQIRUPHG E\ ZKLFK VHFWRU KDV WKH FRPSDUDWLYH DGYDQWDJH LH ZKLFK KDV WKH KLJKHVW µUHODWLYH
HIILFLHQF\¶LQJHQHrating social value?   
 
Social value judgements and ethical principles  
Although OIR and AWR recommendations pose important ethical issues, the type of judgements 
required appear ethically permissible and consistent with the social values and principles that 
underpin existing NICE appraisal.  It was recognised, however, that OIR guidance may be made 
when clinicians and researchers would not be in equipoise about the effectiveness (as opposed to the 
cost-effectiveness) of an intervention.   Therefore, more work on how a useful notion of equipoise 
might be informed by the type of social decisions that bodies like NICE have to make may be 
valuable.  Whether an AWR recommendation will be undertaken by manufacturers also has an ethical 
dimension.  Threatening to withdraw approval if the research fails to report would be unfair on future 
patients because the evidence base would not have changed.  This potential inequity strengthens the 
case to either: ensure enforceable, incentive consistent are in place; or acknowledge that AWR may 
not be possible for these reasons, and OIR is the only effective policy option. 
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How should the assessments be undertaken? 
The order of the assessments in the checklist relate to the sequence of decision nodes that fully 
describe the algorithm in Appendix A. This order of considerations means that all 7 assessments do 
not necessarily need to be made when an earlier judgement can lead directly to guidance.  The 
assessment of whether in principle further research might be worthwhile and what type of evidence 
might be required would need to be undertaken routinely.  If research may be worthwhile, some 
indication of the type of evidence needed would also be useful for those making an assessment of the 
prospects of research (see below) and whether the type of research required to generate it would be 
possible with approval.  Therefore, routine assessment up to point 4 of the checklist would seem 
appropriate before others with expertise and responsibility for research design and commissioning 
considered the prospects of the type of research needed.   
 
One model for an efficient order of assessment would be to consider points 1-5 routinely (some early 
assessment of other sources of uncertainty at point 5 probably ought to be undertaken so that it can 
inform these deliberations).  The AC would then be in a position to either rule out OIR or AWR and 
issue guidance in the usual way or indicate in the ACD that OIR or AWR was provisionally 
recommended subject to advice from a research advisory committee and subsequent analysis to 
support an assessment of points 6 and 7 of the checklist at FAD.  This model would avoid 
unnecessary analysis and assessment and incorporate the judgments of the research community 
without necessarily adding to the time that an appraisal might take.  
 
Some assessment of: i) the type of research needed to address the key uncertainties; ii) whether this 
will be regarded as ethical and can be undertaken while the technology is approved for use; iii) 
whether it is likely to be a priority for public funding and be commissioned; and iv) when it is likely the 
report is required.  Although the NICE appraisal process may be well suited to identifying the need for 
evidence, these other critical assessments (the type of research and its priority) are not necessarily 
ones for which NICE and its advisory committees, as currently constituted, have particular expertise, 
not least because they reflect the decisions of those responsible for research design, prioritisation and 
commissioning.  Without sufficient coordination between these communities there is a danger that 
OIR or AWR could be issued when either the type of research required would not be regarded as 
ethical or feasible, or not of sufficient priority compared to other competing research needs to be 
commissioned.  Since publicly funded research is also budget constrained, it is perfectly possible that 
research which might be valuable from a wider NHS perspective might nevertheless not be a priority if 
other more valuable research might be displaced.  This might be a particular concern if there is a 
possibility that the research could be undertaken by the manufacturer rather than displacing other 
research without a commercial interest.  Therefore, a decision of whether OIR or AWR research 
should be undertaken by the manufacturer or through publicly funded research is one that NICE 
cannot properly take alone.   
 
Informed judgements and better decisions might be possible through greater involvement of the 
research community.  For example, a research advisory committee could be constituted which could 
consider provisional OIR or AWR guidance (at ACD), making recommendations about the type of 
research needed, its ethics, feasibility and likely priority during the consultation period before final 
appraisal and guidance.  It might also make recommendations about whether research should be 
publicly funded or undertaken by the manufacturer with appropriate contractual arrangements (which 
may require the involvement of DH at some stage).  Since some of the assessments which must be 
made in formulating OIR or AWR guidance are, in fact, research decisions which fall outside the NICE 
remit, it would seem sensible to draw on the expertise of those involved in, and responsible for, these 
types of research decisions to help make these assessments, i.e., translating the need for particular 
types of evidence into a need for particular type of research and its prospects. 
 
Triggers for reappraisal also need to be linked to OIR and AWR guidance in two respects: i) to ensure 
that guidance is reconsidered once research findings are available and ii) to reconsider guidance if 
the type of research anticipated as part of AWR or OIR guidance is not undertaken and there is little 
prospect that it will be, e.g., where there is no agreement with a manufacturer or publicly funded 
research was not prioritised or commissioned to avoid unnecessary research.   In addition, other 
changes (prices, entry of new technologies and new evidence) which might mean that research is no 
longer required ought to be included as criteria of reappraisal.  
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What additional information and analysis might be required? 
Cost-effectiveness was presented in terms of net health effects per patient treated and for the 
population of patients over time in Section 3.  This provides information in a way that is directly 
relevant to the assessments that need to be made, especially at point 2 and point 7 for the checklist 
(see Section 3.3.1).  All the information required to express expected cost-effectiveness in these ways 
are generally already available during appraisal and are entirely equivalent to the more familiar ICER.   
 
Amending how irrecoverable capital costs are incorporated into the estimates of expect costs pose 
few technical difficulties.  Considering the significance of the irrecoverable opportunity costs of initially 
negative net health effects of a technology is more nuanced (see Section 2.3.2) and their precise 
effect will depend on assessments made at points 5 and 6, which can be supported by additional 
analysis using the type of economic models developed during appraisal.  However, some early 
indication of their potential importance can be based on their scale relative to expected net health 
effects, the point at which initial losses are expected to be compensated by later gains, whether 
treatment decisions are reversible and what opportunities to improve health might be forgone by a 
delay to initiating treatment.   
 
The judgment at point 3 of the checklist requires some assessment of: i) how uncertain a decision 
based on expected cost-effectiveness might be; and ii) what the consequences, in terms of population 
NHE, are likely to be if an incorrect decision is made.  The methods of analysis presented in Section 
3.4.1 attempt to decompose this assessment into a series of steps each presenting what is already 
available within current methods of appraisal but in ways that can more directly inform the 
assessment required.   
 
This assessment at point 4 of the checklist requires judgements about:  i) how important particular 
types of parameters (inputs to the economic model) are to estimates of cost and QALY; ii) what 
values these parameters  would have to take to change a decision based on expected cost-
effectiveness; iii) how likely is it that parameters might take such values and iv) what would be the 
consequences if they did, i.e., what might be gained in terms of population NHE if the uncertainty in 
the values of these parameters could be immediately resolved?  The methods of analysis presented 
in Section 3.4.2 decompose this assessment in to these series of steps; presenting in turn what is 
already available within current methods of appraisal but in ways that more directly inform the 
assessment required.  It is only when assessing the consequences of uncertainty associated with 
particular parameters that additional analysis (using the results of existing probabilistic analysis) is 
required to provide quantitative estimates.  There are circumstances where this additional 
computation is a significant burden, although increasingly, suitable simplifications and approximations 
are available.     
 
It was recognised by participants that uncertainty in the parameters included in PSA generally do not 
represent all sources of uncertainty.  Commonly there is also uncertainty between alternative 
assumptions judgements that might be made; often represented by alternative scenarios.  How the 
consequences of uncertainty between as well as within scenarios can be presented was explored in 
Sections 3.4.1 and 3.4.2.  Although this analysis GRHVQ¶WUHTXLUHDGGLWLRQDOVLPXODWLRQLWGRHVUHTXLUH
that either the probabilities are made explicit in advance or estimates to be presented for a range of 
probabilities that might represent the judgement of the AC following deliberation.  Rather than make 
alternative assumptions and present extreme scenarios, formal elicitation of the judgement of clinical 
experts about the unknown parameters for which assumption are required is possible.  Such 
elicitation may provide a richer characterisation of uncertainty than weighting alternative scenarios but 
requires relevant experts to be identified in advance and for the AC to accept their judgements.   
 
The current appraisal process generally already provides the information and much of the analysis 
required to complete all the quantitative assessment reported in Section 3.  However, the information 
required to assess whether other sources of uncertainty will resolve over time (point 5 on the 
checklist) requires information that is not commonly sort as part of NICE appraisal.  Many potentially 
useful sources were either proprietary or public access restricted, making it surprisingly difficult to 
inform these assessments with publicly available information.  When information and estimates were 
available they were often not complete or directly relevant to a UK context.  NICE many need to 
consider how access to this type of information can be provided or whether it should extract this type 
of information itself at an earlier stage of appraisal. 
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Since the STA process bases appraisal primarily on manufacturers submissions, any additional 
analysis would need to be included in the submission and be reviewed by the ERG.  Although the 
additional analysis itself is limited (most is already required but sometimes presented in different 
forms), more explicit consideration of OIR and AWR and its link to price would make the critique of 
how uncertainty and its consequences has been characterised more important.   An assessment of 
whether the point estimate of cost±effectiveness is reasonable is inevitably a more limited task than 
also assessing whether the uncertainty surrounding that assessment is credible.  Any additional 
burden on ERGs (and manufacturers) might be eased with clear guidance on the details of how 
analysis should be conducted and presented, what common assumptions are deemed reasonable 
and provision of additional information by the Institute as well as only considering points 6 and 7 on 
the checklist after ACD and following advice from a research advisory committee. 
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Appendix A
  
Appendix A An algorithm for only in research and approval with research decisions
Part I ± Technologies without significant irrecoverable costs
Assess need for evidence
Does 
more research seem 
worthwhile?
What type of evidence is needed?
Is the 
research possible with
Approval?
Yes
Yes
Yes
No
Yes
Will research be conducted?
When will it be available?
How much will be resolved? 
Assess other sources of uncertainty
Will this 
Uncertainty be resolved
over time? 
Yes
No
Assessments
Decisions
Guidance
Key
No
No
No
Assess irrecoverable  costs
Are there 
significant irrecoverable 
costs? 
Assess cost-effectiveness and
population net health effects
Is it cost-effective?
AWR
Assess effects of potential price 
reductions on need for evidence and 
benefits of early approval
Are effective 
price reductions offered 
or possible?
Yes
Re-assess the benefits and costs 
of further research
Are the
benefits of research greater 
than the costs? 
Yes
No
Approve
Go to 
part II
No
Assess the benefits and costs of 
early approval
Are the
benefits of approval greater 
than the costs? 
Approve OIR
Yes
No
Yes
No
Are effective 
price reductions offered 
or possible?
Assess effects of potential price 
reductions on need for evidence and 
benefits of early approval
Re-assess the benefits and costs 
of further research
Are the
benefits of research greater 
than the costs? 
Yes
No
Approve Approve
Is the 
research possible without
Approval?
Yes
No
Does 
more research seem 
worthwhile?
Yes
No
What type of evidence is needed?
Assess irrecoverable  costs
Are there 
significant irrecoverable 
costs? 
No
OIR
Assess effects of potential price 
reductions on need for evidence and 
benefits of early approval
Are effective 
price reductions offered 
or possible?
No
Yes
Re-assess the benefits and costs 
of further research
Are the
benefits of research greater 
than the costs? 
Yes
No
Reject
No
Yes Are effective 
price reductions offered 
or possible?
Assess effects of potential price 
reductions on need for evidence and 
benefits of early approval
AWR Reject
Assess effects of potential price 
reductions on need for evidence and 
benefits of early approval
No
Yes
No
Yes Are effective 
price reductions offered 
or possible?
Assess effects of potential price 
reductions on need for evidence and 
benefits of early approval
Re-assess the benefits and costs 
of further research
Yes
No
Assess the benefits and costs of 
early approval
Are the
benefits of approval greater 
than the costs? 
Yes
No
Are the
benefits of research greater 
than the costs? 
Go to 
part III
Yes Yes
Reject
No
Yes Are effective 
price reductions offered 
or possible?
Assess effects of potential price 
reductions on need for evidence and 
benefits of early approval
Are effective 
price reductions offered 
or possible?
1 1 12 23 4 1 2 2 4
AWR OIR OIR Reject AWR Reject Reject
1 1 2 1 2 2 4
3
3
Will research be conducted?
When will it be available?
How much will be resolved? 
Assess other sources of uncertainty
Will this 
Uncertainty be resolved
over time? 
Yes
No
Will research be conducted?
When will it be available?
How much will be resolved? 
Assess other sources of uncertainty
Will this 
Uncertainty be resolved
over time? 
Yes
No
Will research be conducted?
When will it be available?
How much will be resolved? 
Assess other sources of uncertainty
Will this 
Uncertainty be resolved
over time? 
Yes
No
Assess need for evidence
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Appendix A An algorithm for only in research and approval with research decisions
Part II - Technologies with significant irrecoverable costs, expected to be cost-effective and research needed
Assess need for evidence
Does 
more research seem 
worthwhile?
What type of evidence is needed?
Is the 
research possible with
Approval?
Yes
Yes
Yes
No
Yes
Assessments
Decisions
Guidance
Key
No
No
No
Assess irrecoverable  costs
Are there 
significant irrecoverable 
costs? 
Assess cost-effectiveness and
population net health effects
Is it cost-effective?
AWR
Assess effects of potential price 
reductions on need for evidence and 
benefits of early approval
Are effective 
price reductions offered 
or possible?
Yes
Re-assess the benefits and costs 
of further research
No
Go to 
part I
No
Assess the benefits and costs of 
early approval
Are the
benefits of approval greater 
than the costs? 
Approve Reject
Yes
No
Yes
No
Are effective 
price reductions offered 
or possible?
Assess effects of potential price 
reductions on need for evidence and 
benefits of early approval
Assess irrecoverable  costs
Are there 
significant irrecoverable 
costs? 
No
Go to 
part III
Yes Yes
Assess the benefits and costs of 
early approval
Are the
benefits of approval greater 
than the costs? 
Yes
No
Are the
benefits of research greater 
than the costs? 
Yes
OIR
No
Assess effects of potential price 
reductions on need for evidence and 
benefits of early approval
Are effective 
price reductions offered 
or possible?
AWR
Assess effects of potential price 
reductions on need for evidence and 
benefits of early approval
Are effective 
price reductions offered 
or possible?
No
Yes
Re-assess the benefits and costs 
of further research
Yes
NoAre the
benefits of research greater 
than the costs? 
Assess the benefits and costs of 
early approval
Are the
benefits of approval greater 
than the costs? 
Approve OIR
Yes
No
Yes
No
Are effective 
price reductions offered 
or possible?
Assess effects of potential price 
reductions on need for evidence and 
benefits of early approval
Re-assess the benefits and costs 
of further research
Are the
benefits of research greater 
than the costs? 
Yes
No
Yes
Approve
No
Yes
No
Reject
Are effective 
price reductions offered 
or possible?
Assess the benefits and costs of 
early approval
Are the
benefits of approval greater 
than the costs? 
Assess effects of potential price 
reductions on need for evidence and 
benefits of early approval
Approve
Assess the benefits and costs of 
early approval
Are the
benefits of approval greater 
than the costs? 
Approve OIR
Yes
Assess effects of potential price 
reductions on need for evidence and 
benefits of early approval
Re-assess the benefits and costs 
of further research
Are the
benefits of research greater 
than the costs? 
Yes
No
No
Are effective 
price reductions offered 
or possible?
Assess the benefits and costs of 
early approval
Are the
benefits of approval greater 
than the costs? 
OIR
Yes
No
Yes
No
Are effective 
price reductions offered 
or possible?
Assess effects of potential price 
reductions on need for evidence and 
benefits of early approval
Approve
No
Yes
3 3 5 5 54 4 6 7 8 6 69 10
AWR RejectOIR AWR OIR Reject OIROIR
3 3 5 54 4 6 6
Will research be conducted?
When will it be available?
How much will be resolved? 
Assess other sources of uncertainty
Will this 
Uncertainty be resolved
over time? 
Yes
No
Will research be conducted?
When will it be available?
How much will be resolved? 
Assess other sources of uncertainty
Will this 
Uncertainty be resolved
over time? 
Yes
No
Will research be conducted?
When will it be available?
How much will be resolved? 
Will research be conducted?
When will it be available?
How much will be resolved? 
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Appendix A    An algorithm for only in research and approval with research decisions
Part III - Technologies with significant irrecoverable costs, not expected to be cost-effective or research not needed
Assess need for evidence
Does 
more research seem 
worthwhile?
Yes
Yes
Assessments
Decisions
Guidance
Key
No
No
Assess irrecoverable  costs
Are there 
significant irrecoverable 
costs?
Assess cost-effectiveness and
population net health effects
Is it cost-effective?
Go to 
part I
No
Assess irrecoverable  costs
Are there 
significant irrecoverable 
costs?
No
Yes Yes
Approve
Assess the benefits and costs of 
early approval
Are the
benefits of approval greater 
than the costs? 
Approve Reject
Yes
No
Yes
No
Are effective 
price reductions offered 
or possible?
Assess effects of potential price 
reductions on need for evidence and 
benefits of early approval
Go to 
part II
OIR Reject
Assess effects of potential price 
reductions on need for evidence and 
benefits of early approval
Are effective 
price reductions offered 
or possible?
No
Yes
No
Yes Are effective 
price reductions offered 
or possible?
Assess effects of potential price 
reductions on need for evidence and 
benefits of early approval
Re-assess the benefits and costs 
of further research
Are the
benefits of research greater 
than the costs? 
Yes
No
Assess need for evidence
Does 
more research seem 
worthwhile?
What type of evidence is needed?
Is the 
research possible without
Approval?
Yes
Yes
No
No
AWR Reject
Assess effects of potential price 
reductions on need for evidence and 
benefits of early approval
Are effective 
price reductions offered 
or possible?
No
Yes
No
Are effective 
price reductions offered 
or possible?
Assess effects of potential price 
reductions on need for evidence and 
benefits of early approval
Re-assess the benefits and costs 
of further research
Are the
benefits of research greater 
than the costs? 
Yes
No
Are the
benefits of approval greater 
than the costs? 
Yes
No
Reject
No
Yes Are effective 
price reductions offered 
or possible?
Assess effects of potential price 
reductions on need for evidence and 
benefits of early approval
Assess the benefits and costs of 
early approval
11 127 7 8 5 119
10
Reject OIR Reject AWR Reject Reject
7 7 8 5 119
10
Will research be conducted?
When will it be available?
How much will be resolved? 
Assess other sources of uncertainty
Will this 
Uncertainty be resolved
over time? 
Yes
No
Will research be conducted?
When will it be available?
How much will be resolved? 
Assess other sources of uncertainty
Will this 
Uncertainty be resolved
over time? 
Yes
No
Assess other sources of uncertainty
Will this 
Uncertainty be resolved
over time? 
Yes
No
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Table B1 Types and categories of guidance from using the checklist 
 
 
Assessment 1 2 3 4 5 6 7 Guidance
1 Yes No Yes Yes Yes/No Yes - AWR 1
2 Yes No Yes Yes Yes/No No - Approve 1
3 Yes No Yes No Yes/No Yes Yes Approve 2
4 Yes No Yes No Yes/No Yes No OIR 1
5 Yes No Yes No Yes/No No - Approve3
6 Yes No No - - - - Approve 4
7 No No Yes Yes Yes/No Yes - OIR 2
8 No No Yes Yes Yes/No No - Reject 1
9 No No Yes No Yes/No Yes Yes AWR 2
10 No No Yes No Yes/No Yes No Reject 2
11 No No Yes No Yes/No No - Reject 3
12 No No No - - - - Reject 4
13 Yes Yes Yes Yes Yes Yes Yes AWR 3
14 Yes Yes Yes Yes Yes Yes No OIR 3
15 Yes Yes Yes Yes Yes No Yes Approve 5
16 Yes Yes Yes Yes Yes No No Reject 5
17 Yes Yes Yes Yes No Yes Yes AWR 4
18 Yes Yes Yes Yes No Yes No OIR 4
19 Yes Yes Yes Yes No No - Approve 6
20 Yes Yes Yes No Yes Yes Yes Approve 7
21 Yes Yes Yes No Yes Yes No OIR 5
22 Yes Yes Yes No Yes No Yes Approve 8
23 Yes Yes Yes No Yes No No Reject 6
24 Yes Yes Yes No No Yes Yes Approve 9
25 Yes Yes Yes No No Yes No OIR 6
26 Yes Yes Yes No No No - Approve 10
27 Yes Yes No n/a Yes n/a Yes Approve 11
28 Yes Yes No n/a Yes n/a No Reject 7
29 Yes Yes No n/a No - - Approve 12
30 No Yes Yes Yes Yes/No Yes - OIR 7
31 No Yes Yes Yes Yes/No No - Reject 8
32 No Yes Yes No Yes/No Yes Yes AWR 5
33 No Yes Yes No Yes/No Yes No Reject 9
34 No Yes Yes No Yes/No No - Reject 10
35 No Yes No - - - - Reject 11
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Figure B1 Possible pathways for EECP 
 
Assessments
Decisions
Guidance
Key
Assess need for evidence
Does 
more research seem 
worthwhile?
What type of evidence is needed?
Is the 
research possible with
Approval?
Yes
Yes
Yes
No
No
No
Assess irrecoverable  costs
Are there 
significant irrecoverable 
costs? 
Assess cost-effectiveness and
population net health effects
Is it cost-effective?
No
Yes
Assess other sources of uncertainty
Will this 
Uncertainty be resolved
over time? 
Yes
No
AWR
Re-assess the benefits and costs 
of further research
Yes
NoAre the
benefits of research greater 
than the costs? 
Assess the benefits and costs of 
early approval
Are the
benefits of approval greater 
than the costs? 
Yes
No
4
OIR
4
Approve
6
Will research be conducted?
When will it be available?
How much will be resolved? 
Go to 
Appendix A
Part III 
Go to 
Appendix A
Part I
Go to 
Appendix A
Part III 
Go to 
Appendix A
Part II 
Assess other sources of uncertainty
Will this 
Uncertainty be resolved
over time? 
Yes
No
Approve
Assess the benefits and costs of 
early approval
Are the
benefits of approval greater 
than the costs? 
Approve OIR
Re-assess the benefits and costs 
of further research
Are the
benefits of research greater 
than the costs? 
Yes
No
No
Yes
69 10
Will research be conducted?
When will it be available?
How much will be resolved? 
Go to 
Appendix A
Part II 
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Figure B2 Possible pathways for CLOP  
 
 
 
 
 
 
 
 
Assessments
Decisions
Guidance
Key
Assess need for evidence
Does 
more research seem 
worthwhile?
What type of evidence is needed?
Is the 
research possible with
Approval?
Yes
Yes
Yes
No
No
No
Assess irrecoverable  costs
Are there 
significant irrecoverable 
costs? 
Assess cost-effectiveness and
population net health effects
Is it cost-effective?
Go to
Appendix A 
part II
No
Assess the benefits and costs of 
early approval
Are the
benefits of approval greater 
than the costs? 
Approve OIR
Yes
No
Re-assess the benefits and costs 
of further research
Are the
benefits of research greater 
than the costs? 
Yes
No
Approve
Yes
12 3
Will research be conducted?
When will it be available?
How much will be resolved? 
Assess other sources of uncertainty
Will this 
Uncertainty be resolved
over time? 
Yes
No
Go to 
Appendix A
Part I 
Go to 
Appendix A
Part I 
Go to 
Appendix A
Part I 
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Figure B3 Possible pathways for OMAL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessments
Decisions
Guidance
Key
Yes
No
Assess cost-effectiveness and
population net health effects
Is it cost-effective?
Go to 
Appendix A
Part I 
Assess irrecoverable  costs
Are there 
significant irrecoverable 
costs? 
Yes
Reject
4
Go to 
Appendix A
Part III 
Does 
more research seem 
worthwhile?
Yes
No
No
Assess need for evidence
Go to 
Appendix A
Part I 
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Figure B 4 Possible pathways for PsA 
 
 
Assessments
Decisions
Guidance
Key
Yes
No
Assess cost-effectiveness and
population net health effects
Is it cost-effective?
Go to 
Appendix A
Part I 
Is the 
research possible without
Approval?
Yes
No
Does 
more research seem 
worthwhile?
Yes
No
What type of evidence is needed?
Assess irrecoverable  costs
Are there 
significant irrecoverable 
costs? 
No
OIR
Re-assess the benefits and costs 
of further research
Are the
benefits of research greater 
than the costs? 
Yes
No
Yes
2
Reject
1
AWR Reject
Re-assess the benefits and costs 
of further research
Yes
No
Assess the benefits and costs of 
early approval
Are the
benefits of approval greater 
than the costs? 
Yes
No
Are the
benefits of research greater 
than the costs? 
2 2
3
Will research be conducted?
When will it be available?
How much will be resolved? 
Assess other sources of uncertainty
Will this 
Uncertainty be resolved
over time? 
Yes
No
Will research be conducted?
When will it be available?
How much will be resolved? 
Assess other sources of uncertainty
Will this 
Uncertainty be resolved
over time? 
Yes
No
Assess need for evidence
Go to 
Appendix A
Part III 
Go to 
Appendix A
Part I 
